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4Abstract
Towards the Synthesis of a Macrocyclic E-selectin Antagonis
Introduction
Selectins are involved in the orderly migration of leukocytes from blood vessels to sites
of inflammation. Although extravasation of leukocytes represents an essential defense
mechanism against infection, excessive or inappropriate leukocyte accumulation results
in injury to host tissues. Therefore, the development of selectin-antagonists is
considered as an effective therapeutic approach in inflammatory and other disorders.
Physiological selectin ligands contain a common tetrasaccharide epitope called sialyl
LewisX (1) that has served as the lead structure in our rational design of E-selectin
antagonists.
Purpose
The sLeX analog 2 was rationally designed to explore the role of the spatial orientation of
the pharmacophores in the conformation bound to the receptor. The rigidity of the
macrocyclic core should provide the basis for enhanced bioactivity due to pre-
organization of the functional groups involved in binding in the bioactive conformation.
The building blocks for the synthesis of 2 are L-galactose, elongated at C-6 by Wittig
olefination, D-talose alkylated at the 3-OH with (S)-cyclohexyl lactic acid and an acyclic
replacement of D-GlcNAc. Activity studies of the 2 will provide an important contribution
to the validation of our predictions based on pre-organization determined by molecular
modeling.
Results
The building blocks required by the retrosynthetis of target molecule 2 were synthesized
in good to excellent yields. The core structures 79 and 91b were obtained as the results
of two different synthetic pathways.
The targeted macrocycle could not be synthesized due to major synthetic hurdles that
have been encountered along the two respective pathways.
O
HO
OHOH
AcHN
HO
CO2H
O
O
O O
ORO
O
HO
OH
OH
NHAc
OH OH
O
OO
CO2H
HOOHO
O
O
O
O
H
N
OH
OH
HO
H
H
21
HO
OH
O
O
O
O
O
OBn
BnO
H
79
O
O O
H
N
O
CO2Bn
OH
H
OBn
O
Ph
91b
O
O
HO
O
O
OBn
BnO
H
O
H
N
O
CO2Me
H
OBn
O
MeO
OBz
OH

5Preliminary remarks
For purpose of clarity we summerize here the different names found in the literature for
the selectins:
ELAM-1 = E-selectin = CD62E
GMP-140/PADGEM = P-selectin = CD62P
LECAM-1/LAM-1 = L-selectin = CD62L
Abbreviations
The following abbreviations have been used:
Ac Acetyl
AD Asymmetric dihydroxalation (Sharpless)
AgOTf Silver triflate
Al(CH3)3 Trimethylaluminium
BF3. Et2O Boron trifluoride etherate
Bn Benzyl
BnBr Benzyl bromide
BOM Benzyloxymethylether
Bz Benzoyl
BzCl Benzoyl chloride
cAMP Cyclic adenosine mono phosphate
CAN Cerium (IV) ammonium nitrate
CBr4 Carbon tetrabromide
CCl3CN Trichloroacetonitrile
CHCl3 Chloroform
CHO Chinese hamster ovary
COSY Correlated spectroscopy
CSA Camphor sulfonic acid
CR Complement regulatory-like units
6DCM Dichloromethane (CH2Cl2)
DCE Dichloroethane (CH3CHCl2)
DDQ Dichlorodicyanoquinone (2,3-dichloro-5,6-dicyano-1,4-benzoquinone)
DEAD Diethyl azodicarboxylate
DIPEA Diisopropylethylamine
DMAP 4-(Dimethylamino)pyridine
DME Dimethoxyethane
DMF N,N-Dimethylformamide
DMTST Dimethyl(methylthio)sulfonium trifluoromethanesulfonate
ECM Extracellular matrix
EDA Ethylenediamine
ee Enantiomeric excess
e.g. For example
EGF Epidermal growth factor domain
ELISA Enzyme-linked immunosorbent assay
EtOH Ethanol
eq. Equivalent
Fuc Fucose
Gal Galactose
GlcNAc N-Acetylglucosamine
Glu Glucose
GlyCAM-1 Glycosylated cell adhesion molecule-1
h Hour
H2 Hydrogen
HCl Hydrochloric acid
HClO4 Perchloric acid
HEV High endothelial venules
HUVEC Human umbilical vein endothelium cells
IFN-γ Interferon-γ
IL-1 Interleukine-1
IL-1-β Interleukine 1-β
7IL-3 Interleukine-3
IR Infrared spectroscopy
LAD-2 Leukocyte adhesion deficiency 2
LeX LewisX
LiAlH4 Lithium aluminium hydride
LiOH Lithium hydroxide
Lit. Literature
LPS Lipopolysaccharide
Me Methyl
min. Minute
MMPs Matrix Metalloproteinases
NaH Sodium hydride
NaOMe Sodium methanolate
NeuAc  Neuraminic acid = Sialic acid
NF-κB Nuclear factor of kappa B
NH2OH•HCl Hydroxylamine hydrochloride
NMR Nuclear magnetic resonance
NO Nitric oxide
NOE Nuclear Overhauser effect
OSE cf. TMSEt
Ph Phenyl
Ph3CCl Triphenylchloromethane
PhSH Thiophenol
PhP3 Triphenylphosphine
Py Pyridine
PtO2 Platinum oxide
Rf Retention factor
Rh Rhodium
SLeX Sialyl LewisX
Tal Talose
TBAB tert-Butyl ammonium bromide (Bu4NBr)
8TBAF tert-Butyl ammonium fluoride (Bu4NF)
TFA Trifluoroacetic acid
Tf2O Triflic anhydride
THF Tetrahydrofurane
TLC Thin layer chromatography
TMS Trimethylsilyl, OR tetramethylsilan (depending on context)
TMSEt 2-(Trimethylsilyl)ethanol
TMSE 2-(Trimethylsilyl)ethyl group = OSE
TMSOH Trifluoromethanesulfonic acid
TMSOTf Trimethylsilyl trifluoromethanesulfonate
TMU N,N,N‘,N‘-tetramethylurea
TNF-α Tissue necrosis factor α
Tr Trityl (triphenylmethyl)
trNOE Transfer nuclear Overhauser effect
VCAM-1 Endothelial vascular cell-adhesion molecule-1
CD62P P-selectin
CD62E E-selectin
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I. Outline
Biological relevance of the selectins
Selectins are major players in the adhesion of leukocytes to vascular endothelium during
the early cascade of events leading to inflammation [1]. More specifically, selectins are a
family of carbohydrate-binding proteins expressed at the sites of inflammation in
response to early precursors liberated by the injured tissue. These membrane proteins
mediate the tethering and rolling of leukocytes on blood vessel endothelium, leading to a
slowed leukocyte migration. As a slow displacement of leukocytes on the endothelium is
critical to their subsequent extravasation (movement of leukocytes through endothelial
cell layers to get to an area of infection), selectin binding is an essential step to the
inflammation [2].
Henceforth, control of the leukocyte-endothelial cell adhesion process may prove useful
in cases where excess recruitment of leukocytes can contribute to acute diseases such
as stroke and reperfusion injury, as well as to chronic diseases such as psoriasis and
rheumatoid arthritis [3]. Moreover, in vivo and in vitro studies of selectins have
established their importance in a wide array of other human diseases [4]. For instance, it
has been suggested that cancer may exploit the adhesion process after entering the
bloodstream to metastasize. In this regard, selectin antagonists represent a potential
cancer therapy [5,6].
Natural selectins ligands contain carbohydrate epitopes
The three selectins (L-, E-, and P-) differ in their binding specificities. Current opinion
suggests that carbohydrates including Lewis sugars (at some level of modification such
as sialylation or sulfation) are the biologically relevant ligands [7,8]. In particular, sialyl
LewisX (1) (Figure 1), a subunit of many natural carbohydrate ligands, has been
recognized as a common ligand for all selectins [9]. SLeX (1) has been shown to be an
effective antagonist of selectin function when it blocked the inflammatory process in
various in vitro and animal models. Thus, identification of the carbohydrate ligands
interacting with the selectins has provided an opportunity to develop a novel class of
potential anti-inflammatory drug. Moreover, as will be shown later, the potential of
selectin antagonists as drugs largely exceeds the domain of inflammation [4].
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Figure 1: Representation of sialyl LewisX (1) and the macrocyclic E-selectin antagonist 2.
Development of selectins antagonists
The development of inhibitors of the selectin-ligand interactions occupies an important
place among the numerous approaches taken to interfere with biological processes in
the inflammatory cascade. This goal has provided an exceptional opportunity to apply
interdisciplinary methodologies of the biological and chemical sciences to a problem in
structural biology (table 1).
Structural information about the sLeX -selectins interactions has revealed the nature of
the functional groups on the surface of sLeX (1) that are required for selectin binding [10],
[11,12]. Based on these data, numerous analogs and mimics of sLeX (1) have been
designed and synthesized in order to down-regulate leukocyte-endothelial cell adhesion
events [13,14,15]. The mimics are designed to resemble the structure of the natural
carbohydrate ligand, but are not carbohydrates per se. Indeed, carbohydrates are not
ideal drug candidates: they are difficult to synthesize, bind weakly, and have low oral
bioavailability due to labile glycosidic linkages and poor cell-entry properties.
The enhancement of the activity, stability, and bioavailability profiles of sLeX (1) has been
the major drive for the development of new structures. These improvements include e.g.
elimination of labile glycosidic linkage with C-glycoside mimetics [16], enhancement of the
molecules‘ binding affinities to the proteins by incorporation of secondary groups to
exploit additional binding regions on the proteins and simplification of the initial
carbohydrate structure [17].
The search for small molecules that disrupt selectin-sLeX-mediated recognition events
has met with some success. SLeX (1) analogs with substitutions for NeuNAc or GlcNAc,
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and tethered compounds show comparable or better affinity than sLeX (1) [18,19]. Current
efforts in our group focus on developing small molecules with even improved activity.
Despite the substantial methodological advances in glycosylation chemistry that have
been achieved over the last decade, the assembly of sophisticated oligosaccharides is
still far from routine.  No inhibitor of selectin-mediated cellular adhesion has reached the
market to date. New elements have recently increased our understanding of the selectin-
sLeX interactions. A major breakthrough has been the publication of the X-ray structure
in 2000 [12]. This information along with the knowledge that a second potential binding
site exists proximal of the sLeX (1) binding-site has spurred the development of new
generations of selectin antagonists [20].
Design and synthesis of a macrocyclic E-selectin antagonist
The aim of this work was the synthesis of the macrocyclic E-selectin antagonist 2 (Figure
1) intended to provide valuable data not only to elucidate the mechanism of selectin
recognition, but also to be a possible lead structure for the development of novel
potential therapeutic agents. Macrocyclization of a sLeX (1) analog has been undertaken
in order to explore the spatial orientation of the functional groups in the ligand bound to
E-selectin. In addition, the rigid macrocyclic core was thought to provide the basis for
enhanced bioactivity due to a potentially high pre-organization of the functional groups
involved in binding.
The building blocks for the synthesis of 2 have been L-Gal elongated at C-6 by Wittig
olefination, D-Tal alkylated at the 3-OH with (S)-cyclohexyl lactic acid and an N-naphtoyl
moiety (see Synthesis in Chapter III).
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Table 1: Chronological overview of selectin antagonists research.
1989 Initial characterization of the selectins [21]
Simultaneous cloning of the three selectins [2]
Beginning of the isolation of the receptors
1990 Four groups reported that sLeX  (1) recognizes E-selectin [22]
Beginning of the characterization of the carbohydrate portion of the natural ligand
1991 – 1993 First total synthesis of the minimal carbohydrate ligand sLeX (1) by Hasegawa
and co-workers [23]
First syntheses of sLeX (1) derivatives useful for determining critical functional
groups [24]
Glycoprotein receptors bearing these carbohydrates identified as ESL-1 and
PSGL-1 [25]
1992 Isolation of the natural glycoprotein ligands [25]
1994-1997 Determination of the free and bound conformations of sLeX (1) [26]
Development of novel classes of selectin antagonists [27, 28]
2000 X-ray structure reported by Camphausen et al. [12]
14
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II. Introduction
II.1 General Introduction
Glycobiology
The classical role attributed to carbohydrates is that of a medium for energy storage and
transport. However, the two past decades have seen a Renaissance in carbohydrate
biology and chemistry with the emergence of the field of glycobiology [29]. New insights
have been gained on the enormous structural and functional diversity of this class of
compounds that are involved in living processes not only as energy sources, but also as
critical elements for the structure, function and dynamics of proteins [30].
Of the three main classes of biopolymers - proteins, nucleic acids and sugars - the
sugars, or saccharides, are the most complex and hence the most difficult to study.
Challenging scientists for decades, the numerous roles played by oligosaccharides and
glycoconjugates in biological recognition have nurtured vigorous investigation into the
molecular mechanisms of protein-carbohydrate association. The basis of these roles is
the information potential of oligosaccharides, which are composed of monomers having
more than one linkage position, and which are provided with stereospecific branching
capabilities at each of these positions. These capabilities allow sugars to be built in a
variety of linear or branched fashions. For example, two common sugars, Glu and Man,
can be linked to form a disaccharide in up to 80 different ways. It takes just a few
coupling steps to produce a large number of diverse biological structures, and this
diversity of saccharide structure is exploited in vivo.
A major challenge in cell biology is to identify the sugar code or “glycome” that is, to
define the interactions between cell-coating sugars and proteins and work out how they
recognize each other. The discipline of glycobiology has taken part in and will
undoubtedly contribute to our knowledge of the intricate workings of a vast array of
biological processes. As more and more carbohydrate-related drug-discovery targets are
unveiled and validated, the therapeutic potential of carbohydrates is just beginning to be
exploited by the pharmaceutical industry (Figure 2).
15
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Figure 2: Examples of actual carbohydrate-related drugs:
3: swainsonine mannosidase inhibitor cancer therapy
4: kanamycin B aminoglycoside antibiotic infection therapy
5: acarbose α-glycosidase inhibitor diabetes therapy
6: oseltamivir phosph. neuraminidase inhibitor anti-viral therapy
Interference with protein-carbohydrate interactions offers potential drug targets
Carbohydrate-protein interactions are characterized by notably weak binding [31].
However, cells can readily decode this information with the help of specific protein
receptors. In interfering with these interactions, high affinity mimetics of native
saccharides could modulate biological activity. These compounds have a tremendous
potential therapeutic value in the treatment of various pathologic states such as viral,
parasitic, mycoplasmal and bacterial infections as well as in inflammatory diseases and
in a range of human cancers [32]. Thus, the study of the intimate details of carbohydrate-
recognition by their receptors occupies a central place in carbohydrate chemistry and
biology.
Recent advances of effective methods for characterizing the complex carbohydrate
structures present on the surface of cells are the source of the new appreciation of the
varied biological functions of these molecules [29,33]. New methods for large-scale
syntheses of carbohydrates now allow the evaluation of these compounds’ potential as
pharmaceuticals. An outstanding example of the progresses that have taken place in this
field is the large-scale synthesis of the methyl glycoside of the smallest active segment
of heparin by Petitou, Sinaÿ  and van Boeckel at Organon/Sanofi-Synthelabo. The
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industrial synthesis consists of more than 50 chemical transformations towards the
desired pentasaccharide fondaxaparin (7) (Figure 3) [34,35].
Figure 3: Fondaxaparin (7) is the methyl glycoside of the smallest active segment of
heparin, today industrially synthesized in 61 steps.
The development of carbohydrate drugs has been beset with difficulties of both financial
and practical nature. Primarily, the methods needed to produce even small amounts of
complex carbohydrates are often difficult and expensive, whether they involve synthesis
or isolation from natural sources. Added complications include the low bioavailability of
orally ingested carbohydrates and the inability of many animal models to provide data
relevant to humans. Despite these drawbacks, there are many advantages in favor of
carbohydrate-based therapeutics, such as low toxicity and immunogenicity relative to
their peptide counterparts.
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Blocking the inflammatory process
Our research focuses on the selectin [1], a family of adhesion proteins, and their
glycoprotein ligands. The selectins are involved, along with the integrins and
immunoglobulin-like cell adhesion molecules, in the orderly migration of leukocytes to
sites of inflammation [3].
Figure 4: Leukocytes rolling on the surface of a blood vessel.
Regulated expression of adhesion and signaling molecules directs the recruitment of
leukocytes into lymphatic tissues or sites of inflammation [36]. The critical first event in
this multistep process is the adherence of circulating leukocytes to the vascular wall
under shear forces (Figure 4). Interactions of selectins with cell-surface carbohydrate
ligands initiate the tethering and rolling of leukocytes on endothelial cells, platelets, or
other leukocytes. Reversible multicellular interactions enable leukocytes to encounter
regionally expressed chemokines and lipid autacoids. The activated leukocytes then use
integrins to arrest on the vessel wall and to emigrate into the underlying tissues in
response to chemotactic gradients.
Although this influx normally represents an essential defense mechanism against
infection, excessive or inappropriate leukocyte accumulation results in injury to host
tissues [4]. Hence, control of the leukocyte-endothelial cell adhesion process is sought in
cases where excessive recruitment of leukocytes can contribute to acute and chronic
inflammatory diseases. In other words, inhibiting the interaction of selectins with their
natural or synthetic ligands has the potential to interrupt the inflammatory process and
thus should be beneficial to the treatment of inflammatory diseases. In addition to their
18
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role in the inflammation cascade, selectins are implicated in diverse disease states [4].
For instance, selectins play a role in the hematogenous metastasis of some cancer cells
[6,37]. Interfering with these interactions is a potential starting point for new cancer
therapies.
Figure 5: Selectin ligands contain the common carbohydrate epitope sLeX (1), which was
shown to interact with all three selectins, albeit with different affinities. The other
structures depicted here are sLea (8), LeX (9), and Lea (10).
Selectins antagonists are designed in analogy to a natural carbohydrate epitope
The physiological ligands of the selectins contain a common tetrasaccharide epitope, the
so-called sialyl LewisX (1) (Figure 5) [7,9,22]. It serves as the lead structure in the search
for selectin antagonists. Utilization of structural information about the selectins and their
interactions with sLeX (1)  has been revealed through the use of NMR spectroscopy
[38,39,40] protein X-ray crystallography [12,41] and molecular modeling [42,43].
This investigation is undertaken not only to elucidate the mechanism and the structural
properties of sLeX-selectin recognition. It is also aimed at predicting the 3-dimensional
structures of novel mimics to allow the discovery of therapeutic agents. Numerous
academic and industrial groups have searched for potent selectin antagonists [17,44]. All
these efforts have only partially reached their aims, as the best selectin antagonists
synthesized to date have still not led to therapeutic applications.
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Our group focuses on the development of antagonist of a particular type of selectin, the
E-selectin. The conformation of sLeX (1) bound to E-selectin, the so-called “bioactive
conformation” has been elucidated [26,38,39,40,45,46]. Use of this information was made to
develop a molecular modeling tool helping us to rationally design different classes of E-
selectin antagonists.
The presented work concerns one of these approaches, an attempt to rigidify the LeX (9)
core of the lead structure by a macrocyclic ring formation. Since conformational analyses
have shown that the macrocyclic structure perfectly mimics the bioactive conformation
[46] (Kolb & Ernst, unpublished results), its synthesis and biological evaluation would be
an important reference point for the validation of our molecular modeling tool. Higher
pre-organization of the sugar in its bioactive conformation is believed to lead to a better
affinity with E-selectin because of lower entropy cost.
II.3 State of the research
In the first instance, the following literature reviews provides a description of the nature
and biological significance of the selectins and that of their ligands.  The focus is then
brought on the specific interactions between E-selectin and its ligands. The methods
used to investigate these interactions are described. The developments that have led to
the selectin antagonists known to date are also outlined.
A particular attention is set on the history of selectin antagonists’ development in the
Novartis Selectin Antagonists group. Research in this group, in particular on macrocyclic
antagonists, has served as starting point to our work.  The last section hence allows a
seamless transition to our personal contribution to the field.
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II.3.1 The selectins and their ligands
Nature of the selectins
The selectins are type I membrane glycoproteins that mediate adhesion of leukocytes
and platelets on vascular surfaces. E-, P- and L- selectin were identified in the early 90s.
They are Ca2+-dependent carbohydrate-binding proteins [2].
L (leukocyte) selectin is expressed on most leukocytes. It binds to constitutively
expressed ligands on HEV of lymph nodes, to inducible ligands on endothelium at sites
of inflammation and to ligands on other leukocytes.
E (epithelium) selectin is transiently synthesized by cytokine-activated vascular
endothelium.
P (platelet) selectin, stored in membranes of secretory granules of platelets and
endothelial cells, is rapidly redistributed to the cell surface by thrombin and other
secretagogues. Some cytokines also increase the synthesis of P-selectin in endothelial
cells.
It has recently been shown that E- and P- selectins bind to ligands on myeloid cells and
subsets of lymphocytes, and P-selectin also binds to ligands on HEV of activated cells
[7].
The three selectins are transmembrane glycoproteins. Each selectin is composed of an
N-terminal lectin domain (CRD, Carbohydrate Recognition Domain), an epidermal
growth factor-like (EGF-like) domain, a variable number of complement regulatory-like
repeats, called the consensus repeat or complement regulatory-like (CR) domain, a
transmembrane domain, and a short cytoplasmic tail that may play a role in signal
transduction (Figures 6 & 7). The sLeX (1) binding site has been localized on the lectin
domain [47].
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Figure 6: Schematic representation of the selectins.
Figure 7: Structure of E-selectin.
Natural ligand
Since the initial characterization of the selectins in 1989, a number of ligands have been
identified [25]. Preceding the isolation of the naturally occurring glycoprotein that binds to
selectins, the carbohydrate portions of these ligands were being determined. Early
studies [21] proposed, upon the basis of transfection of a fucosyl transferase, that the
carbohydrate contained fucose. The composition of the carbohydrate was determined
using mass spectrometry [48]. In 1991, it was reported that sLeX  (1,
Neu5Acα2→3Galβ1→4[Fucα1→3]GlcNAc) recognizes E-selectin. SLea (8) and sugar
derivatives (at some level of modification such as sialylation or sulfation) of LeX (9) and
Lea (10) also bind to E-selectin (Figure 5) [21,49].
Hence, the tetrasaccharide sLeX (1) has been generally recognized as a common ligand
for all selectins [8,9]. This compound, together with related sialylated and fucosylated
carbohydrates, is the terminal component of glycans attached to proteins and lipids
located on the surfaces of most leukocytes and of some endothelial cells.
22
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The glycoprotein receptors bearing these carbohydrates were identified in 1994 as ESL-
1 [50], and PSGL-1.  However, the debate over the biologically relevant ligands (Figure 8)
for each of the selectins is still ongoing [25]. The carbohydrate portion of PSGL-1, a
natural ligand of E- and P-selectin, is a trimer of fucosylated GlcNAc groups with a
terminal sialyl group. Sulfation is required for binding to P-selectin, but not E-selectin. It
is relevant to note that P-selectin-mediated, but not E-selectin-mediated, leukocyte
rolling and recruitment are dramatically affected in mice genetically different in PSGL-1
[51]. This suggests that, in vivo, E-selectins effectively utilize other sLeX-modified
glycoconjugates on leukocytes, whereas P-selectins do not. The structure of the natural
ligand on GlyCAM-1 for L-selectin is less understood [25].
Figure 8: The physiological ligands of the three selectins have been isolated and their
structures partially elucidated (ESL-1, PSGL-1, GlyCam) [44].
,
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II.3.2 Biological significance
II.3.2.1 Biological role in the inflammation cascade [52,53]
Discovery from medical observations
The importance of selectins in humans is underscored by the discovery of a congenital
disorder of fucose metabolism termed leukocyte adhesion deficiency 2 (LAD-2) [54].
Because patients with LAD-2 lack fucosylated glycoconjugates, they do not express
functional selectin ligands. Leukocytes from these patients do not tether to and roll on P-
or E-selectin surfaces. Clinically, the patients have more infections, supporting the
concept that the selectins have an important function in initiating recruitment of
leukocytes. Furthermore, the importance of selectins in inflammation has been
experimentally demonstrated in selectin deficient mice. Mice made genetically deficient
in each of the three selectins have defects in leukocyte trafficking in response to specific
challenges [55].
The inflammatory cascade
Released by damaged tissue after an injury, chemical signals initiate and maintain a
host response designed to repair tissues and neutralize the hypothetic microbial
infection. This response involves activation and directed migration of leukocytes
(neutrophils, monocytes and eosinophils) from the venous system to sites of damage by
a complex series of steps, referred to as the inflammatory cascade (Figure 9). The five
important steps in the transfer of leukocytes from the blood stream to site of injury are:
Step 1: Stimulus
The cascade begins when releases cytokines that stimulate the endothelium to
transiently express two proteins: E- and P-selectin. Initial activation of E- and P-
selectins is a consequence of vessel wall exposure to locally produced chemokines and
other mediators (e.g. TNF-α, IL-1, LPS), the so-called inflammatory stimulus [56]. E- and
P-selectin are induced on the surface of vascular endothelium with different expression
kinetics [57]. P-selectin, which is also presented by activated platelets, is translocated
within minutes from intracellular stores and promotes the immediate attachment and
rapid rolling of leukocytes over vascular surfaces. In contrast, E-selectin is
transcriptionally regulated and appears on the activated only several hours (about 8h)
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after activation. For a detailed review of the regulation mechanisms for E-selectin, see
Chapter II.3.3.
Step 2: Attachment and rolling
Attachment (tethering) and subsequent rolling of leukocytes on the cell wall are
mediated by weak interactions between carbohydrate epitopes on the leukocytes and
the E- and P- selectins. The combined action of E- and P- selectins allows leukocyte to
slow down by rolling along the vascular endothelium.L-selectin is constitutively present
on the surface of leukocytes and binds to endothelial ligands (e.g. PSGL-1). These
processes are prerequisites for the adhesion step and are therefore essential to the
inflammatory process.
Step 3:  Secondary activation
Rolling of leukocytes enables the interaction of the vascular endothelium with cytokines
and leukocyte-activating molecules triggering signals that activate and upregulate
leukocyte integrins. Integrins, a group of three proteins sharing the same β-2 chain,
represent another class of leukocyte adhesion molecules that is essential to the
cascade.
Step 4:  Adhesion
Leukocyte rolling allows stronger interaction with the integrins (themselves the target for
chemotherapies). Immobilization of the slowed leukocytes on the surface of the vascular
endothelium is reached by tight adhesion of the integrins to their endothelial ligands
VCAM-1 and MadCAM-1. This step precedes the leukocyte extravasation into the
underlying tissue.
Step 5: Transendothelial migration
The transmigration through the endothelium (extravasation) to sites of injury is
presumably facilitated by extracellular proteases, such as matrix metalloproteinases
(MMPs).
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Figure 9: The inflammation cascade:
- Endothelium activation
- Selectin-mediated capture & rolling
- Secondary activation during slow rolling phase
- Integrin-mediated firm adhesion
- Transmigration
II.3.2.2 Selectins and myocardial ischemia reperfusion (MIR)
Selectins have been extensively investigated in myocardial ischemia/reperfusion (MIR)
injury states. When ischemia provokes the loss of endothelium-derived NO, a rapid
endothelial dysfunction occurs. 10 to 20 min after the subsequent reperfusion, an up-
regulation of P-selectin on the endothelial surface of the affected area is observed. This
leads to increased adhesion of neutrophils to the dysfunctional selectin up-regulated
epithelium. This can result in severe tissue damage. This process is believed to involve
L-, E- and P- selectin. However, in contrast to P- and L- selectin, E-selectin does not
appear to play a major role during the first 4 h post reperfusion [58].
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II.3.2.3 Biological role in cancer-related events
Recent data have expanded the concept that inflammation is a critical component of
tumor progression [59]. Many cancers arise from sites of infection, chronic irritation and
inflammation. It is now becoming clear that the tumor microenvironment, which is largely
orchestrated by inflammatory cells, is an indispensable participant in the neoplastic
process, fostering proliferation, survival and migration. In addition, tumor cells have co-
opted some of the signaling molecules of the innate immune system, such as selectins,
chemokines and their receptors for invasion, migration and metastasis. Hence,
mechanisms used for homing of leukocytes may be appropriated for the dissemination of
tumors via the bloodstream and lymphatics. Experimental data support the implication of
selectins in metastatic processes:
Metastatic progression of many epithelial carcinomas correlates with tumor production of
mucins containing sLeX (1). Lung colonization by melanoma cells that express sLeX (1) is
significantly reduced in E/P-selectin deficient mice. P-selectin deficiency attenuates
tumor growth and metastasis, and tumors are significantly smaller in mice treated with a
receptor antagonist peptide [60, 61]. P-selectin facilitates human carcinoma metastasis in
immunodeficient mice by mediating early interactions of platelets with blood-borne tumor
cells via their cell-surface mucins, a process that can be blocked by heparin. L-selectin
on neutrophils, monocytes and/or NK cells also may facilitate metastasis. Metastasis
could involve the formation of tumor-platelet-leukocyte emboli that interact with the
vasculature of distant organs. In addition, the expression of L-selectin on tumor cells can
foster metastasis to lymph nodes [62,63].
These results indicate that receptors expressed in the vasculature are crucial in targeting
sLeX-dependent cancer cells.  These insights are fostering new anti-inflammatory
therapeutic approaches to cancer development.
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II.3.3 E-selectin regulation
The following section describes the cycle of E-selectin from their expression at the
surface of the vascular endothelium, triggered by specific mediators [64], to their
degradation [52,53]. The expression of E-selectin is highly regulated. The regulatory
pathway involves a specific stimulus, which acts on a region upstream of the coding
region of E-selectin gene, exerting transcription [65,66,67].
Stimulus
Transcription of the E-selectin gene is undetectable in uninduced HUVEC. However,
when these cells are treated with IL-1-β, gene expression increases rapidly within about
30 min., reaches maximal level after 2-4 hours, and then returns to near-basal level
activity at about 24 hours. In addition, TNF-α, LPS, thrombin, IL-3, phorbol esters, and
oxygen radicals also can induce E-selectin expression. The expression of E-selectin on
endothelial cells can be lengthened when these cells are treated with a combination of
IFN-γ and TNF-α. Dexamethasone and 3-deazaadenosine, two anti-inflammatory
agents, may also inhibit the induction of E-selectin by thrombin and LPS. Furthermore,
an increase of cAMP levels in endothelial cells decreases E-selectin expression. Studies
have shown that the cAMP repression of E-selectin occurs at the transcription level and
is abolished by protein kinase A inhibition. Thus, this suggests that the repression of E-
selectin be mediated by a protein kinase A-driven phosphorylation [68,69].
E-selectin gene
Information regarding the regulated expression of E-selectin has been obtained by
sequencing a 1.5 kb fragment containing the 5‘ end of E-selectin gene. Two introns
interrupt the 5‘-untranslated region and the coding region. RNA polymerase II promoter
and enhancer region (CAAT and TATA boxes respectively) are also present.
Furthermore, there is a consensus sequence for NFkB binding site 27 nucleotides
upstream of the CAAT box(promoter). (NFkB is a transcription factor that is involved in
cytokine-induced expression of many genes whose protein products are involved in the
immune and inflammatory responses). In addition, there is a palindromic sequence,
which may serve as a potential DNA binding motif that is located 119 nucleotides
upstream of the NFkB binding sequence. Mutagenesis has been used to demonstrate
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that the region which lies between –223 and –117 nb on the gene is important for the
induction of E-selectin expression by IL-1 [70].
Transcription
The cell-specific and the stimulus-specific induction of E-selectin expression suggest
that the regulation of E-selectin involve complex mechanisms. One mechanism occurs at
the transcriptional level. A transcription factor binds to the NFkB sequence and is
important in the transcriptional activation of the E-selectin gene. This factor specifically
binds the NFkB consensus sequence of the gene when HUVEC are treated with TNF-α,
IL-1, or LPS, but not IL-2, IL-4, IL-6, IFN-γ, histamine, or transforming growth factor-β.
Although, the NFkB transcription factor is essential, it is not sufficient for the cytokine
induction of E-selectin expression [71]. Induction of E-selectin gene activity was also
shown to be mediated by at least two additional complexes. One is referred as NF-
ELAM1 and the other NF-ELAM2. These proteins bind to the promoter at position -154
to -147 nb and -104 to -100 nb, respectively. Although the identity of these proteins has
not been established, it has been shown that a single transcription factor is insufficient to
mediate the induction of E-selectin expression by cytokines. Further work has identified
two additional NFkB sites. They are adjacent to each other, within the E-selectin gene
promoter. Mutagenesis and DNA binding assays also showed that binding of these
factors to the 5'-untranslated of the E-selectin gene is essential for maximal promoter
activity in response to cytokines [72].
E-selectin degradation
In an experiment [73], endothelial cells were induced to express E-selectin by IL-1
treatment for 4 hours and fluorescence-labeled anti-selectin antibody was used to
monitor E-selectin expression. E-selectin was endocytosed and could be detected in
lysosomes 4 hours after it was internalized. 18 hours after endocytosis very little labeling
with anti-selectin could be detected. Antibody labeling was prolonged in cells treated
with a compound that modifies lysosomal pH and leads to reduce protein degradation. In
these cells, E-selectin was detected in large, heterogeneous vacuoles. Thus,
degradation of cell-surface E-selectin takes place by endocytosis and proteolysis in
lysosomes after internalization.
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II.3.4 Therapeutic applications of selectin antagonists
Roles played by selectins in many diseases
The critical role of the selectins in normal and diseases states has been emphasized in
the three precedent chapters. In a productive immune response, leukocyte accumulation
leads to seclusion of infection. However, overzealous transfer of leukocytes causes
widespread tissue damage leading to several disease states such as reperfusion injury,
cardiovascular and allergic diseases. These observations make the development of
selectin antagonists an attractive therapeutic target. Hence, the known biology of the
selectins suggests that inhibition of the selectin-sLeX has the potential to be an effective
approach for treating a variety of states such as [4]:
• Acute allergy-related diseases: stroke, reperfusion injury during myocardial
infarction, organ transplantation, and traumatic shock.
• Chronic allergic diseases such as bronchial asthma, rhinitis, psoriasis and
rheumatoid arthritis.
• Cardiovascular diseases such as arteriosclerosis and peripheral vascular disease.
• Cancer metastasis (Chapter II.3.2).
Attempts with novel therapies and related problems
Use of sLeX (1) itself as a drug candidate has proven to be unsuccessful [44]. The search
for an orally administered selectin-based prophylactic type treatment for inflammation is
still ongoing. Cytel, a U.S.-based company, has sustained a failure in phase III of a
pentasaccharidic compound intended to treat reperfusion injuries. The likely reasons for
the failure are low bioavailability, poor stability to degradative enzymes as well as low
biological affinity.
Need to reduce the carbohydrate character of the antagonists
Like other carbohydrates, sLeX (1)  and its analogs seem to suffer from poor
pharmacokinetic properties, low binding affinity, poor stability in vivo, and complexity of
synthesis. These characteristics represent a major obstacle in the development of novel
compounds.
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II.3.5 A biophysical approach to selectin-mediated neutrophil rolling
The interactions are of dynamic nature
Interactions of selectins with their ligands result in a dramatic decrease in leukocytes‘
velocity, which allows integrins to foster their firm attachment to the endothelium. All
three types of selectins are capable of mediating leukocyte rolling in vitro. However,
neither selectins nor integrins are sufficient by themselves to mediate firm attachment.
Selectins alone slow, but do not completely halt speeding leukocytes, whereas integrins
alone cannot bring about the necessary initial reduction in velocity [74].
SLeX binds to E-selectin with low-affinity (KD of 0.5 mM) 
[17]. However, the strength of the
bonds formed between selectins and their ligands must counteract the physical forces,
which tend to keep the leukocytes in motion. The rates of bond formation (kon) and
breakage (koff), which describe the dynamic nature of leukocyte rolling, are more
informative than affinity constants that describe an equilibrium condition that is not
attained [75,76].
An important consequence of this observation is the need for dynamic assays for the
characterization of sLeX mimics’ binding affinities.  Indeed, static assays like ELISA miss
critical information regarding the dynamic component of sLeX-selectins interactions.
Kinetic considerations- Association/Dissociation requirements (kon/koff)
Requirements for cell adhesion under laminar shear stress are particularly demanding.
To tether to a surface, a free-flowing leukocyte must form adhesive bonds very rapidly.
For the cell to roll, these bonds must dissociate quickly at the trailing edge of the cell as
new bonds form at the leading edge. The adhesive bonds must also resist premature
dissociation by the forces applied to the bond. Otherwise, the cell would immediately
detach into the fluid stream. The biochemical and biophysical features of selectin-ligand
interactions have evolved to meet these specialized requirements. In other words,
leukocyte rolling requires that the forward rate of reaction kon between selectin and
ligand be relatively fast. The reaction could not otherwise occur because of leukocytes'
velocity. The backward rate koff must strike a balance between promoting adhesion and
maintaining cellular integrity. A too slow rate of dissociation could cause loss of the
molecules involved in bond formation. Computer studies [77] suggest that the forward rate
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is the more important of the two rates. A key parameter influencing reaction rate is the
diffusion of the reactants. Selectins, with their series of consensus repeats, have
significant flexibility, which enhances their diffusibility. Several selectin ligands contain
many mucin domains, which are characterized by abundant oligosaccharides presented
on a polypeptide backbone that extends far out into the extracellular region. This
arrangement is conductive to fast reactions. Thus, clustering of selectins or their ligands
may regulate leukocyte adhesion under flow.
Another observation directly concerns the development of our macrocyclic antagonist 2
(Figure 1). Indeed, emphasis has been given on the kon-koff problematic for the design of
our compound. The high pre-organization is believed to increase the kon, which is
important because, as we have seen, not only the static affinity, but also the dynamic
affinity play a critical role in the interactions. Furthermore, the presence of a lipophilic
group in the target molecule is thought to reduce the koff. A too large affinity with water
would have been negative for the dynamic component, because it would have increased
the Kofff. In another study, Vestweber et al. 
[78] demonstrated that the affinity of the E-
selectin-ESL-1 interaction did not change significantly when the temperature was varied
from 5° C to 3° C, indicating that the enthalpic contribution to the binding is small at
physiological temperatures, and that, in contrast to typical protein-carbohydrate
interactions, binding is driven primarily by favorable entropic changes. This observation
would speak in favor of our intention to block the configuration of our macrocycle 2 to
increase the affinity.
Rolling velocities  - Shear stress requirements
Rolling velocities depend on factors such as shear stress, hydrodynamic velocity, and
selectin/ligand density. Typical values for velocity range from <2-15 µm/s [75].  Shear
stress is expressed in dynes/cm2 (a dyne is equal to 10-5 Newtons). Physiologically
relevant shear stresses, such as these may be found in post-capillary venules where
they range from approximately 1 to 10 dynes/cm2. Increases in shear stress are
correlated in a linear fashion with increases in rolling velocity, but beyond a certain shear
stress the velocity reaches a plateau, and further increases result in a complete lack of
rolling. The hydrodynamic velocity is the velocity of the bulk solution.  This value varies
depending on the distance from the vessel wall. The higher velocities occur in the center
of the vessel, and the lowest occur adjacent to the wall. Shear stress should be
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sufficiently low. The inflammatory response involves dilation of blood vessels, which
reduces the hydrodynamic velocity and therefore the shear stress. Small increases in
vessel diameter can cause significant reductions in shear stress, thus facilitating
selectin-mediated rolling. However, experiment also shows that shear stress should be
sufficiently high: the duration of the tethers is very short (≤2 s). It was shown that
physiological shear forces do not significantly decrease tether duration, suggesting that
the bonds have tensile strength that resists dissociation by applied force.
We have seen that the transient nature of selectin-ligand bonds requires that leukocytes
be perfused at or above a minimum shear stress if they are to roll. Shear stress allows
the cell to rotate so that new bonds form to replace those that dissociate, and increased
shear may also enhance the rate at which new bonds form. If shear stress is too low, the
cell does not roll, but instead detaches from the surface.
Instantaneous velocities of rolling leukocytes are highly variable. Large variances might
result from inherently stochastic receptor/ligand interactions (a stochastic process
involves randomness in successive observations), from topological heterogeneity in
receptor/ligand distribution, or from variations in shear stress.
Selectin density
Leukocytes perfused over very low densities (the number of selectins per unit area) of
immobilized P-, E- or L-selectin ligand form transient tethers that do not convert to rolling
adhesions [74,79]. The number of tethers is linearly related to the selectin or selectin ligand
density, suggesting that the transient tethers represent quantal units, or single selectin-
ligand bonds. Rolling velocities are lower for E- than P-selectin at comparable densities.
Also, variance in the rolling velocity is greater for P- than E-selectin. Both observations
are consistent with the idea that E-selectin forms a greater number of bonds.
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II.3.6 Structural determination
A complete knowledge of selectins’ biology requires a comprehensive understanding of
the 3D structure of these proteins, of their carbohydrate ligands and of their complex.
Many methods have been used towards these goals:
- Structure determination using protein crystallography and multi-dimensional NMR
methods.
- Binding studies of modified sLeX (1) analogues.
- Theoretical models of binding complex before X-ray structure were available.
- Binding complex structure solved using X-ray crystallography.
This chapter reviews these structural analysis methods.  We wished to present not only
the most up-to-date data on the E-selectin-sLeX complex, but also the step-by-step
process that led to this knowledge.
II.3.6.1 Structure of the ligand-recognition domain of E-selectin
The main sLeX (1) binding-site has been localized on the lectin domain (CRD,
Carbohydrate Recognition Domain). The whole design efforts that have been published
to date are directed towards antagonists that bind to this domain.
Studies with selectin constructs in which the EGF-like domain and/or CR domain have
been deleted, switched, or mutated, suggest that these domains may contribute to ligand
recognition [3]. But in the case of E-selectin, the data is conflicting. The EGF region is
believed to exert its effect by holding portions of the lectin domain in the proper
conformation. However, in a binding study, a truncated form of E-selectin consisting of
the lectin and the epidermal growth factor domain only (E-selectin lec-EGF), was shown
to be fully active [80]. Thus, the roles of the EGF and CR domains in ligand binding
remain unclear.
The CRD is a globular structure that recognizes its ligands in a shallow depression that
contains a Ca2+ ion and its primary sequence is about 80% homologous to another
structurally characterized sugar protein, the mannose binding protein (MBP) [81].
However, as soon as the first crystal structure of the CRD domain of E-selectin has been
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available in 1994 [41], it was apparent that the lectin domain of E-selectin has some
important differences.
II.3.6.2 Structure and conformation of the carbohydrate epitope
Conformation studies of sLeX (1) in solution and bound to the receptor are vital
information for the subsequent development of selectin antagonists.
Synthetic studies of sLeX (1)
The required synthetic technology for studying the structural features necessary for
selectin binding and for the subsequent preparation of analogue structures has been
made available through initial synthetic studies targeting the sLeX (1) structure itself. Not
only must the synthesis afford suitable quantities of sLeX (1) in a minimum of synthetic
operations, but it also must accommodate considerable structural variation to allow the
preparation of analogue structures.
Chemical synthesis
The first synthesis of sLeX (1) was reported in 1991 [23]. Despite the availability of
effective glycosylation methodology, chemical synthesis generally suffers from the need
to employ selectively protected sugars to control the position of bond formation and
therefore large-scale synthesis becomes increasingly more expensive.
Chemoenzymatic synthesis
The problem has been addressed through the application of enzymatic methodology to
oligosaccharide synthesis [82]. Isotopically labeled sLeX (1) has been prepared by utilizing
UDP-1-13C-Gal with these procedures.
Conformation studies of sLeX (1) using NMR spectroscopy
Labeled and unlabeled structures have proven useful for NMR studies to gain important
conformational information.
Conformation in solution
Early work in this area was aimed at defining the conformation of sLex (1) in solution.
Three independent studies reported conformations that were in general agreement,
suggesting a single conformation in solution [17]. However, subsequent NMR and
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molecular dynamics studies of sLeX (1) in solution indicated that the Gal-NeuAc linkage
was flexible, opening the possibility that sLex (1) exists as an ensemble of low energy
conformations in solution [26,42,83]. Poppe et al. found evidence that the Gal-NeuAc
linkage samples three different conformations, but that data suggested that the other
glycosidic linkages was in single conformations [38].
Homans et al. [40] reinvestigated the conformation of sLeX (1) in solution using 13C-
enriched sLeX (1)  and ROESY-HSQC experiments, These experiments allowed for the
determination of a much greater number of conformational restraints than had previously
been determined. Molecular dynamics (MD) simulations suggest that the three glycosidic
linkages are much more flexible than previously thought. During the course of the short
simulation, a second conformation of sLeX (1) was accessed for a significant amount of
time, indicative of the flexibility of the linkages.
The presence of multiple conformations as well as observation of other receptor-ligand
complexes suggests that only one of these conformations is bioactive. This point is
essential, because the more flexible the molecule, the larger the entropic gain for an
antagonist that is locked in the bioactive conformation.
Bound (bioactive) conformation
The bioactive conformation of sLeX (1) has been determined by NMR and applied for the
rational design of selectin antagonists [26,38,40,45,46].
Cooke et al. utilized differences in the trNOEs of sLeX (1) bound and unbound E-selectin
to study the complex [26]. They suggested that the bound conformation of sLex (1) was
not the same as the unbound conformation of sLeX (1). Hensley et al. reported just the
opposite that the bound conformation of sLeX (1) was identical to the solution
conformation of sLeX (1) [84]. This finding was disputed by Scheffler et al., who obtained
similar results to that of Cooke [39,45] with more extensive NOESY experiments. Poppe et
al. published data [38] on the conformation of sLeX (1) bound to E- and P-selectin. The
bound conformation of sLeX (1) is comparable in both cases, though the largest
difference is in the Gal-NeuAc linkage, which is the most flexible glycosidic linkage in
solution. These results differed from those of Scheffler et al. in the conformation about
Fuc-GlcNAc linkage [44].
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Here also, 3D NOESY-HSQC experiments using 13C-enriched sLeX (1) have permitted to
determine the bound conformation of sLeX (1) bound to E-selectin [40].  This structure of
bound sLeX (1) has differences from that of Scheffler in the galactosyl-sialyl linkage and
that of Poppe in the Fuc-GlcNAc linkage.
Figure 10: Representation of sLeX (1) in the bioactive conformation.
Conclusion
Stable unbound and E-selectin-bound conformations of sLeX (1) differ mainly in the
orientation of the NeuNAc residue [26]. The estimated energy difference between these
conformations is approximately 1.5 kcal/mol. The differences observed between the free
conformation and the conformation of sLeX (1) bound to selectins represent the rationale
for the development of conformationally blocked molecules. Indeed, an antagonist pre-
organized in the bioactive conformation is believed to possess a higher affinity due to
favorable entropic contribution than its torsionally free counterpart.
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II.3.6.3 Structure of the selectin-ligand complex
Structural information about selectins and their interactions with sLex (1)
Like all C-type lectins, selectins bind to carbohydrate ligands in a Ca2+-dependent
manner. Selectins bind selectively, but with low affinity, to sLeX-related ligands. L- and P-
selectin, but not E-selectin, also bind to particular sulfated carbohydrates, such as
heparan sulfate that lack NeuAc and Fuc. Although the selectins bind to many sialylated,
fucosylated, and/or sulfated glycans, they bind with higher affinity or avidity to only a few
appropriately modified glycoproteins on blood or vascular cells.
Different models have been elaborated to investigate E-selectin-sLeX interactions before
X-ray data of the complex were available. However, none of these models could
correctly predict all these interactions, and therefore, represent the actual binding mode.
The major differences between the models and the X-ray structure of the complex are
highlighted in this section. The discrepancies observed are intriguing when we realize
that generations of selectin antagonists are based on these models.
A binding model based on mutagenesis studies was published in 1992 [47]. At that time,
the structure of E-selectin was unknown, and the model used was based on the recently
determined crystal structure of mannose binding protein (MBP) [81]. Mutagenesis data
indicated that five residues were critical for binding sLex (1) (Arg-97, Lys-111, Lys-113,
Ser-47 and Lys-99), and the proposed model indicated that these residues were
clustered at the surface of the protein.
A historically important model [85] proposed by Kogan et al. (Scheme 1) is based on NMR
and X-ray spectroscopy data of E-selectin. At the time of publication, the actual structure
of E-selectin had been determined (non-bounded conformation) by X-ray crystallography
[41]. trNOEs NMR were used to demonstrate the conformational change between the free
and bound conformation of sLeX (1)  [26].
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Scheme 1: Model proposed by Kogan et al. [85]
Model implying the reverse docking-mode
This model is named reverse docking mode (Scheme 2) in opposition to the “normal”
docking modes. Indeed, unlike the models that represent the Fuc interacting with the
calcium ion, the reverse docking mode shows the acid interacting with the ion. Reverse
docking could be an alternative binding mode that actually takes place. This mode could
be favored when the ligands hold aromatic substituents.
Hayashi and co-workers [86] have investigated derivatives of sLeX (1) in which the
reducing carbon contains hydrophobic tails, and derivatives in which the Ac group of the
GlcNAc residue has been replaced with other N-acyl groups. They found that N-naphtoyl
groups increase binding affinities by almost 10-fold over that of N-Ac [20]. Computational
work identified a potential role of hydrophobic groups: chains appear to fit into a
hydrophobic cleft running down the side of the selectins.
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Scheme 2: Representation of the reverse docking mode (Ernst, unpublished results).
X-ray crystallography - Insight into the real binding interactions
The more recently determined X-ray crystal structure of human Lec-EGF selectin with
sLeX (1) [12] has provided new insight into the nature of the interactions  (Scheme 3). The
structure of the sLeX (1) complex reveal that the interactions are almost entirely
electrostatic in nature, and the total buried surface is small (549 Å2 in Lec-EGF) when
compared to the size of the free ligand. Moreover, the selectin-bound Ca2+ ion is ligated
by the 3- and 4- OH groups of the Fuc residue within sLeX (1).
As already stated in the last section, this arrangement is in sharp contrast to proposed
models of selectin/sLeX interactions that predict Fuc ligation to the 2- and 3- OH groups
based on the structure of the homologous rat MBP complexed with oligomannose [87].
The 3- and 4- OH groups of the Fuc must provide a large amount of the sLeX (1) binding
energy. They not only coordinate the bound Ca2+, but also form hydrogen bonds with
selectin residues that are also involved in Ca2+ coordination.
- The Fuc 3-OH group of sLex (1) replaces precisely a Ca2+-ligated water molecule
observed in the unliganded structures and hydrogen bonds to Asn-82 and Glu-80.
- The Fuc 4-OH group displaces another Ca2+-coordinated water molecule, although
its final position is now one Å closer to Asn-105, to which it hydrogen bonds.
-
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In the Lec-EGF/sLeX complex, Asn-83 rotates its X2 torsion angle to 59°, so that it now
builds a hydrogen bond with a water molecule that in turn builds hydrogen bonds with
the Fuc 2- and 3-OH groups and Glu-107. This rotation also allows the Asn-83 side
chain to coordinate the calcium. In the Lec-EGF/sLeX complex, the sLeX-Gal residue
hydrogen bonds to Tyr-94 and Glu-92. The carboxylate group of NeuNAc hydrogen
bounds to Tyr-48 [12].
An extensive set of interactions is observed within the Lec-EGF/sLeX complex facilitated
by a change in conformation of this sugar residue. The positioning of NeuNAc within the
P-selectin/sLeX complex would make unfavorable contacts with Arg-99 in Lec-EGF/sLeX,
and so moves further back to allow for better interactions. In this arrangement, Arg-97
hydrogen bonds to the glycosidic oxygen and the carboxylate group of NeuNAc. These
differences, combined with differences in Fuc binding, appear to be the structural basis
for the relatively high affinity E-selectin/sLeX interaction.
Scheme 3: A scheme depicting the interactions between sLeX (1), E-selectin and the
bound Ca2+.
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II.4 Design of selectins antagonists
Many analogs and mimetics of sLeX (1)  have been designed and synthesized
For about a decade, academic and industrial research groups have aimed at developing
therapeutic agents based upon inhibition of the E-selectin-sLeX binding event [17,44]. Use
of information on the structural characteristics of sLeX (1) binding has been made to
search for alternative structures that exhibit stronger binding to selectins than the natural
ligand [88], as well as simplified structure and improved bioavailaybility.
Most groups have attempted to substitute of sugars in sLeX (1) with other moieties such
that the key interactions are retained. With the identification of the pharmacophores
(residues critical for binding), efforts have focused on removing one or more sugars from
the tetrasaccharide and replacing it with a variety of more stable linkers. Along this
process, we have to keep in mind that sometimes-wrong models have been used to
synthesize antagonists. Highlights of these approaches can be summarized as follows:
- The structure-activity relationship (SAR) study for the lead structure sLeX (1).
The synthesis of analogues incorporating functional group deletions and modificat
ions has been an invaluable method for gaining detailed SAR information [11,24].
- A relatively systematic reductionist approach was performed. Each novel
generation of E-selectin antagonists witnesses a drive towards simpler molecules,
with a progressive abandon of the undesired carbohydrate properties.
II.4.1 Pharmacophores
Systematic identification of the functional groups
Identification of the residues critical for sLeX (1) binding to the selectins illustrates an
important aspect of contemporary organic synthesis. Modern spectroscopic techniques
lend limited insight into the relative importance of different structural features of the
molecule, except in cases where the receptor-ligand complex can be determined. As X-
ray structure is only available since 2000 [12], synthesis of analogues incorporating
functional group deletions and modifications was used to gain information on the SAR-
relationships. Systematic replacement of the functional groups (OH, COO-, or Me) with
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H, followed by affinity evaluation led to the determination of the relative contributions that
these groups make to binding and to the construction of a “functional group map” [10]. For
sLeX (1) binding to E- and L-selectins, all three OH groups of the Fuc, the 2- and 6-OH
groups of the Gal, and the carboxylate of the NeuNAc acid are necessary (see Figure
14). The GlcNAc residue does not play a critical role in these interactions, but is believed
to be important for preorganizing the residues of the tetrasaccharide (1) [89].
Figure 11: Representation of sLeX (1) and its pharmacophores.
II.4.2 Selectin antagonists
The following overview should provide the reader with examples of selectin antagonists
that have been synthesized to date [44].
Trisaccharide mimics - Utility of NeuNAc and its replacement possibilities
The NeuNAc moiety has four substituents - a glycerol sidechain, one hydroxyl, a
carboxylate, and an amide - that can potentially interact with the selectins upon binding.
Most of the substituents have been studied:
• Modifications of the glycerol sidechain resulted in no notable effect on binding to
E-selectin [10,24].
• Removal of the N-Ac group has little effect on binding [24].
• Replacement of the carboxylate by different charged groups resulted in similarly
active molecules [11,24].
Thus, literature shows evidence that the costly NeuNAc sugar can advantageously be
replaced by anionic moieties in sLeX (1) mimics. For instance, sulfated LeX trisaccharide
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11 (Figure 12) does exist, as a natural analog of sLeX (1), and shows superior binding to
E-selectin. One of the most straightforward substitutions of sLeX (1) replaces NeuNAc by
a negatively charged group on the 3-OH of Gal. Several groups replaced NeuNAc by a
sulfate group [24,90]. Affinity for E-selectin has been reported for sulfated Lea
trisaccharides 12 and 13 where GlcNAc has been replaced by glucose. Compounds
sometimes showed selective activity for one selectin. The 1-deoxy-3’-O-sulfo LeX
analogs 14 to 16 were found to be less potent than sLeX (1) in the E-selectin assay but
showed increased potency against P-selectin in a competitive binding assay. Mimics of
sLeX (1) that bear phosphate groups on the 3-OH of Gal and show binding affinities
similar to sLeX (1) have been generated [11]. The 3’-O’-phospho Lea analog 17 was found
to be 20-time more active than the 3’-sulfo LeX derivative against E-selectin in a static
essay [91].
Figure 12: Replacements of NeuNAc.
Alkylation of the Gal-3-OH with glycolic acid derivatives represent the most frequently
used NeuNAc replacement (Figure 13: 18 , 19 ) [17]. The 3-carboxymethyl substituted
analog 18 has similar antagonist affinity as sLeX (1). A more rigid NeuNAc mimic was
also used [18]: in compound 19, the carboxylic acid is fixed in the equatorial position of a
six-membered acetal to mimic the solution phase conformation of sLeX (1). As predicted,
19 was found to be inactive in an E-selectin assay. To date, the relationship between
these groups’ acidities and binding affinities has not been addressed rigorously.
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Figure 13: Substitution of NeuNAc by glycolic (→18) and lactic acid derivatives  (→19).
Interestingly, when lactic acid derivatives were used to build rigid NeuNAc mimics, they
proved to be very active E-selectin inhibitors [18,92]. For instance, one of the prepared 1,2-
deoxyglucose derivatives 20 (Figure 14) was 30 times more potent than sLeX (1) in a
static E-selectin essay. In this compound NeuNAc is replaced by a cyclohexyl lactic acid
moiety.
Figure 14: An active sLeX (1) analog synthesized by Thoma et al. [18]
Compounds have been synthesized where the GlcNAc has been replaced with other
moieties, leaving the three other sugar units intact [17]. When Hanessian et al. replaced
GlcNAc with an indolizidinone unit, the activity of 21 against E-selectin disappeared but
the compound was more active than sLeX (1) in the P-selectin assay [93]. When quinic
acid was chosen to replace GlcNAc in 22, the compound showed the same activity as
sLeX (1). 23, in which GlcNAc is substituted with a trans-1,2-cyclohexanediol unit, is
three times more potent than sLeX (1) in E- and P- selectin essays.
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Figure 15: Replacements GlcNAc.
To sum up, the mimics with three sugar units generally possess comparable or better
activities than sLeX (1). They also allow avoiding costly use of NeuNAc. This observation
has been important in the design of our target molecule, as we have replaced NeuNAc
by a L-cyclohexyl lactic acid moiety in our compound. In general, the tetrasaccharidic
mimics still exhibit similar problems as sLeX (1): cost, stability, and rapid metabolism. It is
therefore important to consider further simplifications.
Mimics containing 2 sugars
The last section showed that a carboxylate moiety on the 3-position of Gal can
adequately mimic NeuNAc. The next steps in the simplification process of sLeX (1) are to
replace the GlcNAc and/or the Gal moiety. Another approach is to replace the Gal-β(1-4)-
GlcNAc disaccharide core with a linker that will position NeuNAc and Fuc in a spatially
similar arrangement as sLeX (1).
Substitution of the GlcNAc moiety
The GlcNAc moiety has three substituents (two OHs and an amide) that can potentially
interact with the selectins on binding. Most studies have suggested that while the
GlcNAc contains none of the functional groups critical for binding, it is likely to be
important for preorganizing the sLeX (1) tetrasaccharide [17]. Thus, the GlcNAc unit was
thought to be merely a linker between Fuc and Gal. Attempts at simplifying the sLeX (1)
structure by replacing GlcNAc with moieties that will preserve the core conformation of
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sLeX (1) were undertaken [16,28]. The mimics contained either carboxymethyl or alkylated
carboxymethyl as NeuNAc surrogates. Simple two-carbon tethers were used to link Gal
and Fuc: ethylene glycol, butane, cis-olefin, and epoxide (Figure 16: 23, 25). The low
activity of these compounds was attributed to their conformational flexibility.
Figure 16: Disaccharide mimics.
Compounds with 1,2-diols used as glucose mimic and a carboxymethyl unit serving as
NeuNAc replacement were synthesized. The diols 24 contain diverse functional groups
and different levels of torsional constraint [89]. In this series, only compound 24 b where a
rigid cyclohexanediol was used was found to be equipotent to sLeX (1) in the E-selectin
assay although most diverse disaccharide mimics were synthesized. In these, the
GlcNAc unit was for instance unsuccessfully replaced by quinic acid 26  or by a
indolizidinone-type template 28 (Figures 17/18) [93]. However, these molecules show only
low levels of inhibition. Of all the replacements for GlcNAc, the cyclohexyl group appears
to best mimic both the shape and rigidity of the pyranose ring. Surprisingly, ethandiol is
almost equally effective. However, the difference between these groups becomes more
pronounced in derivatives in which Gal has also been substituted.
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Figure 17: Disaccharide mimics (suite).
The linking group chosen to replace GlcNAc rarely improves the binding constant. The
most effective mimics for E-selectin of this class were reported by Kolb and Ernst [94,104].
The molecules (e.g. 27, Figure 20) incorporate a novel alkylated derivative of the
“CH2COO
-“ mimic for NeuNAc, and binds with up to 12-fold higher affinity than sLeX (1).
In this potent series, GlcNAc is replaced with R,R-cyclohexanediol and NeuNAc with L-
cyclohexyl lactic acid.
Figure 18: Hanessian’s indolizidinone-based mimetic 28.
Substitution of the Gal moiety
The Gal moiety of sLeX (1) has three OH substituents that can potentially interact with
the selectins upon binding. Stahl et al. [136] examined the role of the 4- and 6-OHs by
synthesizing deoxy-sLeX analogues where the OH was replaced by hydrogen and, in the
case of the 4-OH, by fluorine. The analogues all bound more weakly to E-selectin than
sLeX (1), suggesting that these substituents are important but not crucial to binding.
Several compounds modified at the 6-position were synthesized without showing any
activity. A study [15] has been published on the modification of the 6-OH of the Gal moiety
in two sLeX (1) mimetics, which had better IC50s than sLe
X (1) for E-selectin. Diverse sets
of substituents were employed but all compouds mimetics were inactive. It was
suggested that the Gal 6-OH is optimal. One factor that could contribute to the poor
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potency of the rigid linkers is the lack of functionalities that imitate the 4- and 6-OH of
Gal, which are also necessary for activity.
Replacement of Gal-β(1-4)-GlcNAc by a linker
Another approach taken for building disacharides has been to replace the Gal-GlcNAc
disacharide core with a linker that will position NeuNAc and Fuc in a spatially similar
arrangement as sLeX (1) [17].
Figure 19: Replacement of the Gal-β (1-4)-GlcNAc core by a linker.
Some of the spacers used were flexible alkyl chains. In this class of compound, where
the expensive NeuNAc moiety is kept, the unfunctionalized flexible linkers have shown
low biological activity. A reasonable explanation is that the entropic penalty resulting
from the extreme flexibility of a simple saturated spacer is the reason for the lack of
activity. However, use of a rigid benzenedimethanol 29d/e (Figure 19) moiety resulted in
compounds that were 20-fold less active than sLeX (1) in a static E-selectin assay [17].
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The use of an inflexible spiroketal scaffold 29f resulted in obtaining only low levels of
inhibition of E-selectin. The poor potency of the rigid linkers can be attributed to the lack
of functionalities that imitate the 4- and 6-OH of the Gal, which are necessary for activity.
In sum, mimics for the disaccharide Gal-β(1-4)-GlcNAc have delivered disappointing
results. Inhibitors that contain Fuc or Gal sugars, but use a cyclohexane diol as GlcNAc
and phenyl or cyclohexyl lactic acid as a NeuAc replacement have proven to be the most
effective. However, even if a disaccharidic mimic were to show potent selectin
antagonist activity in vitro, it is not certain that its pharmacokinetic profile would permit to
use it as an orally active drug. This problem may occur due to still strong carbohydrate
properties and relatively important size.
Mimics containing only one sugar moiety
Since the focus is to reduce the carbohydrate nature of the mimics, several efforts have
been made to design and synthesize compounds that contain only the Fuc sugar bound
moiety to an appropriate scaffold to which a carboxyl group is attached. Some selected
examples are cited in the next paragraph. The Fuc moiety of sLeX (1) has four
substituents (three OHs and a Me group) that can potentially interact with the selectins
upon binding. Based on homology to MBP, the Fuc moiety was assumed to function as
the calcium recognition unit of sLeX (1). Each of the substituents was replaced by
hydrogen to determine their importance for the binding of sLeX (1) to E-selectin [95]. The
replacement of any of the OH groups resulted in a complete loss of binding, while
replacement of the methyl group with hydrogen (replacement of Fuc with Ara) resulted in
a molecule five times less active than sLeX (1). Hasegawa et al. [11] investigated the
replacement of each of the hydroxyls in the Fuc of sLeX and found them to be crucial for
binding to E- and L- selectin. Henrichsen [96] showed that replacement of the 2-OH of
Fuc with a methoxy group eliminated binding to E-selectin. Finally, the crystal structure
of the E-selectin/sLeX complex confirmed the importance of the 3- and 4-OH of the Fuc
in the binding [12].
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A series of mimetics with trans-1,2-cyclohexandiol as a replacement for GlcNAc moiety
met with some success. For instance, Toepfer et al. [97] used this functionality to prepare
a series of mimetics with malonic acid derivatives (32, Figure 20). Aryl-cyclohexyl ether
33 was unsuccessfully used as a replacement for the Gal-GlcNAc unit [94]. The authors
suggested that the use of an aromatic spacer instead of Gal probably does not allow for
the preorganization of the molecules needed to fit the binding site. Glycopeptides where
L-Gal was used to mimic the L-Fuc residue were synthesized (e.g. 34, Figure 20). In
these compounds a series of unnatural amino acids were used to replace the D-Gal of
sLeX (1) and a side chain containing a carboxylate group replaced NeuNAc. The best
mimic showed twofold higher activity than sLeX (1) [98].
Figure 20: A selection of 1-sugar mimics.
Conformationally rigid analogs of sLeX (1) that contain Fuc bound directly to tetralin,
naphtalene, anthraquinone, or anthracene were prepared. Glycosides with naphtyl,
flavonoid and phenyl backbones were also patented. All these rigidified compounds
failed to show any activity. These experiences emphasize the need to precisely fix a
novel compound in the right conformation.
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A mannose residue was used instead of Fuc because of considerations of cost, ease of
synthesis and better fit in the E-selectin/sLeX model.  In these compounds, NeuNAc was
replaced by a carboxymethyl group, and a rigid biphenyl spacer was used in place of the
Gal-GlcNAc disaccharide. Several variations in the arrangement and the number of Man
residue and carboxylic acid were made. Dimer 35 was 6 times more active than sLeX (1)
against E-selectin in cell based assays (Figure 21).
Figure 21: A potent E- and P-selectin antagonist.
Selectin antagonists containing a single carbohydrate comprise the largest number of
published inhibitors investigated to date [17,44,99,100]. In all of these molecules the Fuc has
been retained, or replaced with either Man or Gal: all these simple sugars have three of
the six functional groups necessary for selectin binding contained in the Fuc group of
sLeX (1). Additional functional groups (two OHs of Gal, the anion of NeuNAc) have been
incorporated using a variety of linkers.
The activities observed for compounds containing only one carbohydrate unit suggest
that non-carbohydrate antagonists of E- and P-selectin also are a feasible alternative to
sugar-based analogs.
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Other antagonists
C-glycosides
Wong et al. [16,101] suggested that the use of C-glycosides in place of O-glycosides would
increase the stability of the selectin antagonists toward endogenous glycosidases.
Research is ongoing in this field.
High Molecular Weight antagonists
Due to the heterogeneity of the selectin interactions the most active inhibitors come from
multivalent compounds. Even though the molecules in this class are extremely potent
selectin inhibitors, they are not ideal candidates for oral drug development. The more
potent selectin inhibitors so far are carbohydrates carrying lipophilic tails, high molecular
weight charged aggregates, peptides, complex derivatives, and conjugates of the
tetrasaccharide sLeX (1) and its mimetics. But all these compounds are not suitable for
oral drug formulations. Indeed, sugars carrying conjugates, lipophilic chains and charged
aggregates share common structural features with detergents and are dependent on
dosage, molecular weight and negative charge distribution/density. These may be acting
by distortion of the cell membranes in vivo. However, much recent effort has gone into
preparing multimers of sLeX (1) in hopes of mimicking Nature’s use of polyvalency. In
conclusion, even though these molecules are extremely potent selectin inhibitors, they
are no ideal candidates for oral drug development.
II.4.3 Description of relevant previous work at Novartis
Investigation and development of selectin ligands has been carried out at the
carbohydrate section at Ciba-Geigy and later in the selectin project team at Novartis,
[18,19,102,103]. Since October 1998, this work has been carried out at the Institute of
Molecular Pharmacy. In our group [92] like in many others, sLeX (1) has served as a lead
structure in the research for selectin antagonists with increased biological activity,
simplified structure and improved bioavailability. Highlights of this approach can be
summarized as follows:
- The structure/activity (SAR) relationship for the lead structure sLeX (1) was
established [15,94];
53
54
- The bioactive conformation was elucidated using trNOE NMR spectroscopy [39,45];
- A molecular modeling tool enabling the rational design of potential antagonists has
been developed [27,104].
II.4.4 The computational model
The model developed by Kolb & Ernst in 1997 [27,104] is based on the pre-organization of
the pharmacophores in the bioactive conformation. It has been validated successfully by
correlating the pre-organization of numerous selectin antagonists with their biological
activity.
This computational method was used for the analysis of the energy surface of sLeX (1)
and its macrocyclic mimic 2. The method is based on the “Jumping between Wells” [27]
simulation technique implemented in MacroModel 5.0: a Boltzman weighted ensemble of
states is generated by jumping between different energy wells (conformations) and
performing stochastic dynamics simulations within each well. The total simulation time
was 2 ns for compound 2 and 10 ns for sLeX (1). The conformations used for the
MC(JBW)/SD simulations were obtained in proceeding 5000 steps internal coordinate
systematic pseudo-Monte-Carlo (systematic, unbounded multiple minimum search,
SUMM) simulations. All calculations were performed with an augmented AMBER* force
field, containing the α-alkoxyacid parameters, in conjunction with a GB/SA continuum
water model to allow for a more realistic computational representation of the ligand of
interest, as it would exist in a biological environment.
An example of the use of this methodology was published when Ernst et al. [19]
attempted to get higher affinity by designing mimetics that improved preorganization of
the important pharmacophoric elements. The replacement of GlcN Ac by (R,R)-
cyclohexane-1,2-diol and NeuNAc by glycolic acid or cyclohexyl lactic acid was
evaluated.
The data analysis is based on a 2D internal coordinate system to define the spatial
orientation of the relevant pharmacophores, i.e. the COOH group relative to the Fuc
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moiety. The Fuc(C4)-Fuc(C1)-Fuc(O1)-Acid(Cα) angle describes the conformation of the
LeX (9) core. This coordinate is independent of the actual nature of the core. The other
coordinate, the angle Fuc(C1)-Fuc(O1)-Acid(Cα)-Acid(C=O), defines the orientation of
the COOH (acid) group relative to the core (Figure 22).
Figure 22: The two axes chosen to represent the pre-organization of sLeX (1) and its mimics:
a) The core conformation describing the relative orientation of L-Fuc and D-
Gal;
b) The acid orientation relative to the core.
Based on this modeling tool, selectin antagonists showing higher potency than the lead
structure sLeX (1) were designed and synthesized by chemical and/or chemo-enzymatic
approaches. In 1999, the X-ray structure of the complex was not available. The new
antagonist has been planned in accordance with this model.
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II.4.5 Macrocyclic antagonists
The idea of diminishing the entropic factor in locking a selectin antagonist in its bioactive
conformation underlies the synthesis of macrocyclic selectin antagonists. Due to the
weak affinity of sLeX (1) (IC50=1.3-3 mM) for P-selectin, efforts have been directed
toward the design of sLeX (1) mimetics containing minimal functional groups to increase
affinity. Glycopeptide 36 was assayed and its IC50 value in inhibiting P-selectin was
determined to be 1 µm as compared to 118 µm for compound 37 [105]. Therefore, pre-
organization of the necessary point of contacts by introducing a macrolactone ring
significantly increased the potency of the mimics.
Figure 23: A rigid macrocyclic glycopeptide 37 designed as an inhibitor of P-selectin was
found to be 1000-fold more active than sLeX (1) and almost 200-fold more active
than its acyclical analogue 36.
Kolb [106] synthesized a compound where the rigid macrocyclic core was expected to
provide the basis for enhanced bioactivity due to a potentially high pre-organization of
the functional groups involved in binding. However, the synthesized macrocyclic lactone
38 (Figure 24) showed only a partial pre-organization of the core in the bioactive
conformation and, hence, its only modest biological activity (rel. IC50) could be explained.
The conformation of sLeX (1) bound to E-selectin determined with trNOE NMR studies
has been the basis of the design this antagonist that combines the following design
elements:
1) The LeX (9) core is rigidified by linking the 6-position of Fuc to the 2-position of
Gal. Previous work had revealed the receptor’s tolerance to modifications at
these centers [106].
O
HO
OH
OHN
OH
H
N
O
ON
H
HO2C
HO2C
O
OH
OH
HO
OH
N
O
HO2C
CO2H
O
N
H
CO2Me
O O
36 37
188 µM 1 µM
OH
56
57
2) In analogy to pervious studies, sLeX (1) was simplified by replacing GlcNAc and
NeuNAc by (R,R)-1,2-cyclohexanediol and (S)-phenyllactic acid, respectively.
Figure 24: 38: Kolb’s macrocyclic E-selectin antagonist was found to be 3
times less active than sLeX (1);
2: Novel macrocyclic E-selectin antagonist.
Several thousand structures obtained by sampling the MC(JBW)/SD simulations every
picosecond were used to evaluate the possibility for being at any point of the two-
dimensional torsional space at a resolution of 3° by 3° (Scheme 4). The probability data
are displayed using a color code (high density: red, low density: blue). These plots
represent the free energy surfaces of the molecules and they reveal that the locations of
the high probability areas are very similar for both compounds. The graph clearly shows
that the bioactive window is not enough populated in the case of Kolb’s macrocycle [106].
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Scheme 4: Core/Acidic conformation and bioactive window (black box) of macrocyclic
antagonist 2 compared with sLeX (1).
In Scheme 4, the conformational analysis of the novel compound 2 (discussion in
Chapter III.1) shows a high pre-organization in the bioactive conformation. Based on
reduced entropy cost in the binding process, an increase in biological activity is
expected.
II.4.6  Evaluation of target structures
The overall activity of E-selectin/sLeX interactions is weak and the lack of a universal
array for selectin-mimic binding makes direct comparisons of binding affinities difficult.
The selectins make few interactions with their counter receptor. These contacts are for
the most part electrostatic in nature.
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The lack of reproducibility of the assays and the difficult comparison of results obtained
by different methods are important hurdles towards the development of selectin
antagonists. Here, some methods are described that have been used to quantify E-
selectin/sLeX-mimics interactions. In general, cell interaction assays incorporating
physiologically relevant shear forces (e.g. in flow chambers) are more realistic.
Transfer NOE
The use of a biophysical method like NMR is also a valuable tool to avoid some of the
described difficulties with traditional assays. In transfer NOE experiments, molecules
exhibit strong negative trNOEs when bound to the protein and can be differentiated from
non-binding molecules with weak positive NOEs.
Static biological assays
 Novartis used a competitive assay in which wells coated with E-selectin are filled with
the test molecule, a polyacrylamide bearing sLea (10) and biotin. After unbound ligand
and polymer are washed from the plate, streptavidin conjugated to horseradish
peroxidase is added. A colorimetric determination is possible. Absorbances are recorded
at 492 nm and these values are compared to wells containing no test molecule. Novartis
and collaborators at Glycotech Corp. have also published the preparation of complex
glycopolymer, a polylysine bearing sLea (10), which is used in a similar assay [164].
Assays in flow chambers
Cell interaction assays incorporating physiologically relevant shear forces (e. g. in flow
chambers) are more realistic. The in vitro flow assay developed by Patton et al. [165] at
Glycotech Corp. monitors the rolling of leukocytes on stimulated human HUVEC in a
flow chamber. Video records of bright-field microscopic regions of rolling and arrested
cells are analyzed. Leukocyte rolling in vivo can be directly evaluated and quantified by
intravital microscopy. Animals, usually rodent or rabbits, are anesthetized and the tissue
of interest is laid across the stage of a specially prepared microscope.
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III. Synthesis
III.1 Rational design of a selectin antagonist
As described in the introduction (Chapter II.1), the bioactive conformation of the
carbohydrate epitope sLeX (1) was determined by transfer NOE NMR experiments with
the sLeX/E-selectin complex [40,45] before the X-ray structure of the E-selectin co-
crystallized with sLeX were available [12]. Based on this conformational information, a
molecular modeling tool, which allowed to assess the degree of pre-organization of the
designed mimics in the bioactive conformation has been developed [27,104]. Since this
modeling tool has proved to be highly reliable in the search for sLeX (1) mimics, we
decided to apply it for the design of our novel antagonist 2 (Figure 25).
Figure 25: The natural epitope sLex (1), the macrocyclic mimic published by Kolb 38 [106],
and our target molecule 2.
The original idea was to establish a bridge between the 6-position of L-Fuc and the 2-
position of Gal. Since the 2-OH of Gal is not involved in binding, it is inverted into talo-
configuration and can now act as a handle to be bridged with the extended 6-position of
L-Fuc (i.e. L-Gal).
According to the analysis by the modeling tool described by Kolb and Ernst [27,104], a
three atom bridge would fix the core in the bioactive (core conformation approx. 10°). In
sLex (1), GlcNAc acts only as a linker between Gal and Fuc. It is responsible for holding
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the two sugar moieties in the correct spatial orientation. Since this positioning is no
longer necessary in the macrocyclic setup, it was decided to replace it by a 1,2-diol. An
extension would allow to search an additional hydrophobic interaction which was
originally identified by DeFrees [20].
For the replacement of neuraminic acid, the cyclohexyl lactic acid, which proved to be a
valuable mimic in E-selectin antagonist [46], was chosen. The molecular modeling
analysis showed that in the macrocycle 2, the core core conformation is ideally realized
(Scheme 4). In addition, the acid orientation, which was distorted by approx. 30° in
macrocycle 38 [106], is now in perfect agreement with the value obtained for the bioactive
conformation of sLeX (1) .
In the sLeX analog 2 the spatial orientation of the pharmacophores is fixed in the
conformation bound to the receptor. The conformational analysis shows a high pre-
organization in the bioactive conformation. The rigidity of the macrocyclic core should
therefore provide the basis for enhanced bioactivity based on reduced entropy cost in
the binding process.
III.2 Retrosynthesis & Strategy
For the synthesis of 2 four building blocks have been identified (Scheme 5):
a) the fucosyl derivative 15 formed from L-Gal 43 by elongation at C-6 by
Wittig olefination,
b) the (R)-lactic acid derivative 39,
c) the D-Gal moiety 40, and
d) the acyclic mimic 42 of D-GlcNAc.
Glycosylation of 42 with 15 is followed by introduction of 39 by selective introduction on
the 3-position of the D-Gal moiety in ii. Subsequent inversion of the 2-position of D-Gal
should give the D -talo-configuration in i, required for the cyclization step. Final
deprotection is believed to lead to macrocycle 2.
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Scheme 5: Retrosynthesis of target macrocycle 2 revealed:
a) L-Galactose derivative 15,
b) 3,4-dihydroxylated pentanoic acid derivative 42,
c) D-Galactose derivative 40,
d) (R)-lactic acid derivative 39.
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III.3 Synthesis of the building blocks
Retrosynthetic analysis of L-Gal derivative 15
The stable anomeric protection with OSE is used along the major part of the fucosyl
building block’s synthesis  (Scheme 6) [107]. The last step in the synthesis of the building
block 15 is the cleavage of the OSE-protected anomeric position of 44. 44 can be
obtained by palladium-catalyzed reduction of the cis-trans product mixture 45a/45b
issued from Wittig olefination at the oxidized C-6 of Fuc derivative 46.
Scheme 6: Retrosynthesis of fucose derivative 15.
Prior to its Wittig olefination, aldehyde 46 is obtained by Swern oxidation of the free 6-
OH of L-Gal derivative 47 . 47 can be easily obtained in four protection/deprotection
steps from 48. OSE protection of (43) should be introduced by glycosylation of TMSEt,
with trichloroacetimidate donor 49. 49 is available in three steps from L-Gal (43).
Synthesis of L-Gal derivative 15
At first, we investigated the feasibility of the pathway leading to the synthesis of fucosyl
building block 15 in using inexpensive D-Gal (69) as starting material. In parallel, we
performed a similar synthesis starting with a small amount (1 g) of L-Gal (43). After the
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successful synthesis of the first ten steps with D-Gal (69) and subsequently with L-Gal
(43), we decided to carry out the synthesis of 15 from L-Gal (43) in larger scale (15 g) in
order to synthesize a sufficient amount of 15 to reach target molecule 2 [108,109,110,111] . L-
Gal (43) was used as starting material for the preparation of building block 15 (see
Scheme 3). Per-acetylation of the hydroxyl groups of L-Gal (43) was performed using
Ac2O in pyridine (75% yield). The exclusive formation of the α-anomer 50 facilitated the
analysis. When the reaction was performed at 45°C we obtained a mixture of two
anomers 50/50β (α:β=2:1).
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Scheme 7: Synthesis of fucosyl building  block 15. 21 % overall yield from L-Gal (43).
To remove the Ac group at the anomeric position, compound 50 was treated with
ethylenediamine and AcOH in THF to give a mixture of two anomers of 51 in good yield
(89%). We protected the anomeric position of  51 with the trimethylsilylethyl group,
commonly named OSE, which has found widespread use as an anomeric  protecting
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group. The OSE protecting group can be introduced by glycosylation and is stable to a
wide range of reaction conditions [112].
The trichloroacetimidate glycosylation method was used to selectively introduce OSE at
the anomeric position of 51 in two steps. The trichloroacetimidate donor 49 was
synthesized by reacting 51 with CCl3CN and Cs2CO3 in DCM 
[113,114,115,116]. The favored
formation of the β-trichloroacetimidate 49b (49a/49b 2:1) was observed. The second
step of the trichloroacetimidate glycosylation method consisted of the addition of TMSEt
to donor 49 in DCM, with TMSOTf as promotor [112]. The desired β-glycoside 48 was
obtained in good yield (84%), calculated from the free anomeric compound 43. The 3J1,2
coupling of 8.0 Hz is typical of a β-anomeric configuration. The four Ac-groups of 48
were cleaved by treatment with NaOMe in methanol, giving compound 52 with 70%
yield. The bulky trityl (Tr) group was employed for the regioselective protection of the
primary OH-6 in 52, giving compound 53 (73% yield). The slow reaction was accelerated
by addition DMAP [117].  In carbohydrate synthesis, benzyl ethers are often applied as
protecting groups. They are robust to a wide range of basic and acidic conditions and
also withstand hydride reducing agents and mild oxidants, all of which were used in later
stages of the synthesis. According to standard procedures, compound 53 was
benzylated by reaction with BnBr and NaH in DMF to give 54 with excellent yield (96%).
Cleavage of the trityl group in 54 with 80% aqueous TFA yielded alcohol 47 (94%). The
deprotected primary alcohol was subsequently oxidized under Swern conditions [166] to
the corresponding aldehyde 46.
Wittig olefination of 46 with 55 yielded 45 as a 80:20 mixture of the trans-(45a) and cis-
(4 5 b ) isomers, in 91% (2 steps). The Wittig methoxycarbonylmethylene-
triphenylphosphorane (55) was prepared by reaction of methyl bromoacetate with PPh3
and treatment of adduct with base (NaOH in water) (Scheme 8) [118].
Scheme 8: Synthesis of Wittig reagent 55.
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Selective hydrogenation (H2, 1 bar) of the double bond in 45 was readily achieved in
methanol with PtO2 as catalyst, yielding 93% of 44.
Normally applied cleavage conditions for the OSE protecting group are BF3•Et2O in
Ac2O. 
[112,119] or TFA [107]. When the treatment of 44 with TFA/DCM 2:1 was carried out,
we noted the formation of 1-trifluoroacetylated 15 as a by-product. This ester could be
cleaved with NaOMe in MeOH at pH 10 to obtain 15 quantitatively.
Retrosynthetic analysis of cyclic replacement of D-GlcNAc 42
Starting from commercially available methyl-3-pentanoate 63 , lactone 62  can be
obtained by a catalytic hydroxylation according to Sharpless [120]. In the next step, the
secondary alcohol in 62 is protected as BOM ether. The 2-naphtoyl building block 42
was accessible by opening the BOM-protected lactone 60 by a nucleophilic attack of the
free electron pair of the nitrogen of 2-naphtylamine (61) (→59) followed by benzoylation
(→58) and subsequent cleavage of the BOM group (see Scheme 9).
Scheme 9: Retrosynthetic analysis of D-GlcNAc mimic 42.
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Synthesis of cyclic replacement of D-GlcNAc 42
The Sharpless asymmetric dihydroxylation (AD) of the commercially available methyl 3-
pentanoate (63) was used in order to enantioselectively from the lactone 62 (detailed
discussion in Chapter III.6.2) [120,121,122]. The intramolecular cyclization takes place in situ
by nucleophilic attack of the 4-hydroxyl group. Removal of the by-product methane
sulfonamide (CH3SO2NH2) by chromatography on silica gel was followed with the
staining reagent 4-dimethlyaminocinnamaldehyde. The optimized detection method
allowed us to purify the lactone (+)-62 (85 %). Control of the reaction stereoselectivity
was performed using a NMR shift reagent (detailed discussion in Chap. III.6.3) [123,124,125].
The enantiomeric purity of (+)-62 was found to be 95% ee. For control purposes, we also
synthesized rac-62 (Scheme 10) by unselective osmium tetroxyde (OsO4)-mediated
dihydroxylation [126].
Scheme 10: Synthesis of racemate rac-62 as control compound.
For the protection of the secondary hydroxyl group of the lactone (+)-62 the BOM group
was chosen. The BOM protection was introduced by straightforward reaction of 62 with
BOM-Cl in DCM using DIPEA as the activating base to give 60 in 62 % yield.
Lactone 60 was opened under anhydrous conditions by reaction with 2-naphtylamine
(61) in presence of the Lewis acid Al(CH3)3 to afford 59 (82%). For this purpose, the
commercially not available 2-naphtylamine (61) had to be synthesized from 2-naphtoic
acid (64), NH2OH•HCl and polyphosphoric acid at 180°C to form an ammonium salt 65
(see Scheme 7) [127]. According to the literature, neutralization (pH 7) of a solution of salt
65 in water is sufficient to reverse the equilibrium shown in scheme 11. In our hands,
strong basic treatment (pH 12) with aqueous NaOH was required to precipitate (61) with
satisfactory yield (89%).
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Scheme 11: Synthesis of 2-naphtylamine (61).
Benzoylation of the secondary alcohol of 59 with BzCl/pyridine in DCM gave 58 (92%).
In the last step leading to 42 the selective cleavage of the BOM-group in 58 was
planned. Palladium  (Pd/C 10%, H2) catalyzed hydrogenation in dioxane followed by
acidic hydrolysis with acqueous perchloric acid in dioxane is the classic method to
cleave BOM [128]. However, in hour hands this procedure led to the destruction of the
starting material. Other cleavage conditions were unsuccessfully attempted: a THF/water
mixture was used as solvent, different acid concentrations were attemped and HCl was
used instead of HClO4 
[129]. An alternative cleavage method, which consisted of reacting
58 with PhSH/BF3⋅OEt2 in DCM was also attempted without success 
[130].
Scheme 12: Attempt to synthesize 42 according to initial retrosynthesis.
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The failure to cleave the BOM group in 58 forced us to use another protecting group.
tert-butyl-dimethyl-silyl (TBDMS) was thought to be a useful protecting orthogonal to the
Bz group. We used the racemate rac-62 to investigate this new pathway. Reaction of
rac-29 with TBDMS-Cl in DMF with imidazole as the activating base allowed us to obtain
the TBDMS protection with good yield [131,132,133]. The use of DMAP helped to accelerate
the reaction [117,134]. The opening of the TBDMS-protected lactone and the subsequent
benzoylation step were performed without difficulty. Cleavage of the TBDMS group
under standard conditions with TBAF in THF did not lead to the desired product. An
alternative cleavage method with AcOH/water/THF 3:1:1 at 80°C [131] allowed us to
selectively cleave TBDMS in 80% yield and thus to achieve the synthesis of rac-42 with
excellent yields (4 steps, 55 % from rac-62).
We carried out the synthesis in large scale starting with the enantiomerically pure
lactone (+)-29 (Scheme 13) TBDMS protection of (+)-29 was performed by reaction with
TBDMS-Cl and imidazole in DMF to yield 66 quantitatively. The lactone was opened by
nucleophilic attack of 2-naphylamine 61 to give 67 (73%) and the secondary alcohol was
Bz-protected to give 68 quantitatively. TBDMS in 68 was then selectively cleaved in 80%
yield to give stereospecifically compound 42.
Scheme 13: Synthesis of the 2-naphtoyl building block 42.
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Retrosynthetic analysis of D-Gal moiety 40
D-Gal building block 40 is prepared from D-Gal (69) in two steps according to standard
protocols (Scheme 14) [135,137,138].
Scheme 14: Retrosynthesis of the Gal building block 40.
Synthesis of D-Gal moiety 40
Scheme 15: Synthesis of the Gal building block 40.
The large-scale synthesis of per-benzoylated D-galactose (69)  (20 g), which served as
starting material for the synthesis of glycosyl donor 40, was carried out by reaction of D-
Gal 67 with BzCl in pyridine/CHCl3 (Scheme 15) 
[135]. The temperature was maintained
below 35°C during the exothermic reaction, yielding the α-anomer 70 quantitatively after
crystallization [136]. The small 3J1,2 value (3.6 Hz) of the product’s 
1H NMR spectrum,
indicated a α-pyranosyl configuration for the anomeric center. The per-benzoylated
galactosyl bromide 40 was prepared by treatment [137] of 70 with a 33% solution of HBr in
acetic acid. The more stable α-anomer 40 was obtained with high yield (93%).
Retrosynthetic analysis of (R)-cyclohexyl lactic acid  39
For the alkylation of the 3-position of Gal, which occurs under inversion, the triflate 39
with R-configuration was needed [135]. It can be obtained from 72. Benzylation of the acid
72 should be readily performed by base activation. Hydrogenation of the commercially
available D-(+)-phenyl lactic acid (74) should give (R )-cyclohexyl lactic acid (75)
(Scheme 16).
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Scheme 16: Retrosynthetic analysis of (R)-cyclohexyl lactic acid building block 39.
Synthesis of the cyclohexyl moiety 39
Scheme 17: Synthesis of cyclohexyl moiety 39.
Commercially available D-(+)-phenyllactic  acid (74) was quantitatively reduced under
high H2 pressure (4 bar), allowing us to reduce the quantity of expensive catalyst (Rh on
activated alumina) normally required for similar reductions (Scheme 17). The acid moiety
of the reduction product (R)-cyclohexyllactic acid (73) was then esterified by benzylation
(75%). The benzylester 72 was then triflated at the free OH position by treatment with
Tf2O in the presence of a sterically hindered base to give 39 with good yield (80%) 
[139].
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III.4 Total synthesis of macrolactone 2
III.4.1 1st Attempt to synthesize macrocycle 2
Retrosynthetic analysis
Benzyl protection of the Fuc hydroxyl groups is essential for the selectivity of several
reactions along the synthesis of 2 and must therefore be introduced at an early stage of
the synthesis (Scheme 18). Thus, the last step of the synthesis requires deprotection of
three benzyl-groups on the Fuc moiety by hydrogenation in the presence of Perlman’s
catalyst as well as the hydrolysis of the methylester in compound 75.
H.C. Kolb utilized the Yamaguchi cyclization [140] in his synthesis of a macrocyclic
selectin antagonist [46]. The same procedure was believed to be applicable to link the 2-
OH of the D-Tal moiety with the acid of the fucosyl derivative 76. Prior to the cyclisation,
inversion of the 2-OH in 79 to obtain D-talo out of a D-galacto configuration is required.
Before the oxidation and reduction steps, which are necessary to invert the Gal 2-OH
configuration, the 2 esters in 77 had to be orthogonally protected. The selective
deprotection of the allyl ester in 77 is needed before the intramolecular cyclization can
take place (→76).
Inversion from the D-galacto configuration in 79 to the D-talo configuration in 77 should
be achievable in two steps by a Jones oxidation (→78) followed by reduction (→77).
Selective glycosylation of the 3-position of the D-Gal moiety in 80 with 39 can be
achieved through the corresponding tin acetal. Before carrying out the regioselective
glycosylation, the D-Gal moiety of 83 has to be protected with a 4,6-benzylidene group,
yielding 82 .  Allyl protection of the free acid group of 81  is also required and is
accessible after saponification of ester 82 with LiOH. 83 is obtained after Bz deprotection
of the β -galactosylation product 84, which is obtained from donor 40 and glycosyl
acceptor 85. Deprotection of the glycosylation product 86 with NaOMe in methanol
should lead to donor 85. Finally, 86 is obtained by selective α-coupling of the 2-naphtoyl
acceptor 42 with the fucosyl donor 15.
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Scheme 18: Initial retrosynthesis of macrolactone 2.
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Synthesis
α-Selective glycosylation of fucosyl donor 15 with acceptor 42 was performed using the
in situ anomerization procedure developed by Lemieux et al. [141] (detailed discussion in
Chapter III.6.4). This step consists of a preliminary bromination of 15 with oxalyl bromide
(Scheme 19).
A Vilsmeier-Haack reagent (chloromethylenedimethyliminium bromide) was prepared by
reaction of DMF and oxalyl bromide. The anomeric OH in 15 then performs a 1,2-
nucleophilic addition with concomitant elimination of a bromide ion. This reaction results
in the introduction of a very good leaving group, which is displaced by a bromide,
yielding compound 110α (Scheme 28, p. 90) [142]. As 2-O-Bn glycosyl bromides are too
labile for purification on silica gel, 110 was taken as a crude product into the next step.
The in situ anomerization of the obtained α-bromide 110α to the more reactive β-
bromide 110β was then achieved in presence of TBAB. The β-bromide 110β reacted
with 33, leading to an α-stereoselective glycosylation after inversion of the configuration.
Due to the high cost of the building blocks, we attempted to implement the relatively low
yield (44%) and reproducibility of this water-sensitive reaction. Interestingly, analysis of
the reaction by-products showed the presence of an orthoester 111. The formation of
this compound is the result of the faster intramolecular reaction of the 1-bromide 110β
with the methylester tail compared to the intermolecular glycosylation with 33. This
observation led us to investigate the reaction mechanism of the orthoester formation with
the idea of taking benefit of this secondary reaction (Chapter III.6.5).
By basic deprotection of the benzoylated secondary alcohol in 86 was performed using
NaOMe in dry MeOH, the glycosyl acceptor 85 was obtained. The second glycosylation
to link the acceptor 17 to the protected galactosyl bromide donor 40 was carried out in
dry DCM in presence of AgOTf as promotor [143]. The reaction yielded 84 with relatively
low yield (39%). Cleavage of the Bz groups in 84 with NaOMe/MeOH gave 83. A small
amount of dioxane was added to the reaction in order to dissolve the starting material.
Selective 4,6-O-benzylidene protected 82 was obtained with good yield (79%) by trans-
acetalisation of 83 using benzaldehyde dimethyl acetal in the presence of a catalytic
amount of CSA.
75
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The ester in compound 82 was hydrolyzed with LiOH in a water/EtOH mixture to yield
the free acid 81  with excellent yield (96%). Allyl ester was introduced in 81 with
satisfactory yield (70%). Allyl ester was employed to temporary protect the acid of the
Fuc moiety in compound 81. The protecting group is stable to the oxidative and
reductive reaction conditions necessary to invert OH-2 from galacto- to talo-
configuration.
For the selective 3-OH alkylation, the stannylidene derivative was formed by reacting 80
with Bu2SnO under reflux in benzene. The tin acetal was the treated with an excess of
the previously synthesized triflate 39.  In our case, the glycoslyation was carried out with
an unsatisfactory yield (7%) and low regioselectivity.
It is of interest to note that Ernst et al. [19] could achieve a selective 3-OH glycosylation
on unprotected as well as on 6-deprotected Gal moieties. Conversion of diols into
dibutyltin acetals is normally an efficient method to achieve the regioselective alkylations
[144,145,146,147,148,149].
Therefore, a new approach containing two major improvements was explored:
 A) A reduction of the methylester tail of 15 and subsequent protection of the
primary alcohol. The corresponding ether should be inert during the glycosylation
step.
B) Selective 3-OH glycosylation of Gal moiety with the cyclohexyl moiety prior to
glycosylation of the core compound. This would allow to solve the problems
linked with regioselectivity of the alkylation in an earlier step of the synthesis.
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Scheme 19: Last steps leading to the target compound 2.
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III.4.2 2nd Attempt to synthesize macrocycle 2
This new pathway is based on the reduction of the ester at the C-8 position of the
fucoside 14 and subsequent protection of the resulting alcohol 44. We believed that this
approach would eliminate unwanted side reactions like orthoester building during the
glycosylation step and thus would lead to higher yields. Another important modification
made to get around previous problems was the introduction of the (S)-cyclohexyl lactic
acid moiety on the 3-OH of the Gal moiety before glycosylation with the core building
block. This approach would allow to avoid the low yields obtained for the alkylation of
galactose in 80.
 Retrosynthesis 2nd attempt
As in the 1St attempt, we aimed to utilize the stability of Bn protecting groups on the D-
Fucose hydroxyls from an early stage of the synthesis on (Schemes 16 & 17).
Henceforth, the final step requires hydrogenation of the Bn groups in the presence of
Perlman’s catalyst Pd(OH)2/C and hydrolysis of the methylester of the cyclisation
product 75 . To obtain 75, we planned to use the Yamaguchi protocol for macro-
cyclization of 76. The acid needed to perform the cyclization should be obtained by
selective oxidation of the primary alcohol 87 [150].  The alcohol 87 can be obtained by
cleaving the p-methoxy-phenyl protection of OH-8 in 88. Conversion of the β-galactoside
90 to the β-taloside 88 should be stereoselectively accomplished by oxidation/reduction
of the 2-position. The inversion of configuration at the 2-position requires preliminary 4,6-
protection of 91 as benzylidene acetal. 50 should be accessible by prior cleavage of the
Bz groups protecting the of the Gal moiety in 92. 92 can be obtained by glycosylation of
glycosyl acceptor 90 with thioglycoside donor 70. Synthesis of 90 should be possible by
the Bz-protection of the secondary alcohol of 95. Selective α-coupling of glycosyl donor
96 with acceptor 42 should give 95. 96 should be obtained in three steps by reduction of
the methylester in 14 (→98), subsequent protection of the primary alcohol 97 with
hyroquinone monomethylether [151,152] and cleavage of the anomeric protecting group.
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Scheme 20: Retrosynthesis 2nd attempt. Compounds 2 to 93.
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Scheme 21: Retrosynthesis 2nd attempt. Compounds 93 to 44.
Discussion 2nd attempt
Before exploring the new strategy, we wanted to attempt the reduction and protection
step on a test compound (Scheme 22). We chose the glucuronic acid derivative 99 to
optimize these two steps. Reduction of 99 gave 100 in satisfying yield (89%) [153,154].
Protection of the primary hydroxyl in 100 was performed applying the Mitsunobu
procedure [155,156]. Activation of the alcohol with PPh3 and DEAD in THF allowed the
coupling with hydroquinone monomethylether to yield 101 in good yield (85 %). After
successful protection of the test compound, we decided to explore this new approach
sarting with 44.
Scheme 22: Test reaction with glucuronic acid derivative.
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Reduction of 44 was performed with LiAlH4 in dry THF (Scheme 19) 
[153,154].  Work-up of
the reaction was simply carried out by addition of water and subsequent extraction of the
aqueous layer with DCM yielding 95% of 98. Protection of the primary alcohol was
performed using the Mitsunobu coupling procedure [155,156,157]. The primary alcohol was
activated with PPh3 and DEAD and coupled with hyroquinone monomethylether in good
yield (85%). In the next step, 97 was deprotected at the anomeric position with a
TFA/DCM 2:1 mixture, yielding 85% of 96.
In situ bromination of 96 led to the α-glycosyl bromide, which was coupled to 42 with
very satisfactory yield (77%). We note of a substantial improvement of the yield in
comparison with the reaction of 85 with 42 (44%).  Furthermore, we did not observe the
formation of an orthoester by-product. The benzoyl-protected secondary OH of the
coupling product 95 was deprotected in dry MeOH by transesterification with cat.
NaOMe to yield 93 (78%).  The thioglycoside donor 92 was activated with DMTST and
the benzoate protection of 91 were not successful. Whereas, the 4- and 6- benzoates
were readily cleaved under standard conditions   (cat. NaOMe in MeOH) the Bz in the 2-
position resisted deprotection. As a consequence, only the 2-protected product 91b
(79%) was obtained. Other reaction conditions were applied without success: NaOMe in
MeOH with Microwave activation at various reaction times and temperatures, LiOH in
MeOH and KO-tBu [158] in MeOH/dioxane. In particular, NaOMe in MeOH with microwave
activation lead to a cleavage of the benzylester without affecting the 2-OBz.
Interestingly, when 50b was highly diluted in a large quantity of toluene/MeOH 1:1
before NaOMe was added, we could achieve a deprotection of the Gal-2 position
concurrently with a cleavage of the ester. However, reesterification with CH2N2 in THF
only gave moderate yields.
Based on these results. We attempted to selectively alkylate the Gal moiety subsequent
to coupling and deprotection of the Gal. For this purpose, the test compound 107 was
synthezised, in which the Fuc derivative 15 was replaced by L-fucose derivative 102
(Scheme 20). The naphtoyl derivative 42 was α-fucosylated in 78% with the in-situ
anomerisation method. Product 103 was debenzoylated to give 104 and glycosylated
with the thioethyl donor 105 by promotion with DMTST. Interestingly, Bz-deprotection of
glycosylation product 91 was obtained with moderate yield (58%). Attempts to remove
reacted with the acceptor 93 in dry DCM in the presence of molecular sieves 4Å.  The β-
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104 could readily be achieved. However, the selective coupling of the lactic acid moiety
could not be achieved by tin acetal activation of the Gal-3-position.
In parallel with the attempts to solve the Gal-2-OBz cleavage problem, we investigated
methods for the cleavage of hydroquinone monomethylether that was planed in the later
steps of the synthesis. For this purpose, we attempted the cleavage on 92. The poor
yields (30%) obtained with the usual cleavage method using CAN [159] were however the
best of all our attempts to carry out the cleavage. In particular reaction of 92 with DDQ
[160] and microwave activation did not give satisfying results.
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Scheme 23: Synthesis steps towards macrocycle 2 following the new pathway.
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Scheme 24: Test compound with Fuc.
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III.5 Comments on some important steps
III.5.1 Asymmetric dihydroxylation (AD)
Sharpless et al. improved the catalytic asymmetric dihydroxylation (AD) of olefins
between 1988-1992 [120,161]. The research has led to two important discoveries:
- catalytic amounts of specific alkaloid ligands (Figure 26) in the reaction mixture
complex OsO4 and allow to steer the enantiomeric outcome;
- the presence of organic sulfonamides accelerates the osmate ester hydrolysis.
Taken together, these advances have led to a general procedure, which is applicable to
a wide range of olefinic substrates: AD has reached a new level of experimental
simplicity. The AD-mix formulation of the standards reactants was developed and
simplifies performing the reaction on the milimolar scale. Only catalytic amounts of the
ligand and the osmium tetroxide are required. These catalysts (0.6 % by weight) are
blended into the bulk ingredients potassium ferricyanide and potassium carbonate
(99.4% by weight) producing a yellow powder. This AD-mix is stable for months when
protected from exposure to moisture.
Reaction mechanism
The Sharpless AD reaction owes its success to the presence of either of the two
Cinchona alkaloid ligands: (DHQD)2-PHAL in AD-mix-β and (DHQ)2-PHAL in AD-mix-α.
(Figure 26).
Figure 26: Two Cinchona alkaloid ligands: (DHQD)2-PHAL, used in AD-mix-β and
(DHQ)2-PHAL, used in AD-mix-α.
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The alkaloids complex OsO4 via their quinuclidine nitrogens to form a pair of chiral
oxidants that can enantioselectively dihydroxylate substituted alkenes. For 1,2-trans-
disubstituted and trisubstituted alkenes, the enantioselectivity is usually very high.
Sharpless has formulated a simple rule of predicting product stereochemistry in AD
reactions. The choice between AD-mix-α or AD-mix-β is hence made in function of the
desired outcome (Scheme 25). The designations L, M, and S refer to substituents that
are large, medium and small, respectively. It is noteworthy that even though both
oxidants are formally diastereoisomers, they still usually give enantiomeric products. For
the vast majority of substitued achiral alkenes, the Sharpless AD face-selection rule
works well.
Scheme 25: Sharpless rule for predicting product stereochemistry.
Corey et al. [162] and Sharpless et al. [121] both support an AD mechanism in which the
alkene reversibly coordinates to ligand-bound OsO4, prior to participating in an
irreversible [3+2]-cycloaddition (Scheme 26).
Scheme 26: The asymmetric dihydroxylation (AD) mechanism.
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Methane sulfonamide
Addition of methane sulfonamide to the reaction mixture is recommended for
dihydroxylation of non-terminal olefins [120]. The sulfonamide effect is due to an enhanced
rate of osmate-(VI) ester hydrolysis. Therefore, when osmate ester hydrolysis limits the
turnover rate, the presence of methane sulfonamide leads to shorter reaction times,
occasionally up to 50 times shorter. Due to this sulfonamide effect, most AD reactions
can be run at 0°C.
As already stated in the synthesis description, elimination of methane sulfonamide by
column chromatography on silica gel initially was a problem because the substance was
not revealed with the classic TLC reagent (Mostaïne). However, with the 4-
dimethlyaminocinnamaldehyde reagent the problem could be solved.
III.5.2 NMR determination of the enantiomeric purity of lactone 62
Determination of the absolute configuration and enantiomeric purity of the substituted
chiral lactone (+)-62 was required for the synthesis of the GlcNAc moiety replacement.
Chiroptic methods could have been useful for determining the absolute conformations of
lactone 62, but these methods could not be applied to determinate the enantiomeric
purity of the compound. X-ray structural analysis is valuable (in case of suitably
crystalline materials), but time consuming and hence expensive.
We therefore used a NMR-based method [123,124] for simultaneously determining the
enantioemeric purity of γ-lactones (+)-62 and rac-62. Chiral solvating agents as
aryltrifluoromethylcarbinol 109 (Figure 28 & 29).
Figure 28 : (S)-(+)-2,2,2-Trifluoro-1-(9-anthryl)ethanol 109.
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Figure 29: The “two-point” interaction between chiral 2,2,2-trifluoro-1-(9-anthryl) ethanol 109
and the δ-lactone enantiomers is responsible for the nonequivalence of the NMR
spectra of the enantiomers.
III.5.3 In situ anomerisation
α-Selective glycosidation is a meaningful objective in carbohydrate chemistry. Many
biologically active carry an α -glycoside linkage. However, α-glycosylation is not
straightforward and requires optimization of the glycosyl donors, promoters, solvents,
and other reaction conditions. In this respect, a halide ion-catalyzed α-glycosylation has
provided one of the few definitive ways [141].
The introduction of 1,2-cis linkages requires glycosyl donors with a non-participating
protecting group at the 2-position. An interesting approach for the synthesis of α-
glucosides involves the direct nucleophilic substitution of a β-halide by a sugar hydroxyl.
Such a reaction will give inversion of configuration at the anomeric centre resulting in the
formation of the α-glycoside. However, most β-halides are very labile and difficult to
prepare. As a consequence of the anomeric effect, which is particulary powerful in
glycosyl halides, the α-anomer is favored.
A major breakthrough in α-glycosidic bond synthesis came with the introduction of the in
situ anomerisation procedure invented by Lemieux et al. in 1975 [141]. A rapid equilibrium
can be established between α- and β- halides by the addition of TBAB (Scheme 27). The
anomerisation is believed to proceed through several intermediates. At equilibrium, there
is a shift towards the α-bromide since this compound is stabilised by an endoanomeric
effect. Because, the β-bromide is much more reactive towards nucleophilic attack by a
nucleophile, than the more stable α-bromide, glycosylation leads preferentially to α-
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glycosides. An important requirement for this reaction is that the rate of equilibration is
much faster than the rate of glycosylation.
Scheme 27: In situ anomerisation occurring in the synthesis of 86.
The anomeric outcome of the reaction can be discussed in more general mechanistic
terms. First, the product ratio is governed by competing rates of formation of the α- and
β-glycoside and therefore the glycosylation is kinetically controlled. Second, when two
reactants are in fast equilibrium, the position of this equilibrium and therefore the
reactant ratios will not determine the product ratio. The product ratio, however, will
depend on the relative activation energies of the two reactants (α- and β- halide). In the
case of the in situ anomerisation procedure, the activation energy for glycosylation of the
β-anomer is significantly lower than for the α anomer and therefore the reaction
proceeds mainly through the β anomer. The origin of the higher reactivity of β halides is
disputed but follows similar arguments as the explanation of the kinetic anomeric effect.
Probably, the α-anomer is less reactive because of ground-state stabilization by an
endoanomeric effect. It is essential that the reaction be performed in a solvent of low
polarity. In polar solvents, the reaction proceeds via an oxocarbenium ion and the
anomeric selectivity is reduced. In our synthesis, the efficacy of the in situ anomerisation
procedure was demonstrated by the condensation of a fucosyl bromide 110 issued from
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15 with glycosyl acceptor 42 in the presence of TBAB to give 86 as the α-anomer (44%).
As mentioned above, it is very important that the equilibration between the two ion pairs
is faster than the glycosylation, and many parameters affect this requirement. Small
changes in the constitution of the glycosyl donor or acceptor may have a dramatic effect
on the stereochemical outcome of a glycosylation. In our case, the methylester sitting at
the tail of the Fuc moiety of 15 was believed to interfere with the reaction process,
leading to the relatively low yield observed for this reaction and to the building of the
orthoester by-product 111 (see next Chapter).
III.5.4 The orthoester 111 issue
In the glycosylation reaction with the glycosyl donor 110 and the acceptor 42, the
orthoester 111  was isolated as a by-product. The orthoester was formed by
intramolecular reaction of the ester with cyclization of the Gal moiety and then by
nucleophilic attack of the bromide 110 (Scheme 28).
Scheme 28: Presumed orthoester 111 formation.
We synthesized series of orthoesters with inexpensive test compounds (Experiments 39-
43) [163]. These products were reacted in the microwave oven with different alcohols in
the presence of the Lewis acid activator HgBr2. We observed that the synthesized
orthoesters could be readily opened in the microwave through nucleophilic attack by
different alcohols. We applied the same opening conditions orthoester 111 in the
presence of secondary alcohol 16. The successful completion of this reaction was an
interesting observation for three different reasons. Firstly, it gave us another solid proof
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of the purported reaction mechanism of orthoester formation. Secondly, we were able to
recover a certain amount of desired product 33 from the glycosylation by-product.
Finally, we considered possible to carry out the glycosylation by selectively forming the
orthoester and opening the latter using the previously described procedure. However,
we did not succeed in the synthesis of the orthoester and abandoned the idea of a novel
glycosylation method when we put the cost of the building blocks used in the attempts in
relation with the low probability of success.
III.6 Summary
Selectins are involved in the orderly migration of leukocytes from blood vessels to sites
of inflammation. Although extravasation of leukocytes represents an essential defense
mechanism against infection, excessive or inappropriate leukocyte accumulation results
in injury to host tissues. Therefore, the development of selectin-antagonists is
considered as an effective therapeutic approach in inflammatory and and other related
disorders. Physiological selectin ligands contain a common tetrasaccharide epitope sialyl
LewisX (1) that serves as the lead structure in our search for E-selectin antagonists.
This work consists of attempts to synthesize sLeX analog 2, which is aimed to explore
the role of the spatial orientation of the pharmacophores in the bioactive conformation.
The rigid macrocyclic core is thought to provide the basis for enhanced bioactivity due to
a potentially high pre-organization of the functional groups involved in binding.
The building blocks for the synthesis of 2 have been L-galactose elongated at C-6 by
Wittig olefination, D-talose alkylated at the 3-OH with (S)-cyclohexyl lactic acid and a
GalNAc mimic.
We have succeeded in the synthesis of the building blocks required by the
retrosynthesis of target molecule 2 with good to excellent yields (Figure 30). The core
structures 79 and 91b were synthesized as the results of two different synthetic
pathways. These structures, as well as the building blocks 15  and 42  were not
previously described in the literature.
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Figure 30: Structures that have been synthesized.
The targeted macrocycle could not be obtained due to major issues that occurred along
two respective pathways:
In the first attempt (Chapter III.4.1), we encountered:
- low α-glycosylation yields probably due to interactions with the
methylester tail of the Fuc moiety in 15;
- insufficient yields in the late introduction of the cyclohexyl lactic acid
moiety in 80.
These initial problems were successfully addressed in the second pathway. However,
we faced new issues during this attempt (Chapter III.4.2):
- a satisfying method to deprotect the 2-OBz in the Gal moiety in 91b
could not be found;
- another method to obtain 91 proved to be unsuccessful;
- a satisfying method to cleave  the p-methoxy-phenyl protecting group
on our very sensitive compounds could not be found.
Despite major efforts to overcome these hurdles, a satisfying solution was not accessible
in the available time period of this work.
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III.7 Conclusion
The high number of publications [17,44] on the development of selectin antagonists shows
that the disruption of the initial step in the inflammatory cascade is viable approach to
search for novel therapeutics. However, none of the sialyl LewisX (1) mimics synthesized
to date have been developed into an approved drug.
The inherent low affinity of sLeX (1) for the selectins is required by the role it plays in the
rolling process, which suggests that the binding site has evolved to optimize the
specificity and the weakness to the interactions with sLeX (1). Moreover, carbohydrates
are generally prone to rapid metabolism and elimination.
It is thus reasonable to assume that the development of high-affinity antagonists for a
binding site that has been evolved for weak interactions with a readily degradable ligand
is more difficult than the traditional drug target
In planning the synthesis of 2, our approach was thought more as a proof of concept
than as the direct development of a therapeutic compound. Activity studies of target
molecule 2 would have provided an important contribution to the validation of our
predictions based on pre-organization determined by molecular modeling.
We strongly hope that the synthesis of the major building blocks towards 2, as well as
the experience collected along the two attempted pathways will provide the basis for the
successful syntheses of related compounds.
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IV. Experimental part
IV.1 General methods
Optical rotation
Optical rotations were measured with a Perkin-Elmer 241 polarimeter. Na-D optical
rotations were extrapolated from the measured Hg values (546 and 578 nm) with the
help of Drude’s equation [167]:
α[ ]D
Τ
=
α[ ]579
Τ •3.199
4.199 − α[ ]579
Τ
α[ ]546
Τ
 with α[ ]λ
T
=
α •100
c •d
α = Measured optical rotation
c = Concentration in g/100 ml
d = Recipient length in dm
T = Temperature in °C
λ = Wavelength in nm
The solvents used for the measurements were CH3Cl p.a. (Fluka) and MeOH p.a.
(Fluka).
Infrared spectroscopy (IR)
Infrared spectra were recorded with a Perkin-Elmer Spectra One FT-IR Spectrometer.
Nuclear Magnetic Resonance Spectroscopy (NMR)
Proton (1H NMR) and carbon-13 (13C NMR) nuclear magnetic resonance spectra were
recorded on a Bruker UltraShieldTM Supraconducting NMR 500/70B spectrometer.
1H NMR spectra were recorded at 500.1 MHz and 13C NMR spectra were recorded at
125.8 MHz in CDCl3, MeOD or D2O. Chemical shifts are given in δ units, parts per million
(ppm) downfield from tetramethylsilane (TMS).
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Values for CDCl3 
[168]: 1H NMR: 7.26 13C NMR: 77.16 +/- 0.06
Values for CD3OD 
[168]: 1H NMR: 3.31 13C NMR: 49.00 +/- 0.01
Elementary analyses
Elementary analyses were performed at the Institute of Organic Chemistry (University of
Basel, Switzerland).
Thin Layer Chromatography (TLC)
Reactions were monitored by TLC using glass plates coated with silica gel 60 F254
(Merck). The spots were detected under short wavelength UV light (254 nm) or charring
with Mostain, a molybdate solution (a 0.02 M solution of ceric ammonium sulfate and
ammonium molybdate tetrahydrate in aqueous 10% H2SO4. The plates were then
heated for 2 min at 155°C.
Filtration and chromatography
Flash chromatography was performed with 200-400 mesh silica gel 60 under argon or
air pressure. Thin layer chromatography was used to monitor column fractions. [Still,
1978 #8]
Hydrogenations
Hydrogenations under pressure were performed in a protected mixing device from Parr
Instrument Company, (Moline, IL, USA) in 250 mL bottles.
Solvents
Absolute solvents like CH2Cl2 and CH3CN were prepared by filtration over basic
aluminium oxide (Fluka, type 5016 A  basic).
Absolute solvents like THF, MeOH and dioxane were dried by refluxing with sodium and
distilled immediately before use.
Pyridine was freshly distilled under argon in the presence of CaH2.
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IV.2 Synthesis
IV.2.1 L-Gal building block 15
Experiment 1: MAR-69 / I
Penta-O-acetyl-α-L-galactopyranose (50): Ac2O (15.0 mL, 159 mmol) was added
slowly to a mixture of L-galactose (43) (5.00 g, 27.8 mmol) in freshly distilled pyridine (75
mL) and stirred at -16°C for 7 days under argon. Evaporation of the solvents at 10-3 Torr
gave an oil, which was diluted with EtOAc (120 mL) and washed with 10% aqueous
NaCl (2 x 45 mL), saturated NaHCO3 (50 mL), H2O (50 mL) and 0.5 M CuSO4 (3 x 35
mL). The organic layer was dried with Na2SO4, filtered, concentrated and purified by
column chromatography on silica gel (petroleum ether-EtOAc 2:1) yielding 50 as an oil
(8.12 g, 75%).
1H NMR (500.1 MHz, CDCl3): δ 2.00-2.16 (m,
 15 H, 5 CH3), 4.09 (m, 2 H, H-6), 4.34 (m,
1 H, H-5), 5.33 (m, 2 H, H-2, H-3), 5.51 (d, 3J3,4 = 1.2 Hz, 1 H, H-4), 6.37 (d, 
3J1,2 = 1.5
Hz, 1 H, H-1);
13C NMR (125.8 MHz, CDCl3): δ 20.7, 20.8, 21.0 (5 C, 5 CH3), 61.4 (C-6), 66.6, 67.4,
67.5  (3 C, C-2, C-3, C-4), 68.9 (C-5), 89.8 (C-1), 170.3 (5 C, 5 CO).
Elementary analysis
C16 H22 O11 calculated C 49.23 H 5.68
(390.34) found C 48.87 H 5.55
Experiment 2: MAR-109
2,3,4,6-Tetra-O-acetyl-L-galactopyranose (51): AcOH (2.84 g, 47.1 mmol) was added
to a solution of EDA (2.43 g, 40.3 mmol) in THF (492 mL) at 25°C under argon to give a
white suspension. 50 (13.1 g, 33.6 mmol) was added to the mixture which was stirred for
19 h at 25°C under argon. H2O (300 mL) was then added and the mixture was extracted
with CH2Cl2 (5 x 75 mL). The combined organic layers were washed with aqueous HCl 5
% (200mL) and saturated NaHCO3 solution (300 ml), dried with Na2SO4 and
concentrated to give 12.2 g of crude product. The crude product was purified by column
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chromatography on silica gel (petroleum ether-EtOAc 3:2) to yield 51 (α/β 81:19) as an
oily syrup (10.4 g, 89%).
1H NMR (500.1 MHz, CDCl3) of the mixture 51α /51β (81:19):
51α: δ3.65 (d, 1 H, OH), 4.06-4.16 (m, 2 H, H-6), 4.45 (m, 1 H, H-5), 5.16 (dd, 3J1,2 = 3.5,
3J2,3 = 10.8 Hz , 1 H, H-2), 5.41 (m, 1 H, H-3), 5.47 (dd, 
3J3,4 = 3.3, 
3J4,5 =1.1 Hz, H-4),
5.52 (m, 1 H, H-1); 51β: δ 3.14 (d, 1 H, OH), 3.96 (m, 1 H, H-5), 4.06-4.16 (m, 2 H, H-6),
4.69 (m, 1 H, H-1), 5.06 (m, 1 H, H-2), 5.07 (m, 1 H, H-3), 5.41 (m, 1 H, H-4);
13C NMR (125.8 MHz, CDCl3) of the mixture 51α /51β (81:19):
51α: δ  20.7, 20.8 (4 C, 4 CH3), 62.0 (C-6), 66.5 (C-5), 67.3 (C-3), 68.3, 68.4 (2 C, C-2,
C-4), 90.9 (C-1), 170.2 (4 C, 4 CO);51β: δ 20.7, 20.8 (4 C, 4 CH3), 62.0 (C-6), 67.2 (C-
4), 70.3 (2 C, C-2, C-3), 71.2 (C-5), 96.2 (C-1), 170.2 (4 C, 4 CO).
[α]D
20 = - 73.6 ( c = 1.01, CHCl3, 51α /51β 81:19)
Elementary analysis
C14 H20 O10 calculated C 48.28 H 5.79
(348.31) found C 48.46 H 5.77
Experiment 3: MAR-117
2,3,4,6-Tetra-O-acetyl-L-galactopyranosyl-1-trichloroacetimidate (49): Cs2CO3 (1.08
g, 3.33 mmol) and CCl3CN (16.7 mL, 166 mmol) were added to a solution of 51 (11.6 g,
33.3 mmol) in dry CH2Cl2 (140 mL) under argon. After stirring at 25°C for 24 h, the
solution was filtered through Celite and washed with CH2Cl2 (50 mL). The filtrate was
dried with Na2SO4, evaporated and then dried at 10
-3 Torr to yield a mixture of the two
isomeres (α /β  2:1). The crude product (16.1 g, 98%) was used without further
purification in the next step.
1H NMR (500 MHz, CDCl3) of the mixture 49α /49β (2:1):
49α: δ 2.00-2.16 (m, 12 H, 4 CH3), 4.05-4.17 (m, 2 H, H-6), 4.42 (m, 1 H, H-5), 5.33-5.42
(m, 2 H, H-2, H-3), 5.54 (m, 1 H, H-4), 6.58 (d, 3J1,2 = 3.5 Hz, 1 H, H-1), 8.66 (s, 1 H,
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NH); 49β:  δ 2.00-2.04 (m, 12 H, 4 CH3), 4.11 (m, 1 H, H-5), 4.19 (m, 2 H, H-6), 5.12 (dd,
3J2,3 = 10.4, 
3J3,4 = 3.5 Hz, 1 H, H-3), 5.46 (m, 1 H, H-4), 5.49 (dd,
 3J1,2 = 8.3, 
3J2,3 = 10.4
Hz ,1 H, H-2), 5.83 (d, 3J1,2 = 8.3 Hz, 1 H, H-1), 8.71 (s, 1 H, NH).
[α]D
20 = - 103.1 ( c = 1.02, CHCl3, 49α/49β 2:1)
Elementary analysis
C16H20Cl13NO10 calculated C 39.01 H 4.09 N 2.84
(492.69) found C 38.35 H 4.10 N 2.54
Experiment 4: MAR-122
2-(Trimethylsilyl)ethyl 2,3,4,6-tetra-O-acetyl-β -L-galactopyranoside (48): To a
solution of crude 49 (16.1 g, 32.6 mmol) in dry CH2Cl2 (220 mL) were added molecular
sieves 3Å (5 g) and TMSEt (4.24 g, 35.8 mmol) under argon. The mixture was stirred at
25°C for 30 min and then cooled to –20°C. TMSOTf (0.65 mL, 3.26 mmol) was added
dropwise within 1 min with a syringe. After stirring for 1 h at –20°C, pyridine (1.7 mL)
was added to the mixture and stirring continued for 5 min at this temperature. The
mixture was warmed to 25°C, filtered trough Celite, and washed with CH2Cl2 (2 x 20mL).
Concentration of the filtrate afforded a crude residue, which was purified by column
chromatography on silica gel (petroleum ether-EtOAc 3:1) yielding 48 (14.2 g, 98%) as a
white solid.
1H NMR (500.1 MHz, CDCl3): δ 0.86-1.00 (m, 2 H, H-2’), 1.96, 2.02, 2.03, 2.13 (4 s, 12
H, 4 CH3), 3.52 (m, 1 H, H-1’a), 3.89 (m, 1 H, H-5), 3.97 (m, 1 H, H-1’b), 4.10 (dd, 
3J5,6a =
7.1, 3J6a,6b = 11.2 Hz, 1 H, H-6a), 4.18 (dd, 
3J5,6b = 6.4, 
3J6a,6b = 11.2 Hz, 1 H, H-6b), 4.47
(m, 3J1,2 = 8.0, 1 H, H-1), 4.99 (dd, 
3J2,3 = 10.4, 
3J3,4 = 3.4 Hz, 1 H, H-3), 5.17 (dd, 
3J1,2 =
8.0, 3J2,3 = 10.4 Hz, 1 H, H-2), 5.36 (m, 1 H, H-4);
13C NMR (125.8 MHz, CDCl3): δ 18.1 (C-2’), 20.7, 20.8, 20.9 (4 C, 4 CH3), 61.4 (C-6),
67.2 (C-4), 67.7 (C-1’), 69.1 (C-2), 70.6 (C-5), 71.2 (C-3), 100.8 (C-1), 169.5, 170.3,
170.5, 170.6 (4 C, 4 CO).
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Experiment 5: MAR-125
2-(Trimethylsilyl)ethyl β-L-galactopyranoside (52): 1 M NaOMe in MeOH (0.8 mL)
was added to a solution of 48 (14.2 g, 31.8 mmol) in MeOH (80 mL) under argon until
the solution reached pH 10. The mixture was stirred for 2 h at 25°C, the pH of the
solution was then adjusted to pH 7 by addition of Amberlyst 15 ion exchange resin. The
suspension was filtered through Celite, concentrated and purified by column
chromatography on silica gel (petroleum ether-EtOAc 1:5) yielding 52 (6.21 g, 70 %).
1H NMR (500.1 MHz, CD3OD): δ 1.01 (m, 2 H, H-2’), 3.47 (m, 3 H, H-2, H-3, H-5), 3.62
(m, 1 H, H-1’), 3.73 (m, 2 H, H-6), 3.82 (m, 1 H, H-4), 4.01 (m, 1 H, H-1’b), 4.22 (d, 3J1,2
= 7.4 Hz, 1 H, H-1);
13C NMR (125.8 MHz, CD3OD): δ 19.1 (C-2’), 62.5 (C-6), 68.0 (C-1’), 70.3 (C-4), 72.6,
75.1, 76.6 (3 C, C-2, C-3, C-5), 104.5 (C-1).
Experiment 6: MAR-131
2-(Trimethylsilyl)ethyl 6-O-trityl-β-L-galactopyranoside (53): Ph3CCl (9.73 g, 34.9
mmol) and DMAP (0.46 g, 3.8 mmol) were added at 25°C to a solution of 52 (6.21 g,
24.9 mmol) in pyridine (25 mL) under argon. The mixture was stirred for 4 h. Additional
Ph3CCl (3.50 g, 12.6 mmol) and DMAP (0.16 g, 1.3 mmol) were added to the reaction,
which was stirred for another 12 h. The mixture was diluted with CH2Cl2 (200 mL) and
washed with 10 % aqueous NaCl (90 mL). The aqueous layer was washed with EtOAc
(2 x 60 mL). The combined organic phases were washed with 1M KH2PO4 (60 mL) and
brine (2 x 60mL), dried with Na2SO4, concentrated and purified by column
chromatography (petroleum ether-EtOAc 2:1) yielding 53 (8.33 g, 72%) as an oily
product.
1H NMR (500.1 MHz, CDCl3): δ 1.01 (m, 2 H, H-2’), 2.37, 2.56, 2.74  (4 s, 4 H, 4 OH),
3.35 (dd, 3J5,6a = 5.7, 
3J6a,6b = 9.6 Hz, 1 H, H-6a), 3.44 (dd, 
3J5,6b = 5.7, 
3J6a,6b = 9.6 Hz, 1
H, H-6b), 3.58 (m, 4 H, H-2, H-4, H-5, H-1’a), 4.01 (m, 2 H, H-3, H-1’b), 4.22 (d, 3J1,2 =
7.2 Hz, 1 H, H-1), 7.45-7.21 (m, 15 H, 3 C6H5);
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13C NMR (125.8 MHz, CDCl3): δ 18.4 (C-2’), 62.7 (C-6), 67.4 (C-1’), 69.3 (C-3), 72.5,
73.7, 73.8 (3 C, C-2, C-4, C-5), 87.1 (CPh3), 103.8 (C-1), 127.3, 143.8 (18 C, 3 C6H5).
[α]D
20 = + 36.0 ( c = 0.49, CHCl3, 53)
Experiment 7: MAR-132
2-(Trimethylsilyl)ethyl 2,3,4-tri-O-benzyl-6-O-trityl-β-L-galactopyranoside (54): NaH
(2.60 g of a 55% powder in oil, 66.1 mmol) was added to a solution of 53 (8.27 g, 15.8
mmol) in dry DMF (38 mL) under argon and the mixture was stirred for 5 min. BnBr (10.2
g, 7.05 mL, 59.3 mmol) was slowly added to the suspension and the inner temperature
was maintained with an ice bath between 25°C and 30°C during the exothermic reaction.
The mixture was stirred for 3 h at 25°C. Thiourea was then added to the mixture causing
a strong gas emission. After stirring for another 30 min, 1M KH2PO4 (100 mL) was added
to the suspension and the mixture was diluted with EtOAc (100 mL). The aqueous layer
was washed with EtOAc (3 x 100mL). The combined organic phases were washed with
brine (3 x 100mL), dried with Na2SO4, concentrated in vacuo and purified by column
chromatography (petroleum ether-EtOAc 20:1) yielding 54 (11.2 g, 96 %) as an oil.
1H NMR (500.1 MHz, CDCl3): δ 1.01 (m, 2 H, H-2’), 3.19 (dd, 
3J5,6a = 7.0, 
3J6a,6b = 9.2 Hz,
1 H, H-6a), 3.36 (m, 1 H, H-5), 3.48 (m, 2 H, 3-H, H-6b), 3.56 (m, 1 H, H-1’a), 3.76 (dd,
3J1,2 = 7.7, 
3J2,3 = 9.7 Hz, 1 H, H-2), 3.85 (m, 1 H, H-4), 4.00 (m, 1H, H-1’b), 4.31 (d, 
3J1,2
= 7.7 Hz, 1 H, H-1), 4.47-4.93 (m, 6 H, 3 CH2Ph), 7.10-7.40 (m, 30 H, 6 C6H5);
13C NMR (125.8 MHz, CDCl3): δ 18.6 (C-2’), 62.9 (C-6), 67.4 (C-1’), 73.2-75.3 (5 C, 3
CH2Ph, C-4, C-5), 79.9 (CPh3), 82.4 (C-2), 87.0 (C-3), 103.6 (C-1), 127.2, 127.3, 127.6,
127.7, 128.0, 128.1, 128.2, 128.3,128.4, 128.5, 128.8, 138.8, 140.1, 144.1  (36 C, 6
C6H5).
[α]D
20 = + 3.2 ( c = 1.02, CHCl3, 54)
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Experiment 8: MAR-133
2-(Trimethylsilyl)ethyl 2,3,4-tri-O-benzyl-β-L-galactopyranoside (47): To a solution of
54 (11.2 g, 14.1 mmol) in CH2Cl2 (250 mL) was added aqueous TFA 80% (11.3 mL).
The mixture was stirred for 5 min at 25°C. H2O (5.5 mL) was added and the mixture was
stirred for another 5 min. The yellow mixture was neutralized with saturated aqueous
NaHCO3 solution (80 mL) and the aqueous layer extracted with CH2Cl2 (3 x 80 mL). The
combined organic phases were washed with H2O (100 mL), dried with Na2SO4,
concentrated and purified by column chromatography on silica gel (petroleum ether-
EtOAc 4:1) yielding 47  (7.33 g, 94%) as an oil.
1H NMR (500.1 MHz, CDCl3): δ 1.03 (m, 2 H, H-2’), 3.37 (m, 1 H, H-5), 3.49 (m, 1 H, H-
6a), 3.53 (m, 1 H, H-3), 3.57 (m, 1 H, H-1’a), 3.76 (m, 2 H, H-4, H-6b), 3.83 (dd, 3J1,2 =
7.7, 3J2,3 = 9.7 Hz, 1 H, H-2), 4.00 (m, 1 H, H-1’b), 4.37 (d, 
3J1,2 = 7.7 Hz, 1 H, 1-H), 4.66,
4.78 (A of AB, 2J= 11.9 Hz, 2 H, CH2Ph), 4.74, 4.81 (B of AB, 
2J= 11.8 Hz, 2 H, CH2Ph),
4.95-4.97 (m, 2 H, 2 CH2Ph), 7.26-7.38 (m, 15 H, 3 C6H5);
13C NMR (125.8 MHz, CDCl3): δ 18.5 (C-2’), 62.0 (C-6), 67.5 (C-1’), 72.8 (C-4), 73.3,
74.0, 74.4, 75.2 (4 C, C-5, 3 CH2Ph), 79.7 (C-2), 82.3 (C-3), 103.5 (C-1), 127.5, 127.6,
127.7, 127.9, 128.1, 128.2, 128.4, 128.6, 138.2, 138.7, 138.8 (18 C, 3 C6H5).
[α]D
20 = + 20.0 (c = 0.49, CHCl3, 47)
Experiment 9: MAR-134 first step
2 - (T r imethy ls i l y l ) e thy l  2 ,3 ,4 - t r i -O-benzyl-β-L-galacto-hexo-1,6-dialdo-1,5-
pyranoside (46): Under argon, DMSO (2.91 g, 2.65 mL, 37.3 mmol) was added to a
solution of oxalyl chloride (2.37 g, 1.60 mL, 18.7 mmol) in dry CH2Cl2 (25 mL) at –78°C
and stirred for 5 min. A solution of 47 (7.33 g, 13.3 mmol) in dry CH2Cl2 (12 mL) was
added to the mixture. After stirring for 15 min at –78°C, Et3N (4.04 g, 5.57 mL, 39.9
mmol) was added to the stirred mixture which was then warmed up to 25°C within 30
min. The reaction was quenched with saturated aqueous NH4Cl  (50 mL) and the
aqueous layer was extracted with CH2Cl2 (3 x 60 mL). The combined organic phases
were dried with Na2SO4 and concentrated. The residue 46 (7.7 g) was dried for 1 h at
10-3 Torr and directly used in the next step.
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Experiment 10: MAR-134
Methyl [2-(Trimethylsilyl)ethyl tri-2,3,4-O-benzyl-6,7-dideoxy-6,7-en-β-L-galacto-
octopyranoside]uronate (45a/45b): A cold (-20°C) solution of Ph3PCHCOOMe (6.68 g,
20.0 mmol) in dry CH2Cl2 (24 mL) was added within 20 min to a solution of crude 46 (7.7
g) in dry CH2Cl2 (45 mL) at –20°C under argon. After stirring for 2 h at this temperature,
a solution of Ph3PCHCOOMe (0.89 g, 2.7 mmol) in dry CH2Cl2 (3 mL) was added to the
mixture which was stirred for another 1 h at –20°C. The mixture was filtered through
Celite and washed with petroleum ether-EtOAc 2:1  (80 mL). The filtrate was dried with
Na2SO4, concentrated and purified by column chromatography on silica gel (petroleum
ether-EtOAc 8:1) yielding trans isomer 45a (5.68 g, 73 %) and cis isomer 45b (1.48 g, 18
%) as oils.
(E)-Methyl [2-(trimethylsilyl)ethyl 2,3,4-tri-O-benzyl-6,7-dideoxy-6,7-en-β-L-galacto-
octopyranoside]uronate (45a):
1H NMR (500.1 MHz, CDCl3): δ 1.02 (m, 2 H, H-2’), 3.55 (m, 1H, H-1’a), 3.64 (dd, 
3J2,3 =
9.8, 3J3,4 = 2.9 Hz, 1 H, H-3), 3.66 (s, 3 H, CH3), 3.83 (dd, 
3J1,2 = 7.7, 
3J2,3 = 9.8 Hz, 1 H,
H-2), 4.00 (m, 1 H, H-1’b), 4.08 (dd, 3J3,4 = 2.9, 
3J4,5 = 0.1 Hz, 1 H, H-4), 4.39 (d, 
3J1,2 =
7.7 Hz, 1 H, H-1), 4.55, 4.85 (A,B of AB, 2J = 11.8 Hz, 2 H, CH2Ph), 4.73, 4.79 (A,B of
AB, 2J = 11.7 Hz, 2 H, CH2Ph), 4.78, 4.94 (A,B of AB, 
2J = 11.0 Hz, 2 H, CH2Ph), 4.89
(m, 1 H, H-5), 5.69 (d, 3J6,7 = 11.7 Hz 1 H, H-7), 6.36 (dd, 
3J5,6 = 6.8, 
3J6,7 = 11.7 Hz, 1 H,
H-6), 7.21-7.37 (m, 15 H, 3 C6H5);
13C NMR (125.8 MHz, CDCl3): δ 19.9 (C-2’), 53.0 (CH3), 68.8 (C-1’), 74.6 (CH2Ph), 74.8
(C-4), 75.6, 76.4 (2 CH2Ph), 76.6 (C-5), 80.7 (C-2), 83.3 (C-3), 104.8 (C-1), 123.2 (C-7),
127.6, 127.7, 127.8, 128.0, 128.1, 128.2, 128.3, 128.5, 129.0, 137.9, 138.3, 138.7 (18 C,
3 C6H5), 145.6 (C-6), 168.0 (CO).
Elementary analysis
C35H44O7Si calculated C 69.51 H 7.33 
(604.81) found C 69.47 H 7.31
[α]D
20 = + 78.0 (c = 0.98, CHCl3, 45a)
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(Z)-Methyl [2-(trimethylsilyl)ethyl 2,3,4-tri-O-benzyl-6,7-dideoxy-6,7-en-β-L-galacto-
octopyranoside]uronate (45b):
1H NMR (500.1 MHz, CDCl3): δ 1.02 (m, 2 H, H-2’), 3.52 (dd, 
3J2,3 = 9.7, 
3J3,4 = 2.9 Hz, 1
H, H-3), 3.57 (m, 1 H, H-1’a), 3.74 (m, 4 H, H-4, CH3), 3.83 (dd, 
3J1,2 = 7.7, 
3J2,3 = 9.7 Hz,
1 H, H-2), 3.94 (m, 1 H, H-5), 4.08 (m, 1 H, H-1’b), 4.38 (d, 3J1,2 = 7.7 Hz, 1 H, H-1),
4.65, 4.81 (A,B of AB, 2J = 12.0 Hz, 2 H, CH2Ph), 4.67, 4.72 (A,B of AB, 
2J = 11.9 Hz, 2
H, CH2Ph), 4.76, 4.93 (A,B of AB, 
2J = 10.9 Hz, 2 H, CH2Ph), 6.09 (dd,
 4J5,7 =1.9, 
3J6,7 =
15.7 Hz, H-7), 6.73 (dd, 3J5,6 = 4.1, 
3J6,7 = 15.7 Hz, 1 H, H-6), 7.37-7.21 (m, 15 H, 3
C6H5);
13C NMR (125.8 MHz, CDCl3): δ 18.4 (C-2’), 51.5 (CH3), 67.3 (C-1’), 73.1 (CH2Ph), 73.3
(C-4), 74.1, 74.9 (2 CH2Ph), 73.6 (C-5), 77.7 (C-2), 81.8 (C-3), 103.3 (C-1), 121.7 (C-7),
127.5, 127.6, 127.7, 127.8, 128.0, 128.1, 128.2, 128.3, 128.5, 137.9, 138.3, 138.7 (18 C,
3 C6H5), 144.1 (C-6), 166.6 (CO).
Experiment 11: MAR-135
M e t h y l  [ 2 - (trimethylsilyl)ethyl 2,3,4-tri-O-benzyl-6,7-dideoxy-β-L-galacto-
octopyranoside]uronate  (44): Compound 45 (7.32 g, 12.1 mmol) was dissolved in dry
degased MeOH (110 mL) and hydrogenated at 25°C and 4 bar H2 in the presence of 10
% Pd-C (170 mg, 0.73 mmol) for 3h. The mixture was filtered trough Celite and the
filtrate was concentrated and purified by column chromatography on silica gel (petroleum
ether-EtOAc 9:1) yielding 44 (6.36 g, 86 %).
1H NMR (500.1 MHz, CDCl3): δ 1.01  (m, 2 H, H-2’), 1.62 (m, 1 H, H-6a), 2.08 (m, 1 H,
H-6b), 2.30 (m, 2 H, H-7), 3.27 (m, 1 H, H-5), 3.48 (m, 3J2,3 = 9.7, 
3J3,4 = 2.9 Hz, 1 H, H-
3), 3.54 (m 1 H, H-1’a), 3.63 (s, 3 H, CH3), 3.78 (dd, 
3J1,2 = 7.7, 
3J2,3 = 9.7 Hz, 1 H, H-2),
3.97 (m, 1 H, H-1’b), 4.27 (d, 3J1,2 = 7.7 Hz, 1 H, H-1), 4.66, 4.96 (A,B of AB, 
2J = 11.7
Hz, 2 H, CH2Ph), 4.71, 4.78 (A,B of AB, 
2J = 11.9 Hz, 2 H, CH2Ph), 4.75, 4.93 (A,B of
AB, 2J = 11.1 Hz, 2 H, CH2Ph), 7.23-7.37 (m, 15 H, 3 C6H5).
[α]D
20 = - 18.8 ( c = 1.02, CHCl3, 44)
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Elementary analysis
C34 H46 O7 Si calculated C 69.27 H 7.64
(606.82) found C 69.38 H 7.72
Experiment 12: MAR-179
Methyl [2,3,4-tri-O-benzyl-6,7-dideoxy-L-galacto-octopyranose]uronate (15): TFA
(16.5 mL) was added dropwise within 15 min to a solution of 44 (1.00 g, 1.65 mmol) in
CH2Cl2 (8.3 mL) under argon at 0°C to give a yellow solution. The mixture was stirred for
30 min at 0°C. The mixture was diluted with toluene (150 mL) and EtOAc (50 mL),
concentrated and purified by column chromatography on silica gel (toluene-EtOAc 4:1)
yielding 15 (0.83 mg, 99 %, 15α/15β 64:36).
1H NMR (500.1 MHz, CDCl3) of mixture 15α/15β (64:36):
15α: δ 1.62-1.68 (m, 1 H, H-6a), 1.95-2.08 (m, 1 H, H-6b), 2.22-2.35 (m, 2 H, H-7), 3.63
(s, 3 H, CH3), 3.75 (m, 1 H, H-4), 3.89 (m, 2 H, H-3, H-5), 4.03 (dd, 
3J1,2 = 3.7, 
3J2,3 = 9.9
Hz, 1 H, H-2), 4.65 (A of AB, 2J = 11.6 Hz, 1 H, CH2Ph), 4.71 (A of AB, 
2J = 11.8 Hz, 1 H,
CH2Ph), 4.75-4.82 (m, 2 H, CH2Ph), 4.83 (B of AB, 
2J = 11.7 Hz, 1 H, CH2Ph), 4.97 (B of
AB, 2J = 11.5 Hz, 1 H, CH2Ph), 5.24 (d, 
3J1,2 = 3.7 Hz, 1 H, H-1), 7.24-7.40 (m, 15 H, 3
C6H5); 15β: δ 1.62-1.68 (m, 1 H, H-6a), 1.95-2.08 (m, 1 H, H-6b), 2.22-2.35 (m, 2 H, H-
7), 3.37 (m, 1 H, H-5), 3.53 (dd, 3J2,3 = 9.6, 
3J3,4 = 2.8 Hz, 1 H, H-3), 3.63 (s, 3 H, CH3),
3.66 (m, 1 H, H-4), 3.75 (m, 1 H, H-2), 4.58 (d, 3J1,2 = 7.5 Hz, 1 H, H-1), 4.67 (A of AB, 
2J
= 11.6 Hz, 1 H, CH2Ph), 4.73-4.83 (m, 3 H, CH2Ph), 4.92 (B of AB, 
2J = 11.1 Hz, 1 H,
CH2Ph), 4.99 (B of AB, 
2J = 11.6 Hz, 1 H, CH2Ph), 7.24-7.40 (m, 15 H, 3 C6H5);
13C NMR (125.8 MHz, CDCl3) of mixture 15α/15β (64:36):
15α: δ 26.1 (C-7), 30.2 (C-6), 51.6 (CH3), 73.2, 74.5, 75.0, 75.3, 76.6 (5 C, C-4, C-5, 3
CH2Ph), 79.1 (C-2), 82.5 (C-3), 91.7 (C-1), 127.5, 127.6, 127.7, 127.8, 128.2, 128.3,
128.4, 138.2, 138.4, 138.6 (18 C, 3 C6H5), 173.9 (CO); 15β: δ 26.2 (C-7), 29.9 (C-6),
51.6 (CH3), 69.5, 73.1, 73.5, 74.6, 76.2 (6 C, C-3, C-4, C-5, 3 CH2Ph), 80.8 (C-2), 97.8
(C-1), 127.5, 127.6, 127.7, 127.8, 128.2, 128.3, 128.4, 138.2, 138.4, 138.6 (18 C, 3
C6H5), 173.9 (CO).
[α]D
20 = + 56.7 ( c = 1.02, CHCl3, 15α/15β 64:36)
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IV.2.2 GalNAc mimic 42
Experiment 13: MAR-158
2-Naphtylamine (61): To a mixture of NH2OH⋅HCl (6.8 g, 98 mmol) and β-naphtoic acid
(16.0 g, 92.9 mmol) was added polyphosphoric acid (200 g). The mixture was stirred
mechanically and the temperature was gradually raised. At 160°C the evolution of
carbon dioxide ceased and the dark-brown mixture was poured on crushed ice (1000
mL). Filtration of the mixture yielded 2.8 g of an orange solid that was eliminated. The
filtrate was brought to pH 12 with a saturated KOH solution. The precipitated amine was
collected, dried and purified by column chromatography on silica gel (petroleum ether-
EtOAc 5:1) yielding light tan 2-naphtylamine 61 (9.13 g, 69%).
Elementary analysis
C10 H9 N calculated C 83.88 H 6.34 N 9.78
(143.19) found C 83.56 H 6.52 N 9.61
Experiment 14: MAR-100
4-Hydroxy-5-methyldihydro-2(3H)-furanone (rac-62): To a solution of NMO·2H2O
(1.82 g , 13.5 mmol) and  OsO4 (8 mg, 0.03 mmol) in H2O (5 mL), acetone (2 mL) and
tBuOH (0.8 mL) was added methyl 3-pentenoate 63 (0.79 mL,10 mmol). The slightly
exothermic reaction was maintained at 25°C with a water bath and stirred for 12 h at this
temperature. Na2S2O4 (0.1 g), magnesium trisilicate (1.2 g), and H2O (8 mL) were added
to the mixture, which was then filtrated. The filtrate was brought to pH 7 by dropwise
addition of 1N H2SO4, washed with brine (30 mL) and extracted with EtOAc (3 x 30 mL).
The combined organic layers were dried with Na2SO4, concentrated and purified by
column chromatography (petroleum ether-EtOAc 2:1) yielding rac-62 (0.98 g, 86%).
1H NMR (500.1 MHz, CDCl3): δ1.44 (d, 
3J4,5 = 6.4 Hz, 3 H, H-5), 2.57 (dd, 
2J2a,2b = 17.8,
3J2a,3 = 1.1 Hz, 1 H, H-2a), 2.82 (dd, 
2J2a,2b = 17.8,
 3J2b,3 = 5.6 Hz, 1H, H-2b), 4.45 (m, 1
H, H-3), 4.59 (dq, 3J3,4 = 3.8,
 3J4,5 = 6.5 Hz, 1 H, H-4);
13C NMR (125.8 MHz, CDCl3): δ 13.8 (C-5), 37.5 (C-2), 69.5 (C-3), 81.3 (C-4), 176.5 (C-
1).
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Experiment 15: MAR-169
(+)-(4R,5R)-4-Hydroxy-5-methyldihydro-2(3H)-furanone ((+)-62): To a mixture of AD-
mix-β (50 g) and CH2SO2NH2 (2.38 g, 25 mmol) in tBuOH/H2O 1:1 (360 mL) was added
methyl 3-pentenoate 63 (4.08 g, 4.39 mL, 35.7 mmol) at 0°C. The reaction was stirred
for 28 h at this temperature and then quenched by addition of Na2SO3 (53.5 g, 425
mmol). The mixture was stirred for 1 h and then extracted with EtOAc (3 x 100 mL). The
combined organic layers were dried with Na2SO4, concentrated and purified by column
chromatography on silica gel (CH2Cl2-MeOH 19:1) yielding 62 as an oil (3.32 g, 80%). 4-
Dimethylaminocinnamaldehyde-HCl reagent was used as TLC reagent.
1H NMR (500.1 MHz, CDCl3): δ 1.42 (d, 
3J4,5 = 6.4 Hz, 3 H, H-5), 2.55 (dd, 
2J2a,2b = 17.8 ,
3J2a,3 = 0.6 Hz, 1 H, H-2a), 2.80 (dd, 
2J2,2b = 17.8,
 3J2b,3 = 5.6 Hz, 1 H, H-2b), 4.45 (m, 1
H, H-3), 4.57 (dq, 3J3,4 = 3.8,
 3J4,5 = 6.5 Hz, 1 H, H-4);
13C NMR (125.8 MHz, CDCl3): δ 13.8 (C-5), 37.5 (C-2), 69.5 (C-3), 81.3 (C-4), 176.5 (C-
1).
[α]D
20 = + 56.7 ( c = 1.02, CHCl3, (+)-62)
Elementary analysis
C5 H8 O3 calculated C 51.72 H 6.94
(116.12) found C 51.34 H 6.98
 IV.2.2.1 Test with shift reagent:
Racemate MAR-100
rac-62 (6.5 mg) and (S)-(+)-2,2,2-Trifluoro-1-(9-anthryl)ethanol 109  (48 mg) were
dissolved with stirring in CDCl3/TMS in a NMR tube. The NMR spectrum was
immediately recorded.
1H NMR (500.1 MHz, CDCl3): δ 1.21 (d, 
3J4,5 = 6.5 Hz, 3 H, HA-5), 1.25 (d, 
3J4,5 = 6.5 Hz,
3 H, HB-5), 2.57 (m, 2 H, HA-2a, HB-2a), 2.46-2.56 (m, 2 H, HA-2b, HB-2b), 4.12 (m, 2 H,
HA-3, HB-3), 4.26-4.32 (m, 2 H, HA-4, HB-4), 6.49-8.92 (Shift reagent).
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Stereospecific MAR-169
(+)-62  (5.6 mg) and (S)-(+)-2,2,2-Trifluoro-1-(9-anthryl)ethanol 109 (36 mg) were
dissolved with stirring in CDCl3/TMS in a NMR tube. The NMR spectrum was
immediately recorded.
1H NMR (500.1 MHz, CDCl3): δ 1.26 (d, 
3J4,5 = 6.5 Hz, 3 H, H-5), 2.38 (m, 1 H, H-2a),
2.59 (dd, 2J2a,2b = 17.8,
 3J2,3 = 5.6 Hz, 1H, H-2b), 4.19 (m, 1 H, H-3), 4.35 (m, 1 H, H-4),
6.53-8.94 (Shift reagent).
Experiment 16: MAR-79
(4R,5R)-4-Benzyloxymethoxy-5-methyl-dihydro-furan-2-one (60): To a solution of
(+)-62 (480 mg, 4.13 mmol) in CH2Cl2 (2.4 mL) were added DIPEA (1.60 g, 12.4 mmol)
and BOM-Cl (1.45 g, 1.72 mL of a 60% solution in CH2Cl2, 9.28 mmol) under argon. The
reaction was stirred for 2.5 h at 25°C and additional DIPEA (0.53 g, 4.1 mmol) and BOM-
Cl (0.48 g, 0.57 mL of a 60% solution in CH2Cl2, 3.06 mmol) were added. The mixture
was stirred for another 12 h and quenched with 1 M aqueous KH2PO4 (50 mL). The
aqueous layer was extracted with CH2Cl2 (3 x 40 mL). The combined organic phases
were dried with Na2SO4, concentrated and purified by column chromatography on silica
gel (petroleum ether-EtOAc 4:1) yielding 60 (610 mg, 62%).
1H NMR (500.1 MHz, CDCl3): δ 1.43 (d, 
3J4,5 = 6.5 Hz, 3 H, H-5), 2.65 (dd, 
2J2a,2b = 17.7,
3J2a,3 = 2.2 Hz, 1 H, H-2a), 2.71 (dd, 
2J2a,2b = 17.7,
 3J2b,3 = 5.5 Hz, 1 H, H-2b), 4.40 (m, 1
H, H-3), 4.62 (s, 2 H, OCH2OBn), 4.64 (m, 1 H, H-4), 4.70-4.84 (m, 2 H, CH2Ph), 7.30-
7.38 (m, 5 H, C6H5);
13C NMR (125.8 MHz, CDCl3): δ 14.2 (C-5), 36.7 (C-2), 70.1 (CH2Ph), 74.0 (C-3), 80.0
(C-4), 93.7 (OCH2OBn), 127.9, 128.0, 128.6, 137.2 (6C, C6H5), 175.1 (C-1).
[α]D
20 = - 11.2 ( c = 0.25, CHCl3, 60)
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Experiment 17: MAR-87
(3R,4R)-3-Benzyloxymethoxy-4-hydroxy-N-(2-naphtyl) pentanoic amide (59): To a
solution of 2-naphtylamine 61 (810 mg, 5.65 mmol) in dry CH2Cl2 (28 mL) was added
AlMe3 (410 mg, 2.81 mL of a 2M solution in heptane, 5.65 mmol) under argon. The
mixture was stirred for 15 min at 25°C. A solution of 60 (1.29 g, 5.14 mmol) in CH2Cl2
(56 mL) was added to the mixture, which was stirred for 30 min at 25°C. 61 (200 mg,
1.41 mmol) in dry CH2Cl2 (7 mL) and AlMe3 (100 g, 0.70 mL, 1.41 mmol) were added to
the mixture, which was stirred for another 16 h, quenched with 0.1N HCl (100 mL) and
extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were dried with Na2SO4,
concentrated and purified by column chromatography on silica gel (petroleum ether-
EtOAc 65:35) yielding 59 (1.73 g, 82%).
1H NMR (500.1 MHz, CDCl3): δ 1.22 (d, 3 H, H-5), 2.53-2.68 (dd, 1 H, H-2a), 2.71-2.84
(dd, 1 H, H-2b), 2.97 (s, 1 H, OH), 3.84-3.97 (m, 2 H, H-3, H-4), 4.67 (s, 2 H OCH2OBn),
4.85 (m, 2 H, CH2Ph), 7.23-8.15 (m, 12 H, C6H5, C10H7);
13C NMR (125.8 MHz, CDCl3): δ 19.8 (C-5), 41.4 (C-2), 69.8 (C-4), 70.1 (CH2Ph), 82.3
(C-3), 95.6 (OCH2OBn), 118.1, 120.7, 125.3, 126.4, 127.6, 128.2, 132.1, 134.6, 135.7,
137.5 (m, 16 C, C6H5, C10H7), 169.0, 172.3 (2 C, C-1, CO).
[α]D
20 = - 14.7 ( c = 0.49, CHCl3, 59)
Experiment 18: MAR-88
(3R,4R)-3-Benzyloxymethoxy-4-benzoyloxy-N-(2-naphtyl)-pentanoic acid (58):
Pyridine (0.73 mL, 9.1 mmol) and BzCl (0.69 mL, 5.9 mmol) were added to a solution of
alcohol 59 (1.73 g, 4.55 mmol) in CH2Cl2 (5 ml) at 0°C under argon. The mixture was
stirred for 30 min, quenched with 1M KH2PO4 (30 mL), diluted with CH2Cl2 (30 mL) and
extracted with CH2Cl2 (3 x 30 mL). The combined organic layers were dried with Na2SO4,
concentrated and purified by column chromatography on silica gel (petroleum ether-
EtOAc 7:3) yielding 58 (2.01 g, 92 %).
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1H NMR (500.1 MHz, CDCl3): δ 1.43 (d, 3 H, H-5), 1.66 (s, 1 H, NH), 2.67-2.75 (dd, 1 H,
H-2a), 2.79-2.85 (dd, 1 H, H-2b), 4.33 (m, 1 H, H-3), 4.66 (s, 2 H, OCH2OBn), 4.95 (m, 2
H, CH2Ph), 5.46 (m, 1 H, H-4), 7.27-8.25 (m, 17 H, 2 C6H5, C10H7);
13C NMR (125.8 MHz, CDCl3): δ 16.0 (C-5), 40.0 (C-2), 68.8 (C-4), 70.8 (CH2Ph), 71.8
(C-3), 95.6 (OCH2OBn), 117.0, 119.8, 120.2, 125.4, 126.8, 127.9, 128.1, 128.2, 128.8,
128.9, 129.1, 130.1, 130.4, 131.0, 133.6, 134.2, 135.7, 136.6 (m, 22 C, 2 C6H5, C10H7),
166.3,169.0 (2 C, C-1, CO).
[α]D
20 = - 36.4 ( c = 0.51, CHCl3, 58)
Experiment 19: MAR-89
(3R,4R)-4-Benzoyloxy-3-hydroxy-N-(2-naphtyl)-pentanoic amide (42): Pd-C 10%
(52 mg) was added to a solution of 58 (100 mg, 0.213 mmol) in dioxane (6.5 mL) and
HClO4 60% (2 µL). The solution was degased under argon and hydrogenated for 12 h
(1.2 Bar H2) with vigorous stirring at 25°C. The mixture was filtered on Celite and
washed with dioxane (2 x 10 mL). The filtrate was concentrated, dried with Na2SO4 and
purified by column chromatography on silica gel (petroleum ether-EtOAc, 3:2) yielding
34 mg (45%) of product 42.
1H NMR (500.1 MHz, CDCl3): δ 1.46 (d, 
3J4,5 = 6.5 Hz, 1 H, H-5), 2.67 (m, 2 H, H-2), 4.29
(m, 1H, H-3), 5.25 (m, 1 H, H-3), 7.38-8.13 (m, 12 H, C6H5, C10H7);
13C NMR (125.8 MHz, CDCl3): δ 16.4 (C-5), 40.5 (C-2), 71.0 (C-4), 73.6 (C-3), 117.0,
120.0, 125.2, 126.6, 127.6, 127.8, 128.6, 128.9, 129.8, 129.9, 130.8, 133.4, 133.9, 135.0
(16C, C6H5, C10H7), 170.0 (C-1).
[α]D
20 = + 3.1 ( c = 1.00, CHCl3, 42)
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Experiment 20: MAR-168 / MAR-118
(4R,5R)-4-(tert-Butyldimethylsilyloxy)-5-methyl-dihydrofuran-2-one (66):
To a solution of TBDMS-Cl (1.95 g, 12.9 mmol) and imidazole (1.17 g, 17.2 mmol) in dry
DMF (3 mL) was added (+)-62 (1.00 g, 8.6 mmol) under argon. The mixture was stirred
at 50°C for 12 h then H2O (40 mL) and MeOH (20 mL) were added. The mixture was
extracted with CH2Cl2 (5 x 50 mL). The combined organic layers were dried with Na2SO4,
concentrated and purified by column chromatography on silica gel (petroleum ether-
EtOAc 8:1) yielding 66 as a white solid (1.91 g, 96 %).
1H NMR (500.1 MHz, CDCl3): δ 0.08 (s, 6 H, 2 CH3), 0.90 [s, 9 H, C(CH3)3], 1.37 (d, 
3J4,5
= 6.4 Hz, 3 H, H-5), 2.45 (dd, 2J2a,2b = 17.3,
 3J2a,3 = 1.6 Hz, 1 H, H-2a), 2.73 (dd, 
2J2a,2b =
17.3, 3J2b,3 = 5.4 Hz, 1 H, H-2b), 4.38 (m, 1 H, H-3), 4.54 (dq, 
3J3,4 = 4.0,
 3J4,5 = 6.4 Hz, 1
H, H-4);
13C NMR (125.8 MHz, CDCl3): δ   -5.0 (2 C, 2 CH3), 14.5 (C-5), 18.2 [C(CH3)3], 25.7
[C(CH3)3], 39.9 (C-2), 70.1 (C-3), 81.3 (C-4), 175.7 (C-1).
[α]D
20 = + 15.2 ( c = 1.00, CHCl3, 66)
Experiment 21: MAR-120
(3R,4R)-3-(tert-Butyldimethylsilyloxy)-4-hydroxy-N -(2-naphtyl)-pentanoic amide
(67): To a solution of 2-naphtylamine 61 (1.6 g, 11.2 mmol) in dry CH2Cl2 (40 mL) was
added AlMe3 (5.56 mL of a 2 M solution in heptane, 11.2 mmol) under argon and the
mixture was stirred for 15 min at 25°C. A solution of 66 (2.34 g, 10.2 mmol) in CH2Cl2
(80 mL) was added to the mixture, which was stirred for 30 min at 25°C. The mixture
was quenched with 0.1 N HCl (100 mL) and extracted with CH2Cl2 (5 x 75 mL). The
combined organic layers were dried with Na2SO4, concentrated and purified by column
chromatography on silica gel (petroleum ether-EtOAc 3:1) yielding 67 (3.23 g, 85%).
1H NMR (500.1 MHz, CDCl3): δ 0.14, 0.17 (2 s, 6 H, 2 CH3), 0.95  [s, 9 H, C(CH3)3], 1.23
(d, 3J4,5 = 6.4 Hz, 1 H, H-5), 2.56 (dd, 
2J2a,2b = 14.6,
 3J2a,3 = 5.4 Hz, 1 H, H-2a), 2.78 (dd,
2J2a,2b = 14.6,
 3J2b,3 = 6.0 Hz, 1 H, H-2b), 3.83 (m, 1 H, H-4), 4.06 (m, 1 H, H-3), 7.38-8.21
(m, 7 H, C10H7).
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13C NMR (125.8 MHz, CDCl3): δ  -4.6, -4.4 (2 C, 2 CH3), 18.2 [C(CH3)3], 19.7 (C-5), 26.0
[C(CH3)3], 42.6 (C-2), 69.8 (C-3), 73.8 (C-4), 116.6, 119.8, 125.1, 126.6, 127.7, 127.8,
128.9, 130.7, 134.0, 135.4 (10 C, C10H7), 168.0 (CO).
[α]D
20 = - 19.1 ( c = 1.02, CHCl3, 67)
Experiment 22: MAR-124
 (3R,4R)-4-Benzoyloxy-3-(tert-butyldimethylsilyloxy)-N-(2-naphtyl)-pentanoic
amide (68): Pyridine (1.39 mL, 17.3 mmol) and BzCl (1.30 mL, 11.2 mmol) were added
to a solution of alcohol 67 (3.23 g, 8.63 mmol) in CH2Cl2 (30 ml) at 0°C under argon. The
mixture was stirred for 12 h at 0°C, quenched with 1 M KH2PO4 (35 mL), diluted with
CH2Cl2 (30 mL) and extracted with CH2Cl2 (3 x 30 mL). The combined organic layers
were dried with Na2SO4, concentrated and purified by column chromatography on silica
gel (petroleum ether-EtOAc 7:3) yielding 68 (4.12 g, quant.).
1H NMR (500.1 MHz, CDCl3): δ 0.10, 0.14 (2 s, 6 H, 2 CH3), 0.90 [s, 9 H, C(CH3)3], 1.38
(d, 3J4,5 = 6.5 Hz, 1 H, H-5), 2.58 (dd, 
2J2a,2b = 14.5,
 3J2a,3 = 6.6 Hz, 1 H, H-2a), 2.78 (dd,
2J2a,2b = 14.5,
 3J2b,3 = 4.3 Hz, 1 H, H-2b), 4.37 (m, 1 H, H-3), 5.36 (m, 1 H, H-4), 7.38-8.24
(m, 12 H, C6H5, C10H7);
13C NMR (125.8 MHz, CDCl3):  δ -4.6 (2 C, 2 CH3), 15.4 (C-5), 18.1 [C(CH3)3], 25.9
[C(CH3)3], 41.7 (C-2), 71.3 (C-3), 72.4 (C-4), 116.7, 119.9, 120.1, 125.1, 126.6, 127.7,
127.9, 128.5, 128.9, 129.0, 129.9, 130.3, 130.7, 130.8, 133.2, 134.0, 135.5  (16 C, C6H5,
C10H7), 166.1, 169.1 (2 C, C-1, CO).
[α]D
20 = - 50.1 ( c = 1.01, CHCl3, 68)
Elementary analysis
C28H35O4N Si calculated C 70.40 H 7.39 N 2.93
(477.67) found C 70.15 H 7.28 N 2.72
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Experiment 23: MAR-129
(3R,4R)-4-Benzoyloxy-3-hydroxy-N-(2-naphtyl)-pentanoic amide (42): 68  (3.46 g,
7.25 mmol) was added to a solution of AcOH (21 mL), H2O (7 mL) and THF (7 mL).  The
mixture was stirred for 4 h at 70°C, neutralized (pH 7) with 2 M KHCO3 (150 mL) and
extracted with CH2Cl2 (5 x 40 mL). The combined organic layers were dried with Na2SO4,
concentrated and purified by column chromatography on silica gel (petroleum ether-
EtOAc 4:1) yielding 42 (2.38 g, 90%).
1H NMR (500.1 MHz, CDCl3): δ 1.46 (d, 
3J4,5 = 6.5 Hz, 1 H, H-5), 2.67 (m, 2 H, H-2), 4.29
(m, 1 H, H-3), 5.25 (m, 1 H, H-4), 7.38-8.13 (m, 7 H, C10H7);
13C NMR (125.8 MHz, CDCl3): δ 16.4 (C-5), 40.5 (C-2), 71.0 (C-4), 73.6 (C-3), 117.0,
120.0, 125.2, 126.6, 127.6, 127.8, 128.6, 128.9, 129.8, 129.9, 130.8, 133.4, 133.9, 135.0
(16 C, C6H5, C10H7), 170.0 (2 C, C-1, CO).
[α]D
20 = + 3.1 ( c = 1.00, CHCl3, 42)
Elementary analysis
C30H22O4 calculated C 72.71 H 5.82 N 3.85
found C 72.65 H 5.99 N 3.85
IV.2.3 D-Gal building block 40
Experiment 24: MAR-67
1,2,3,4,6-Penta-O-benzoyl-α-D-galactopyranose (70): Anhydrous α-D-galactose 69
(6.66 g, 9.50 mmol) was added stepwise, while maintaining the temperature below 35°C,
to a stirred solution of pyridine (39 mL) and BzCl (33 mL) in dry chloroform (66 mL)
under argon. The mixture was stirred at 25°C for 1 h and then at 5°C for 20 h.
Chloroform (150 mL) was added to the mixture and pyridine was removed by washing
with 3 N sulfuric acid (3 x 20 mL), 5% aqueous NaHCO3 (40 mL) and water (40 mL). The
organic layer was dried with Na2SO4 and concetrated. The residue was crystallized from
ethanol yielding 70 as white crystals (21.7 g, 84 %). Literature [135] (89 %, [α]D
20 = +
187.1)
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1H NMR (500.1 MHz, CDCl3): δ 4.42 (dd, 
3J5,6a = 7.0, 
2J6a,6b = 11.4 Hz, 1 H, H-6a), 4.63
(dd, 3J5,6b = 6.5
 , 2J6a,6b = 11.4 Hz, 1 H, H-6b), 4.83 (m, 1 H, H-5), 6.03 (dd, 
3J1,2 = 3.6,
3J2,3 = 10.7 Hz, 1 H, H-2), 6.13 (dd, 
3J2,3 =10.7, 
3J3,4 = 3.3 Hz, 1 H, H-3), 6.19 (d, 
3J3,4 =
3.3 Hz, 1 H, H-4), 6.95 (d, 3J1,2 =3.6 Hz, 1 H, H-1), 7.26-8.13 (m, 25 H, 5 C6H5).
[α]D
20 = + 184.3 ( c = 1.00, CHCl3, 70 )
Elementary analysis
C41 H32 O11 calculated C 70.28 H 4.60  
(700.72) found C 70.14 H 4.58
Experiment 25: MAR-139
2,3,4,6-Tetra-O-benzoyl-α-D-galactopyranosyl bromide (40): To a solution of 70 (1.51
g, 2.14 mmol) in CH2Cl2 (1.5 mL) was added a 33% solution of HBr in AcOH (5 mL)
containing Ac2O (0.1 mL). The mixture was stirred for 2 h at 25°C, diluted with CH2Cl2
(30 mL), washed successively with an ice/water mixture (30 mL), a saturated NaHCO3
solution (30 mL), dried with Na2SO4 and concentrated. The residue was dried at 10
-3
Torr for 12 h yielding 40 (1.39 g, 99%). The compound was used without further
purification. Literature (100%, [α]D
20 = + 157)
1H NMR (500.1 MHz, CDCl3): δ 4.47 (dd, 
3J5,6a = 6.0
 , 2J6a,6b = 11.6 Hz, 1 H, H-6a), 4.64
(dd, 3J5,6b = 6.8, 
2J6a,6b = 11.6 Hz,1 H, H-6b), 4.92 (m, 1 H, H-5), 5.67 (dd, 
3J1,2 = 4.0, 
3J2,3
= 10.4 Hz, 1 H, H-2), 6.06 (dd, 3J2,3 = 10.4, 
3J3,4 = 3.4 Hz, 1 H, H-3), 6.12 (dd, 
3J3,4 = 3.4,
3J4,5 = 4.4 Hz, 1 H, H-4), 6.98 (d, 
3J1,2 = 4.0 Hz, 1 H, H-1), 7.25-8.08 (m, 20 H, 4 C6H5);
13C NMR (125.8 MHz, CDCl3): δ 61.7 (C-6), 68.1 (C-4), 68.6 (C-2), 71.8 (C-5), 88.3 (C-
1), 128.4, 128.5, 128.6, 128.7, 128.8, 129.3, 129.8, 129.9, 130.0, 133.3, 133.4, 133.8
(24 C, 4 C6H5), 165.9, 165.4 (4 C, 4 CO).
[α]D
20 = + 155.8 ( c = 1.00, CHCl3, 40)
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IV.2.4 Cyclohexyl lactic acid building block 39
Experiment 27: MAR-152
(R)-3-Cyclohexyl-2-hydroxy-propionic acid (73): Commercially available D-(+)-
phenyllactic acid (74) (5.00 g, 30.1 mmol) was dissolved in H2O (80 mL), dioxane (40
mL) and AcOH (18 mL) and hydrogenated (3 bar H2) in the presence of 5% Rh/Al2O3
(0.75 g) for 48 h. 5% Rh/Al2O3 (0.25 g) was added and the mixture was hydrogenated for
another 24 h. The black suspension was filtered and the filtrate concentrated. H2O was
removed by co-evaporation with toluene (2 x 50 mL). The residue was dried at 10-3 Torr
yielding 73 as a white solid (5.18 g, 100 %).
1H NMR (500 MHz, CDCl3): δ 0.87-1.86 (m, 11 H, C6H11), 1.59 (m, 2 H, H-3), 4.32 (m, 1
H, H-2);
13C NMR (125 MHz, CDCl3): δC 26.0, 26.2, 26.4, 32.2, 33.9 (6 C, C6H11), 41.9 (C-3), 68.6
(C-2), 185.8 (C-1).
Experiment 28: MAR-161
Benzyl (R)-3-Cyclohexyl-2-hydroxy-propionate (72): 73  (5.18 g, 30.1 mmol) was
dissolved in MeOH/H2O (9:1, 35 mL). The pH was adjusted to 8 by dropwise addition of
20% Cs2CO3 in H2O to give a clear yellowish solution. The mixture was concentrated
and co-evaporated with EtOH (2 x 30 mL) and hexane (2 x 30 mL). The residue was
dried at 10-3 Torr for 45 min. The remaining oil was dissolved in DMF (35 mL) and BnBr
(3.57 mL, 30.1 mmol) was added. After stirring for 1 h at 25°C, the white suspension was
diluted with CH2Cl2 (50 mL), filtered and washed with CH2Cl2 (3 x 50 mL). The combined
organic phases were concentrated and purified by column chromatography on silica gel
(petroleum ether-EtOAc 2:1) yielding 73 (4.47 g, 75%).
1H NMR (500.1 MHz, CDCl3): δ 0.85-1.82 (m, 12 H, H-3, C6H11), 4.27 (m, 1 H, H-2), 5.20
(s, 2 H, CH2Ph), 7.33-7.40 (m, 5 H, C6H5);
13C NMR (125.8 MHz, CDCl3): δ 26.0, 26.3, 32.3, 33.7, 33.9 (6 C, C6H11), 42.1 (C-3),
67.3 (CH2Ph), 68.6 (C-2), 128.4, 128.6, 128.7, 135.2 (6 C, C6H5), 175.9 (C-1).
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Experiment 29: MAR-164
Benzyl (R )-3-cyclohexyl-2-trifluoromethanesulfonyloxy-propionate (39): To a
solution of 72 (4.47 g, 27.3 mmol) in CH2Cl2 (50 mL) and 2,6-di-tert-butylpyridine (0.45
mL, 0.27 mmol) was added dropwise Tf2O (4.24 mL, 27.3 mmol) within 1.5 h at –20°C
under argon. 1 M KH2PO4 (30 mL) and CH2Cl2 (50 mL) were added to the mixture, which
was extracted with CH2Cl2 (3 x 30 mL). The combined organic layers were washed with
H2O (30 mL), dried with Na2SO4, concentrated and purified by column chromatography
on silica gel (petroleum ether-CH2Cl2 4:1) yielding 39 (5.80 g, 80 %).
1H NMR (500.1 MHz, CDCl3): δ 0.85-1.94 (m, 13 H, H-3, C6H11), 5.17 (m, 1 H, H-2), 5.25
(s, 2 H, CH2Ph), 7.31-7.40 (m, 5 H, C6H5);
13C NMR (125.8 MHz, CDCl3): δ 25.7, 26.0, 26.1, 32.0, 33.2, 33.4 (6 C, C6H11), 39.2 (C-
3), 68.2 (2 C, C-2, CH2Ph), 81.9 (CF3), 128.6, 128.7, 128.9, 134.4 (6 C, C6H5), 167.6 (C-
1).
Elementary analysis
C17 H21 F3O3S calculated C 51.77 H 5.37  
(394.41) found C 51.67 H 5.41
IV.2.5 1st Attempt
Experiment 30: MAR-140/R
(3R,4R)-(Methyl 2,3,4-tri-O-benzyl-6,7-dideoxy-α-L-galacto-octopyranosyl-uronate)-
(1→3)-4-benzoyloxy-3-hydroxy-N-(2-naphtyl)-pentanoic amide (86 ): 15  (801 mg,
1.58 mmol) was dissolved in dry CH2Cl2 (11.7 mL) and dry DMF (1.8 mL) under argon.
The mixture was cooled to 0°C and (COBr)2 (0.332 mL, 3.04 mmol) was added to give a
white suspension. The reaction was warmed to 25°C within 20 min and the mixture was
stirred for 2 h, giving a thick white suspension. The suspension was filtered with, washed
with Et2O (2 x 20 mL) and the filtrate was concentrated. The residue was dried for 30
min at 10-3 Torr to give a dark yellow oil (1.3 g). The oil was dissolved in CH2Cl2 (5.7 mL)
and the solution added to a suspension of 42 (1.15 g, 3.16 mmol), MS4Å (500 mg) and
Bu4NBr (0.510 g, 1.58 mmol) in dry CH2Cl2 (5.85 mL) / DMF (3.84 mL) under argon. The
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mixture was stirred for 16 h at 25°C, diluted with CH2Cl2 (20 mL) and filtered through
Celite. The filtrate was quenched with KHCO3 10% (20 mL) and extracted with CH2Cl2 (3
x 30 mL). The organic layer was washed with 1 M KH2PO4 (30 mL). The aqueous layer
was extracted with CH2Cl2 (2 x 20mL). The combined organic layers were dried with
Na2SO4, concentrated and purified by column chromatography (EtOAc-toluene 1:4)
yielding 86 (594 mg, 44%) and 111 (378 mg, 28%).
1H NMR (500.1 MHz, CDCl3): δ 1.41 (d, 3 H, 
3J4,5 = 6.5 Hz, 1 H, H-5), 1.53 (m, 1 H, Fuc-
H6a), 1.79 (m, 1 H, Fuc-H6b), 1.88 (m, 2 H, Fuc-H7), 2.53 (dd, 2J2a,2b = 15.3,
 3J2a,3 = 4.0
Hz, 1 H, H-2a), 2.80 (dd, 2J2a,2b = 15.3,
 3J2b,3 = 4.0 Hz, 1 H, H-2b), 3.55 (m, 1 H, Fuc-H4),
3.61 (s, 3 H, CH3), 3.99 (m, 
3J2,3 = 10.3, 
3J3,4 = 2.5 Hz, 1 H, Fuc-H3), 4.05 (m, 1 H, H-3),
4.19 (dd, 3J1,2 = 3.7, 
3J2,3 = 10.3 Hz, 1 H, Fuc-H2), 4.88-4.56 (m, 4 H, 2 CH2Ph), 4.89 (d,
3J1,2 = 3.7 Hz,1 H, H-1), 4.96 (m, 2 H, CH2Ph), 5.48 (m, 1 H, H-4), 7.13-9.47 (m, 28 H, 3
C6H5, C10H7);
13C NMR (125.8 MHz, CDCl3): δ 16.4 (C-5), 25.7 (Fuc-C6), 29.5 (Fuc-C7), 37.9 (C-2),
51.5 (CH3), 70.7 (C-4), 73.1, 74.7, 74.8 (3 C, 3 CH2Ph), 75.5 (Fuc-C2), 75.7 (Fuc-C4),
76.9 (C-3), 79.7 (Fuc-C3), 97.1 (Fuc-C1), 116.8, 120.2, 124.7, 125.3, 126.1, 127.3,
127.4, 127.7, 127.8, 128.3, 128.4, 128.6, 128.7, 128.8, 129.0, 129.5, 130.0, 130.5,
133.0, 133.9, 136.0, 137.1, 137.9, 138.2, 138.3 (34 C, 4 C6H5, C 10H7), 173.3, 168.2,
165.5 (3 CO).
[α]D
20 = - 115.3  ( c = 1.04, CHCl3, 86)
Elementary analysis
C53H55 NO10 calculated C 73.31 H 6.27 N 1.64
(852.00) found C 73.14 H 6.19 N 1.47
 Orthoester (111)
1H NMR (500.1 MHz, CDCl3): δ 1.44 (d, 1 H, H-1), 1.57 (m, 1 H, Fuc-H6a), 2.00 (m, 1 H,
Fuc-H6b),2.21-2.38 (m, 2 H, Fuc-H7), 2.74 (m, 1 H, H-4), 3.59 (m, 1 H, Fuc-H4), 3.60 (s,
3 H, CH3), 3.74 (m, 1 H, Fuc-H5), 3.86 (dd, 
3J2,3 = 10.0, 
3J3,4 = 2.6 Hz 1 H, Fuc-H3), 4.07
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(dd, 3J1,2 = 3.7,
 3J2,3 = 10.0 Hz 1 H, Fuc-H2), 4.43 (2 d, 2 H, 
3Jvic-2’ = 11.5 Hz, H-2), 4.48
(m, 1 H, H-3), 4.54-4.90 (m, 6 H, 3 CH2Ph), 5.29 (d, 
3J1,2 = 3.7 Hz, 1 H, Fuc-H1), 7.19-
8.86 (m, 22 H, 3 C6H5 C10H7);
13C NMR (125.8 MHz, CDCl3): δ 15.4 (C-5), 20.9 (Fuc-C7), 41.2 (C-2), 51.7 (CH3), 70.2
(Fuc-C5), 71.3 (C-4), 74.3, 75.7 (4 C, 3 C6H5, C-3), 76.1 (Fuc-C4), 76.2 (Fuc-C3), 96.6
(Fuc-C1), 116.1,128.4, 128.5,128.7, 133.0 (28 C, 3 C6H5, C10H7).
Elementary analysis
C52H53NO10 calculated C 73.31 H 6.27  N 1.64
(851.99) found C 72.21 H 6.52 N 1.35
Experiment 31: MAR-138, MAR-142
(3R,4R)-(Methyl 2,3,4-tri-O-benzyl-6,7-dideoxy-α-L-galacto-octopyranosyl-uronate)-
(1→3)-3,4-dihydroxy-N-(2-naphtyl)-pentanoic amide (85): 86 (594 mg, 0.697 mmol)
was dissolved in dry MeOH (2 mL) to give a clear solution. 1 M NaOMe (200 µL) in dry
MeOH was added dropwise to bring the solution’s pH to 10. The mixture was stirred for
28 h at 25°C, brought to pH 7 by addition of Amberlyst 15, filtered through Celite,
washed with MeOH (50 mL) and CH2Cl2 (80 mL). The filtrate was concentrated and
purified by column chromatography (petroleum ether-EtOAc 45:55) yielding 85 (316 mg,
61% yield).
1H NMR (500.1 MHz, CDCl3): δ 1.30 (d, 3 H, 
3J4,5 = 6.4 Hz, 1 H, H-5), 1.61 (m, 1 H, Fuc-
H6a), 2.05 (m, 1 H, Fuc-H6b), 2.38-2.23 (m, 2 H, Fuc-H7), 2.42 (dd, 2J2a,2b = 14.5,
 3J2a,3 =
3.1 Hz, 1 H, H-2a), 2.68 (dd, 2J2a,2b = 14.5,
 3J2b,3 = 4.2 Hz, 1 H, H-2b), 3.62 (m, 1 H, H-3),
3.63 (s, 3 H, CH3), 3.83 (m, 2 H, Fuc-H4, H-4), 4.08 (m, 2 H, Fuc-H3, Fuc-H5), 4.25 (dd,
3J1,2 = 3.8, 
3J2,3 = 10.2 Hz, 1 H, Fuc-H2), 4.85 (m, 1 H, Fuc-H1), 5.02-4.66 (m, 6 H, 3
CH2Ph), 7.18-9.36 (m, 22 H, 3 C6H5, C10H7);
13C NMR (125.8 MHz, CDCl3): δ 19.8 (C-5), 41.2 (C-2), 51.6 (CH3), 70.6 (C-4), 74.5,
74.7, 74.8 (3 C, 3 CH2Ph), 76.3 (Fuc-C2), 80.1 (Fuc-C3), 81.8 (C-3), 97.5 (Fuc-C1),
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116.2, 119.8, 124.6, 126.2, 127.2, 127.4, 127.5, 127.6, 127.9, 128.3, 128.4, 128.5,
128.6, 128.7, 129.0 (28 C, 3 C6H5, C10H7).
[α]D
20 = - 152.5 ( c = 1.01, CHCl3, 85)
Experiment 32: MAR-143 and MAR-144
(3R,4R)-(2,3,4,6-Tetra-O-benzoyl-β-D-galactopyranosyl)-(1→4)-[(methyl 2,3,4-tri-O -
benzyl-6,7-dideoxy-α-L-galacto-octopyranosyluronate)-(1→3)]-3,4-dihydroxy-N-(2-
naphtyl)-pentanoic amide (84): Under argon and light exclusion, 85 (286 mg, 0.382
mmol) was added to a suspension of 40 (755 mg, 1.15 mmol) and MS3Å (950 mg) in dry
CH2Cl2 (5 mL). AgOTf (25.6 mg, 0.032 mmol) was added to the mixture, which was
stirred for 1h at 25°C, filtered through Celite and washed with CH2Cl2 (50 mL). The
filtrate was concentrated and the residue purified by column chromatography (toluene-
EtOAc 85:15) yielding 84 (193 mg, 38%).
1H NMR (500.1 MHz, CDCl3): δ 1.13 (d, 
3J4,5 = 6.2 Hz, 3 H, H-5), 1.82 (m, 1 H, Fuc-H6a),
2.17 (m, 1 H, Fuc-H6b), 2.40-2.50 (m, 3 H, Fuc-H7, H-2a), 2.72 (m, 1 H, H-2b), 3.64 (m,
3 H, CH3), 3.82 (m, 1 H, Fuc-H4), 4.03-4.11 (m, 3 H, Fuc-H3, H-3, H-4), 4.14 (dd,
 3J1,2 =
3.5, 3J2,3 = 10.1 Hz, 1 H, Fuc-H2), 4.18 (m, 1 H, Fuc-H5), 4.24 (m, 1 H, Gal-H5), 4.37-
4.46 (m, 2 H, Gal-H6), 4.58-4.98 (m, 6 H, 3 CH2Ph), 4.86 (d, 
3J1,2 = 8.0 Hz, 1 H, Gal-H1),
4.87 (d, 3J1,2 = 3.5 Hz, 1 H, Fuc-H1), 5.57 (dd, 
3J2,3 = 10.4, 
3J3,4 = 3.5 Hz, 1 H, Gal-H3),
5.74 (dd, 3J1,2 = 8.0, 
3J2,3 = 10.4 Hz, 1 H, Gal-H2), 5.98 (m, 1 H, Gal-H4), 7.07-9.31 (m,
42 H, 7 C6H5, C10H7).
13C NMR (125.8 MHz, CDCl3): δ 15.6 (C-5), 21.5 (Fuc-C6), 51.5 (CH3), 61.9 (Gal-C6),
68.3 (Gal-C4), 69.5 (Fuc-C3), 70.6 (Gal-C3), 71.4 (Fuc-C2), 71.7 (Gal-C5), 73.0 (Gal-
C2), 75.0, 75.9, 76.5, (5 C, C-3, C-4, 3 CH2Ph), 76.6 (C-2), 79.8 (Fuc-C3), 96.7 (Fuc-
C1), 100.6 (Gal-C1), 116.9, 120.3, 124.7, 125.3, 126.2, 127.0, 127.4, 127.5, 127.7,
128.1, 128.2, 128.3, 128.5, 128.6, 128.7, 128.8, 129.0, 129.2, 129.3, 129.7, 129.8,
130.5, 133.2, 133.3, 133.7, 133.8, 133.9, 135.9, 137.3, 138.5 (56 C, 7 C6H5, C 10H7),
165.0, 165.5, 165.6, 165.8,168.9, 173.9 (6 CO).
[α]D
20 = - 41.3 (c = 1.01, CHCl3, 84)
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Experiment 33: MAR-145
(3R,4R)-(β-D-Galactopyranosyl)-(1→4)-[(methyl 2,3,4-tri-O-benzyl-6,7-dideoxy-α-L-
galacto-octopyranosyluronate)-(1→3)]-3,4-dihydroxy-N-(2-naphtyl)-pentanoic
amide (83): 84 (215 mg, 0.162 mmol) was dissolved in dry MeOH (3 mL) and dioxane
(0.3 mL) under argon. 1 M NaOMe (200 µL) in dry MeOH was added to bring the
solution’s pH to 10. The mixture was stirred for 16 h at 25°C, brought to pH 7 with
Amberlyst 15 (ion exchanger), filtered through Celite and washed with CH2Cl2 (30 mL).
The organic layer was co-evaporated with toluene (2 x 20 mL) and concentrated to give
the crude product 83 (146 mg, 99%).
1H NMR (500.1 MHz, CDCl3): δ 1.19 (d, 
3J4,5 = 6.1 Hz, 3 H, H-5), 1.64-1.70 (m, 1 H, Fuc-
H6a), 1.97-2.04 (m, 1 H, Fuc-H6b), 2.32 (m, 2 H, Fuc-H7), 2.46 (m, 1 H, H-2a), 2.79 (m,
1 H, H-2b), 3.35 (m, 1 H, Gal-H5), 3.52 (m, 1 H, Gal-H3), 3.58-3.63 (m, 4 H, CH3, Gal-
H2), 3.66-3.77 (m, 2 H, Gal-H6), 3.81 (m, 1 H, Fuc-H4), 3.94 (m, 1 H, Gal-H4), 3.99-4.08
(m, 3 H, Fuc-H5, H-3, H-4), 4.13 (dd, 3J1,2 = 3.5,
 3J2,3 = 10.1 Hz, 1 H, Fuc-H2), 4.23 (d,
3J1,2 = 7.5 Hz, 1 H, Gal-H1), 4.60-5.00 (m, 6 H, 3 CH2Ph), 4.90 (d, 
3J1,2 = 3.2 Hz, 1 H,
Fuc-H1), 7.10-9.31 (m, 22 H, 3 C6H5, C10H7);
13C NMR (125.8 MHz, CDCl3): δ 15.8 (C-5), 51.9 (CH3), 62.5 (Gal-C6), 67.8 (Fuc-C5),
70.0 (Gal-C4), 71.8 (Gal-C2), 73.2 (Gal-C3), 73.8 (Gal-C4), 74.3, 74.8, 75.3 (4 C, Gal-
C5, 3 CH2Ph), 75.8 (C-4), 76.5 (Fuc-C4), 79.9 (C-2), 98.1 (Fuc-C1), 101.2 (Gal-C1),
116.7, 120.1, 124.8, 125.3, 126.3, 127.3. 127.5, 127.7, 128.1, 128.2, 128.3, 128.5,
128.6, 129.0, 130.5, 133.8, 135.8, 137.4, 137.9, 138.4, 138.6 (28 C, 3 C6H5, C 10H7),
174.5 (2 C, 2 CO).
Experiment 34: MAR-146
(3R,4R)-(4,6-O-Benzylidene-β-D-galactopyranosyl)-(1→4)-[(methyl 2,3,4-tri-O -
benzyl-6,7-dideoxy-α-L-galacto-octopyranosyluronate)-(1→3)]-3,4-dihydroxy-N-(2-
naphtyl)-pentanoic amide (82): 83 (146 mg, 0.160 mmol) was azeotropically dried with
toluene (4 x 10 mL), concentrated, dried for 1 h at 10-3 Torr and dissolved in dry MeCN
(4.40 mL) under argon. PhCH(OMe)2 (90.2 mg, 0.593 mmol) and CSA (15.6 mg, 0.06
mmol) were added to the solution and the mixture was stirred for 100 min at 25°C. The
mixture was quenched with 1 M KHCO3 (25 ml) and extracted with CH2Cl2 (3 x 15 mL).
The organic layers were brought together, dried with Na2SO4, concentrated and purified
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by column chromatography on silica gel (petroleum ether-EtOAc 1:2) yielding 82 (126
mg, 79 %).
1H NMR (500.1 MHz, CDCl3): δ1.26 (d, 
3J4,5 = 2.3 Hz, 3 H, H-5), 1.59-1.66 (m, 1 H, Fuc-
H6a), 1.93-2.01 (m, 1 H, Fuc-H6b), 1.93-2.01 (m, 3 H, Fuc-H7, H-2a), 2.67 (m, 1 H, H-
2b), 3.25 (m, 1 H, Gal-H5), 3.42 (m, 1 H, Fuc-H4), 3.67-3.70 (m, 5 H, Gal-H2, Gal-H3,
CH3), 3.77 (m, 1 H, H-3), 3.87 (m, 1 H, H-4), 3.91-4.00 (m, 1 H, Gal-H6), 4.06-4.13 (m, 3
H, Fuc-H2, Fuc-H3, Gal-H4), 4.20 (d, 3J1,2 = 7.3 Hz, 1 H, Gal-H1), 4.48 (m, 1 H, Fuc-H5),
4.56-4.83 (m, 6 H, CH2Ph), 4.74 (d, 
3J1,2 = 2.8 Hz, 1 H, Fuc-H1), 5.56 (s, 1 H, CH), 7.06-
9.68 (m, 27 H, 4 C6H5, C10H7);
13C NMR (125.8 MHz, CDCl3): δ 16.9 (C-5), 51.8 (CH3), 66.3 (Gal-C5), 70.0 (C-4), 71.2
(Gal-C2), 72.4 (Gal-C3), 72.6, 74.8, 75.1 (3 C, 3 CH2Ph), 75.1 (Gal-C6), 75.3 (Gal-C4),
75.9 (C-3), 76.3 (Fuc-C3), 77.8 (Fuc-C4), 79.8 (Fuc-C3), 95.4 (Fuc-C1), 100.1 (CH),
100.8 (Gal-C1), 116.3, 120.0, 124.7, 125.3, 126.0, 126.3, 127.1, 127.3, 127.4, 127.6,
127.8, 128.1, 128.2, 128.3, 128.4, 128.5, 128.6, 128.9, 129.0, 129.7, 130.3, 130.9,
132.3, 133.9, 134.5, 136.2, 137.3, 137.9, 139.0, 139.1 (34 C, 4 C6H5, C10H7), 174.9,
168.5 (2 C, 2 CO).
Experiment 35: MAR-149
(3R,4R)-(4,6-O-Benzylidene-β-D-galactopyranosyl)-(1→4)-[(2,3,4-tri-O-benzyl-6,7-
dideoxy-α-L-galacto-octopyranosiduronic acid)-(1→3)]-3,4-dihydroxy-N-(2-
naphtyl)-pentanoic amide (81): 82 (140 mg, 0.140 mmol) and LiOH (25 mg, 0.60
mmol) were dissolved in H2O (1.4 mL) and EtOH (5.3 mL). The mixture was warmed to
60°C and stirred for 2 h at this temperature. The mixture was neutralized with Amberlyst
15 and washed with ethanol (20 mL) and CH2Cl2 (20 mL). The filtrate was concentrated
and the residue dried at 10-3 Torr to give 21 (136 mg, 96% yield) as a crude product,
which was directly used in the next step.
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Experiment 36: MAR- 151
(3R,4R)-(4,6-O-Benzylidene-β-D-galactopyranosyl)-(1→4)-[(allyl 2,3,4-tri-O-benzyl-
6,7-dideoxy-α-L-galacto-octopyranosyluronate)-(1→3)]-3,4-dihydroxy-N-(2-
naphtyl)-pentanoic amide (80): Cs2CO3 (51.8 mg, 0.159 mmol) in H2O (200 µL) was
added to a solution of 81 (136 mg, 0.138 mmol) in EtOH (2.5 mL) to give a white
suspension with pH 12. The mixture was stirred for 5 min at 25°C, co-evaporated with
benzene (3 x 10 mL) and dried for 1 h at 10-3 Torr. The residue was dissolved in dry
DMF (2.5 mL) under argon and allyl bromide (23 mg, 16 µL, 0.19 mmol) was added. The
mixture was stirred for 5 h at 25°C, diluted with CH2Cl2 (20 mL), filtered through Celite
and washed with CH2Cl2 (2 x 10 mL). The filtrate was concentrated and purified by
column chromatography (petroleum ether-EtOAc gradient 6:4 to 1:1, then CH2Cl2-MeOH
19:1) yielding 80 (99 mg, 70%).
1H NMR (500.1 MHz, CDCl3): δ 1.26 (d, 
3J4,5 = 6.4 Hz, 3 H, H-5), 1.59-1.66 (m, 1 H, Fuc-
H6a), 1.95-2.03 (m, 1 H, Fuc-H6b), 2.27-2.69 (m, 3 H, Fuc-H7, H-2), 3.26 (m, 1 H, Gal-
H5), 3.42 (m, 1 H, Fuc-H4), 3.62-3.70 (m, 2 H, Gal-H2, Gal-H3), 3.77 (m, 1 H, H-3), 3.89
(m, 1 H, H-4), 3.94-4.00 (m, 1 H, Gal-H6), 4.06-4.12 (m, 1 H, Fuc-H2, Fuc-H3), 4.14 (m,
1 H, Gal-H4), 4.20 (d, 3J1,2 = 7.2 Hz, 1 H, Gal-H1), 4.48 (m, 1 H, Fuc-H5), 4.57-4.84 (m,
6 H, 3 CH2Ph), 4.58 (m, 2 H, CH2-CH=CH2), 4.74 (d, 
3J1,2 = 2.7 Hz, 1 H, Fuc-H1), 5.23-
5.34 (m, 2 H, CH2-CH=CH2), 5.57 (s, 1 H, CH), 5.88-5.96 (m, 1 H, CH2-CH=CH2), 7.08-
9.67 (m, 27 H, 4 C6H5, C10H7);
13C NMR (125.8 MHz, CDCl3): δ 16.9 (C-5), 25.7 (Fuc-C6), 30.7 (Fuc-C7), 31.4 (C-2),
65.2 (CH2-CH=CH2), 66.3 (Gal-C5), 69.3 (Gal-C6), 70.1 (Fuc-C5), 72.5 (Gal-C3), 72.6
(Gal-C2), 74.8, 75.1, 75.2, 75.3 (4 C, 3 CH2Ph, C-4), 76.0 (C-3), 76.3 (Fuc-C2), 77.7
(Fuc-C4), 79.8 (Fuc-C3), 95.4 (Fuc-C1), 100.1 (CH), 100.8 (Gal-C1), 118.3 (CH2-
CH=CH2), 120.0, 124.7, 125.9, 126.3, 126.5, 127.0, 127.1, 127.4, 127.5, 127.6, 127.7,
127.8, 128.1, 128.2, 128.3, 128.4, 128.5, 128.6, 128.9, 129.0, 129.3, 129.5, 129.8,
130.3, 133.9, 136.2, 137.3, 137.8, 138.9, 139.1, 140.9 (34 C, 4 C6H5, C10H7), 132.2
(CH2-CH=CH2),168.5, 174.0 (2 C, CO).
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Experiment 38: MAR-182
(3R,4R)-{3-[(2S)-Benzyl-3-cyclohexyl-2-hydroxypropanoate-2-O-yl]-4,6-O-
benzylidene-β-D-galactopyranosyl}-(1→4)-[(allyl 2,3,4-tri-O-benzyl-6,7-dideoxy-α-L-
galacto-octopyranosyluronate)-(1→3)]-3,4-dihydroxy-N-(2-naphtyl)-pentanoic
amide (79): 80 (82 mg, 0.08 mmol) and Bu2SnO (30 mg, 0.12 mmol) were dissolved in
C6H6 (1.5 mL) and stirred for 12 h at 90°C under argon. The mixture was concentrated
and dried at 10-3 Torr for 1 h. CsF (37 mg, 0.24 mmol) and 39 (189 mg, 0.48 mmol) were
added under argon and dissolved in DME (1 mL). The mixture was stirred for 21 h at
25°C, quenched with KF/KH2PO4 10 % (10 mL) and extracted with CH2Cl2 (3 x 10 mL).
The combined organic layers were dried with Na2SO4, concentrated and purified by
column chromatography (petroleum ether-EtOAc gradient 6:4 to 1:1, then CH2Cl2-MeOH
9:1) yielding 79 (7 mg, 7%).
1H NMR (500.1 MHz, CDCl3): δ 0.71-1.71 (m, 13 H, C6H11, CH2C6H11), 1.28 (d, 
3J4,5 = 6.5
Hz, 3 H, H-5), 1.59-1.66 (m, 1 H, Fuc-H6a), 1.92-2.06 (m, 1 H, Fuc-H6b), 2.30-2.73 (m,
3 H, Fuc-H7, H-2), 3.26 (m, 1 H, Gal-H5), 3.35 (m, 1 H, Gal-H3), 3.42 (m, 1 H, Fuc-H4),
3.62-3.70 (m, 3 H, Gal-H2, H-3, H-4), 3.89-4.04 (m, 2 H, Gal-H6), 4.06-4.15 (m, 3 H,
Fuc-H2, Fuc-H3, Gal-H4), 4.23 (d, 3J1,2 = 7.4 Hz, 1 H, Gal-H1), 4.36 (m, 1 H, Cyc-2),
4.42-4.84 (m, 6 H, 3 CH2Ph), 4.53 (m, 1 H, Fuc-H5), 4.59 (m, 2 H, CH2-CH=CH2), 4.72
(d, 3J1,2 = 2.6 Hz, 1 H, Fuc-H1), 5.14-5.22 (m,
 2 H, CH2-CH=CH2), 5.49 (s, 1 H, CH),
5.89-5.96 (m, 1 H, CH2-CH=CH2), 7.04-9.70 (m, 32 H, 5 C6H5, C10H7);
13C NMR (125.8 MHz, CDCl3): δ 16.1 (C-5), 24.6, 24.9, 28.3, 29.6, 32.0, 32.9 (6 C,
C6H11, C6H11), 25.3 (Fuc-C6), 30.7 (Fuc-C7), 31.4 (C-2), 63.8 (CH2-CH=CH2), 64.6 (Gal-
C5), 64.9 (Cyc-C2), 66.2 (Gal-C2), 67.7 (Gal-C6), 68.4 (Fuc-C5), 69.1 (Gal-C4), 71.0
(CH2Ph), 73.2, 73.8, 74.1, 74.7, 75.3, 75.8 (5 C, 3 CH2Ph, Fuc-C2, C-3, C-4), 76.2 (Fuc-
C4), 78.7 (Fuc-C3), 79.7 (Gal-C3), 94.1 (Fuc-C1), 98.7 (CH), 100.4 (Gal-C1), 119.0
(CH2-CH=CH2), 115.2, 116.7, 119.0, 125.0, 125.2, 126.1, 126.2, 126.3, 126.4, 126.6,
126.7, 127.0, 127.1, 127.2, 127.4, 127.5, 127.6, 127.8, 128.8, 129.2, 129.9, 130.2,
131.3, 131.6, 134.1, 135.4, 136.8, 138.1, 138.4 (40 C, 5 C6H5, C10H7), 132.9 (CH2-
CH=CH2), 168.5, 172.4, 174.0 (3 C, 3 CO).
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IV.2.6 Orthoesters
Experiment 39: MAR-191
1,2-O-(1-Ethoxyethylidene)-3,4,6-tri-O-benzyl-D-glucopyranose  (113): 1-chloro-
2,N,N-trimethyl-propenylamine (89.5 mg, 0.67 mmol, 95.0 µL) was added to a solution of
2-O-acetyl-3,4,6-tri-O-benzyl-D-galactopyranose 112 (300 mg, 0.617 mmol)  in CHCl3
under argon. The mixture was stirred at 25°C for 12 h. EtOH (31 mg, 0.67 mmol) and
NEt3 (68 mg, 0.67 mmol) were added and the mixture was stirred for another 12 h at
50°C and then extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were
dried with Na2SO4, concentrated and purified by column chromatography (petroleum
ether-EtOAc gradient 9:1 to 7:3 with 1% NEt3) yielding 113 (127 mg, 40 %).
1H NMR (500.1 MHz, CDCl3): δ 1.19 (m, 3 H, CH2CH3), 1.66 (s, 3 H, CH3), 3.49-3.59 (m,
2 H, CH2CH3), 3.62-3.68 (m, 2 H, H-6), 3.71 (m, 1 H, H-4), 3.78 (m, 1 H, H-5), 3.87 (m, 1
H, H-3), 4.37-4.71 (m, 6 H, 3 CH2Ph), 4.41 (m, 1 H, H-2), 5.76 (d, 1 H, 
3J1,2 = 5.2 Hz, H-
1), 7.17-7.36 (m, 15 H, 3 C6H5);
13C NMR (125.8 MHz, CDCl3): δ 15.3 (CH2CH3), 58.7 (CH2CH3), 69.1 (C-6), 70.5 (C-5),
71.9, 72.9, 73.4, 74.9, 75.8 (5 C, C-2, C-4, 3 CH2Ph), 78.8 (C-3), 97.8 (C-1), 121.0,
127.6, 127.8, 127.9, 128.0, 128.1, 128.3, 128.4, 128.5, 132.0, 137.7, 137.9, 138.1 (18 C,
3 C6H5).
Experiment 40: MAR-193
1,2-O-(1-Ethoxyethylidene)-3,4,6-tri-O-acetyl-D-glucopyranose (115): 1-chloro-
2,N,N-trimethyl-propenylamine (49 mg, 0.63 mmol, 89 µL) was added to a solution of
2,3,4,6-tetra-O-acetyl-D-galactopyranose 114  (200 mg, 0.57 mmol)  in CHCl3 under
argon. The mixture was stirred at 25°C for 12 h. EtOH (29 mg, 0.63 mmol) and NEt3 (64
mg, 0.63 mmol) were added and the mixture was stirred for another 12 h at 50°C and
then extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were dried with
Na2SO4, concentrated and purified by column chromatography (petroleum ether-EtOAc
8:2 with 1% NEt3) yielding 115 (151 mg, 70 %).
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1H NMR (500.1 MHz, CDCl3): δ 1.18 (m, 3 H, CH2CH3), 1.72 (s, 3 H, CH3), 2.04-2.12 (m,
9 H, 3 CH3), 3.52-3.57 (m, 2 H, CH2CH3), 3.95 (m, 1 H, H-5), 4.19 (m, 1 H, H-6), 4.32 (m,
1 H, H-2), 4.90 (m, 1 H, H-4), 5.19 (m, 1 H, H-3), 5.71 (d, 1 H, 3J1,2 = 8.2 Hz, H-1);
13C NMR (125.8 MHz, CDCl3): δ 15.3 (CH2CH3), 20.7, 20.8 (4 C, 4 CH3), 59.2 (CH2CH3),
63.1 (C-2), 66.9 (C-6), 68.2 (C-5), 70.1 (C-4), 13.0 (C-3), 96.9 (C-1), 121.3 (O-C-O),
169.2, 169.7, 170.8 (3 C, 3 CO).
Experiment 41: MAR-194
1,2-O-(1-Ethoxyphenylmethylene)-3,4,6-tri-O-benzoyl-D-galactopyranose (117):  1 -
chloro-2,N,N-trimethyl-propenylamine (49 mg, 0.37 mmol, 52 µL) was added to a
solution of 2,3,4,6-tetra-O-benzoyl-D-galactopyranose 116 (200 mg, 0.33 mmol)  in
CHCl3 under argon. The mixture was stirred at 25°C for 12 h. EtOH (17 mg, 0.37 mmol)
and NEt3 (37 mg, 0.37 mmol) were added and the mixture was stirred for another 12 h at
50°C and then extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were
dried with Na2SO4, concentrated and purified by column chromatography (petroleum
ether-EtOAc 8:2 with 1% NEt3) yielding 117 (150 mg, 72 %).
1H NMR (500.1 MHz, CDCl3): δ 1.13 (m, 3 H, CH2CH3), 3.30-3.45 (m, 2 H, CH2CH3),
4.13 (m, 1 H, H-5), 4.37 (m, 1 H, H-6a), 4.51 (m, 1 H, H-6b), 4.78 (m, 1 H, H-2), 5.50 (m,
1 H, H-4), 5.77 (m, 1 H, H-3), 6.05 (d, 3J1,2 = 5.3, 1 H, H-1), 7.24-8.10 (m, 20 H, 4 C6H5).
Experiment 42: MAR- 192
Ethyl 2-O-acetyl-3,4,6-tri-O-benzyl-β-D-glucopyranoside (118): HgBr2 (5 mg, mmol)
was added to a solution of 115 (20 mg, 0.003 mmol) in DCE (1 mL). EtOH (30 µL, 0.003
mmol) was added and the mixture was heated in the microwave for 30 min at 120°C.
The reaction flask was washed with CH2Cl2 (3 x 2 mL). The combined organic layers
were concentrated and purified by column chromatography on silica gel (petroleum
ether-EtOAc 3:1) yielding 118 (5 mg, 25 %).
1H NMR (500.1 MHz, CDCl3): δ 1.18 (m,
 3J = 7.1, 3 H, CH2CH3), 1.97 (s, 3 H, CH3), 3.48
(m, 1 H, H-5), 3.52-3.58 (m, 1 H, CH2CH3-Ha), 3.64-3.76 (m, 4 H, H-3, H-4, H-6), 3.86-
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3.92 (m, 1 H, C H2CH3-Hb), 4.36 (d, 
3J1,2 = 8.0 Hz, 1 H, H-1), 4.54-4.80 (m, 6 H, 3
CH2Ph), 3.98 (m, 1 H, H-2), 7.17-7.35 (m, 15 H, 3 C6H5);
13C NMR (125.8 MHz, CDCl3): δ 15.1 (CH2CH3), 20.9 (CH3), 65.1 (CH2CH3), 68.8 (C-6),
73.2 (C-2), 73.5, 75.0, 75,1, 75.2 (4 C, C-5, 3 CH2Ph), 78.1 (C-4), 83.0 (C-3), 100.7 (C-
1), 127.6, 127.7, 127.8, 127.9, 128.1, 128.4, 130.0, 137.9, 138.1, 138.2 (18 C, 3 C6H5),
169.6 (CO).
Experiment 43: MAR-197
4-Methoxybenzyl 2,3,4,6-tetra-O-benzoyl-β-D-glucopyranose (119): HgBr2 (15 mg,
mmol) was added to a solution of 117 (60 mg, mmol) in DCE (3mL). Dihydroquinone
monoethylether (30 µL, mmol) was added and the mixture was heated in the microwave
for 30 min at 120°C. The mixture was concentrated and purified by column
chromatography on silica gel (petroleum ether-EtOAc 4:1) yielding 119 (23.5 mg, 39 %).
1H NMR (500.1 MHz, CDCl3): δ 3.76 (s, 3 H, CH3), 4.11 (m, 1 H, H-5), 4.52 (m, 1 H, H-
6a), 4.62-4.85 (m, 3 H, H-6b, CH2C6H4), 4.79 (d,
 3J1,2 = 7.9 Hz, 1 H, H-1), 5.57 (dd, 
3J1,2 =
7.9, 3J2,3 = 9.7 Hz, 1 H, H-2), 5.67 (m, 1 H, H-4), 5.82 (m, 1 H, H-3), 6.68-7.10 (m, 4 H,
C6H4), 7.26-8.07 (m, 20 H, 4 C6H5);
13C NMR (125.8 MHz, CDCl3): δ 55.2 (CH3), 63.2 (C-6), 69.8 (C-4), 70.2 (CH2C6H4), 71.8
(C-2), 72.3 (C-5), 72.9 (C-3), 98.7 (C-1), 110.2, 113.8, 117.4, 128.3, 128.4, 128.7, 128.8,
129.3, 129.7, 129.8, 129.9, 133.2, 133.4, 159.4 (30 C, C6H4, 4 C 6H5), 165.0, 165.2,
165.8, 166.2 (4 C, 4 CO).
IV.2.7 2nd Attempt
Experiment 44: MAR-220 and MAR-227
Methyl 2,3,4-tri-O-benzyl-α-D-glucopyranoside (100): LiAlH4 (20.0 mg, 0.52 mmol)
was added to a solution of methyl 2,3,4-tri-O-benzyl-α-D-glucopyranosiduronic acid 99
(300 mg, 0.52 mmol) in dry THF (3 mL) under argon. The mixture was stirred for 1 h at
25°C. LiAlH4 (40.6 mg, 2.12 mmol) was added and the mixture was stirred for another 30
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min. The reaction was quenched with H2O (10 mL) and extracted with CH2Cl2 (5 x 10
mL). The combined organic layers were dried with Na2SO4, concentrated and purified by
column chromatography on silica gel (petroleum ether-EtOAc 3:1) yielding 100 (215 mg,
88 %).
1H NMR (500.1 MHz, CDCl3): δ 3.36 (s, 1 H, CH3), 3.49-3.54 (m, 2 H, H-2, H-4), 3.63 (m,
1 H, H-5), 3.66-3.78 (m, 2 H, H-6), 4.05 (m, 1 H, H-3), 4.56 (d, 3J1,2 = 3.5 Hz,  1 H, H-1),
4.58-5.00 (m, 6 H, 3 CH2Ph), 7.25-7.37 (m, 15 H, 3 C6H5);
13C NMR (125.8 MHz, CDCl3): δ 55.2 (CH3), 60.4 (C-5), 61.9 (C-6), 70.7 (C-5), 73.4,
75.0, 75.8 (3 C, 3 CH2Ph), 77.4 (C-4), 80.0 (C-2), 82.0 (C-3), 98.2 (C-1), 127.6, 127.9,
128.0, 128.1, 128.2, 128.4, 128.5, 130.9, 138.1, 138.2, 138.7 (18 C, 3 C6H5).
[α]D
20 = + 22.4 ( c = 0.77, CHCl3, 100)
Experiment 45: MAR-226
Methyl-2,3,4-tri-O-benzyl-6-O-(4-methoxyphenyl)-α-D-glucopyranoside (101): DEAD
(49.6 mg, 0.284 mmol) was slowly added to a solution of 100 (60.0 mg, 0.129 mmol),
Ph3P (74.5 mg, 0.284 mmol), hydroquinone monomethyl ether (81.8 mg, 0.659 mmol) in
dry THF (2 mL) at 80°C under argon. The mixture was stirred for 5 h under reflux at this
temperature, quenched with a saturated solution of NaHCO3 (10 mL) and extracted with
CH2Cl2 (4 x 10 mL). The combined organic layers were dried with Na2SO4, concentrated
and purified by column chromatography on silica gel (toluene-EtOAc 19:1) yielding 101
(63 mg, 85 %).
1H NMR (500.1 MHz, CDCl3): δ 3.39 (s, 3 H, OCH3), 3.60 (dd, 
3J1,2 = 3.5, 
3J2,3 = 9.6 Hz,
1 H, H-2), 3.72 (m, 1 H, H-4), 3.76 (s, 3 H, OCH3), 3.88 (m, 1 H, H-5), 4.02 (m, 1 H, H-3),
4.05-4.09 (m, 2 H, H-6), 4.50-5.01 (m, 6 H, 3 CH2Ph), 4.64 (d, 
3J1,2 = 3.5 Hz, 1 H, H-1),
6.79 (m, 4 H, C6H4), 7.16-7.38 (m, 15 H, 3 C6H5);
13C NMR (125.8 MHz, CDCl3): δ 55.3, 55.7  (2 C, 2 OCH3), 67.1 (C-5), 69.4 (C-6), 73.5,
75.2, 75.8 (3 C, 3 CH2Ph), 77.5 (C-4), 79.9 (C-2), 82.1 (C-3), 98.3 (C-1), 114.6, 115.5,
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127.7, 127.8, 128.0, 128.1, 128.2, 128.4, 128.5, 138.1, 138.2, 138.7, 152.8, 154.0 (24 C,
3 C6H5, C6H4).
III.3.2 2nd Attempt for the synthesis of macrocycle (2)
Experiment 46: MAR-233
2-(Trimethylsilyl)ethyl 2,3,4-tri-O-benzyl-6,7-dideoxy-β-L-galacto-octopyranoside
(98): LiAlH4 (81.3 mg, 2.14 mmol) was added to a solution of 44 (1.3 g, 2.14 mmol) in
dry THF (10 mL) under argon. The mixture was stirred for 1 h at 25°C. LiAlH4 (40.6 mg,
2.12 mmol) was added and the mixture was stirred for another 30 min. The reaction was
quenched by addition of H2O (20 mL) and extracted with CH2Cl2 (5 x 10 mL). The
combined organic layers were dried with Na2SO4, concentrated and purified by column
chromatography on silica gel (petroleum ether-EtOAc 3:1) yielding 98 (1.14 g, 92 %).
1H NMR (500.1 MHz, CDCl3): δ 1.02 (m, 2 H, H-2’), 1.34-1.45 (m, 2 H, H-6a, H-7a),
1.51-1.60 (m, 2 H, OH, H-7b), 1.80 (m, 1 H, H-6b), 3.23 (m, 1 H, H-5), 3.60 (m, 1 H, H-
4), 3.48-3.58 (m, 4 H, H-1’a, H-3, H-8), 3.80 (dd, 3J1,2 = 7.7, 
3J2,3 = 9.7 Hz, 1 H, H-2),
3.98 (m, 1 H, H-1’b), 4.31 (d, 3J1,2 = 7.7 Hz, 1 H, H-1), 4.65-4.98(m, 6 H, 3 CH2Ph), 7.23-
7.37 (m, 15 H, 3 C6H5);
13C NMR (125.8 MHz, CDCl3): δ 19.9 (C-2’), 28.8 (C-6), 30.7 (C-7), 64.0 (C-8), 68.6 (C-
1’), 75.8, 75.9, 76.5 (3 C, CH2Ph), 76.8 (C-4), 81.1 (C-2), 84.0 (C-3), 104.4 (C-1), 128.9,
129.0, 129.1, 129.2, 129.5, 129.6, 129.7, 129.8, 130.0, 130.2, 130.3, 140.0, 140.1, 140.4
(18 C, 3 C6H5).
[α]D
20 = + 8.3 ( c = 1.02, CHCl3, 98)
Elementary analysis
C34H46O6Si calculated C 70.55 H 8.01
(578.81) found C 69.16 H 7.82
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Experiment 47: MAR-234
 2-(Trimethylsilyl)ethyl 2,3,4-Tri-O–benzyl-6,7–dideoxy-8-O-(4-methoxyphenyl)-L-
galacto-octopyranoside (97): DEAD (748 mg, 4.28 mmol) was slowly added to a
solution of 98 (1.13 g, 1.95 mmol), Ph3P (1.12 g, 4.28 mmol), hydroquinone monomethyl
ether (1.23 g, 9.93 mmol) in dry THF (18 mL) at 80°C under argon. The mixture was
stirred for 5 h under reflux at this temperature, quenched with a saturated solution of
NaHCO3 (50 mL) and extracted with CH2Cl2 (5 x 10 mL). The combined organic layers
were dried with Na2SO4, concentrated and purified by column chromatography on silica
gel (toluene-EtOAc 19:1) yielding 97 (1.14 g, 85 %).
1H NMR (500.1 MHz, CDCl3): δ 1.03 (m, 2 H, H-2’), 1.52-1.62 (m, 2 H, H-6a, H-7a),
1.77-1.91 (m, 2 H, H-6b, H-7b), 3.28 (m, 1 H, H-5), 3.50 (dd, 3J2,3 = 9.9, 
3J3,4 = 3.0 Hz, 1
H, H-3), 3.55 (m, 1 H, H-1’a), 3.64 (m, 1 H, H-4), 3.76 (m, 1 H, OCH3), 3.78-3.90 (m, 3 H,
H-2, H-8), 4.00 (m, 1 H, H-1’b), 4.31 (d, 1 H, 3J1,2 = 7.7 Hz, H-1), 4.67-4.99 (m, 6 H, 3
CH2Ph), 6.76-6.82 (m, 4 H, C6H4), 7.22-7.39 (m, 15 H, 3 C6H5);
13C NMR (125.8 MHz, CDCl3): δ 18.6 (C-2’), 25.9, 27.8 (2 C, C-6, C-7), 55.9 (OCH3),
67.2 (C-1’), 68.4 (C-8), 73.3, 74.2, 74.4, 75.1, 75.3 (5 C, C-4, C-5, 3 CH2Ph), 79.9 (C-2),
82.8 (C-3), 103.6 (C-1), 114.8, 115.5, 127.7, 128.3, 128.4, 128.5, 128.7, 131.1, 133.1,
138.8, 139.1 (24 C, 3 C6H5, C6H5).
Elementary analysis
C41H52O7Si calculated C 71.90 H 7.65
(684.93) found C 71.98 H 7.67
Experiment 48: MAR-230
2,3,4-Tri-O-benzyl-6,7-dideoxy-8-O-(4-methoxyphenyl)-β-L-galacto-octopyranose
(96): TFA (0.57 mL) was added dropwise within 15 min to a solution of 97 (99 mg, 0.14
mmol) in CH2Cl2 (0.29 mL) at 0°C under argon. The mixture was stirred for 30 min at this
temperature, the pH of the solution was adjusted to pH 7 by addition of 10 % aqueous
NaHCO3 (11 mL). The mixture was extracted with CH2Cl2 (4 x 10 mL). The combined
organic layers were dried with Na2SO4, concentrated and purified by column
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chromatography (toluene-EtOAc 4:1) yielding 96 as a mixture of two i "somers (α/β 3.14:1;
65 mg, 76%).
1H NMR (500 MHz, CDCl3): of the mixture 96α /96β (3.14:1): 96α: δ1.56-1.59 (m, 2 H,
H-6a, H-7a), 1.73-1.87 (m, 2 H, H-6b, H-7b), 2.87 (s, 1H, OH), 3.76 (s, 3 H, OCH3), 3.78-
3.90 (m, 3 H, H-3, H-8), 3.94 (m, 1 H, H-5), 4.02 (s, 1 H, H-2), 5.26 (m, 3J1,2 = 3.4 Hz, 1
H, H-1), 4.65-5.00 (m, 6 H, 3 CH2Ph), 6.76-6.82 (m, 4 H, C6H4), 6.24-7.40 (m, 15 H, 3
C6H5); 96β: δ 1.56-1.59 (m, 2 H, H-6a, H-7a), 1.73-1.87 (m, 2 H, H-6b, H-7b), 3.02 (s, 1
H, OH), 3.37 (m, 1 H, H-5), 3.54 (m, 1H, H-3), 3.69 (m, 1 H, H-4), 3.76 (s, 3 H, OCH3),
3.78-3.90 (m, 2 H, H-8), 4.60 (m, 3J1,2 = 7.3 Hz, 1 H, H-1), 4.65-5.00 (m, 6 H, 3 CH2Ph),
6.76-6.82 (m, 4 H, C6H4), 6.24-7.40 (m, 15 H, 3 C6H5);
13C NMR (125.8 MHz, CDCl3) of the mixture 96α /96β (3.14:1): δ 25.9, 27.8 (C-6, C-7),
55.7 (CH3), 68.5 (C-8), 70.7 (C-5), 73.4, 74.0, 75.0 (3 C, 3 CH2Ph), 75.4 (C-4), 76.4 (C-
2), 79.7 (C-3), 92.2 (C-1), 115.0, 115.8, 127.5, 127.6, 127.7, 127.9, 128.0, 128.2, 128.3,
128.4, 128.5 (24 C, 3 C6H5, C6H4).
Elementary analysis
C36H40O7 calculated C 73.95 H 6.90  
(584.70) found C 73.80 H 7.04
Experiment 49: MAR-239
(3R,4R)-[2,3,4-Tri-O-benzyl-6,7-dideoxy-8-O-(4-methoxyphenyl)-α-L-galacto-
octopyranosyl]-(1→3)-4-benzoyloxy-3-hydroxy-N-(2-naphtyl)-pentanoic amide (95):
96 (695 mg, 1.19 mmol) was dissolved in dry CH2Cl2 (10.2 mL) and dry DMF (1.5 mL)
under argon. The mixture was cooled to 0°C and (COBr)2 (0.332 mL, 30.4 mmol) was
added to give a white suspension, which was stirred for 5 min. The reaction was warmed
to 25°C within 20 min and the mixture was stirred for 2 h, giving a thick white
suspension. The suspension was filtered, washed with dry CH2Cl2 (3 x 5 mL) and the
filtrate was concentrated. The residue was dried for 30 min at 10-3 Torr to give a dark
yellow oil (980 mg). The oil was dissolved in CH2Cl2 (4.9 mL) and the solution added to a
suspension of 42 (864 mg, 2.38 mmol), MS4Å (1.0 g) and Bu4NBr (383 mg, 1.19 mmol)
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in dry in CH2Cl2 (2 mL) / DMF (3.2 mL) under argon. The mixture was stirred for 12 h at
25°C, diluted with CH2Cl2 (20 mL) and filtered through Celite. The filtrate was quenched
with NaHCO3 10% (20 mL) and extracted with CH2Cl2 (3 x 30 mL). The organic layer
was washed with 1 M KH2PO4 (30 mL). The aqueous layer was extracted with CH2Cl2 (2
x 20mL). The combined organic layers were dried with Na2SO4, concentrated and
purified by column chromatography (toluene-EtOAc 4:1) yielding 95 (840 mg, 76%).
1H NMR (500.1 MHz, CDCl3): δ 1.39-1.59 (m, 2 H, Fuc-H7), 1.42 (d, 3 H, 
3J4,5 = 6.5 Hz,
1 H, H-5), 1.44-1.50 (m, 2 H, Fuc-H6), 2.52 (dd, 2Ja,b = 15.2,
 3J2,3 = 3.9 Hz, 1 H, H-2a),
2.52 (dd, 2Ja,b = 15.2,
 3J2,3 = 3.9 Hz, 1 H, H-2b), 3.53-3.63 (m, 2 H, Fuc-H8), 3.66 (m, 1
H, Fuc-H4), 3.70 (m, 1 H, Fuc-H5), 3.75 (s, 3 H, OCH3), 4.00 (m, 1 H, Fuc-H3), 4.06 (m,
1 H, H-3), 4.20 (dd, 3J1,2 = 3.7, 
3J2,3 = 10.2 Hz, 1 H, Fuc-H2), 4.55-4.88 (m, 6 H, 3
CH2Ph), 4.89 (d, 
3J1,2 = 3.7 Hz, 1 H, Fuc-H1), 4.49 (m, 1 H, H-4), 6.73-6.82 (m, 4 H,
C6H4), 7.13-9.52(m, 22 H, 3 C6H5, C10H7);
13C NMR (125.8 MHz, CDCl3): δ 16.7 (C-5), 25.2, 27.1 (2 C, Fuc-C6, Fuc-C7), 38.1 (C-
2), 55.7 (OCH3), 68.1 (Fuc-C8), 70.9 (C-4), 71.5 (Fuc-C5), 73.0, 74.8, 74.9, 75.5, 75.8 (5
C, Fuc-C2, Fuc-C4, 3 CH2Ph), 97.3 (Fuc-C1), 114.6, 115.3, 115.4, 116.8, 119.7, 120.2,
124.6, 125.3, 126.1, 127.3, 127.4, 127.5, 127.7, 127.8, 128.2, 128.3, 128.4, 128.5,
128.6, 128.9, 129.0, 129.6, 129.8, 130.1, 130.5, 133.0, 133.4, 136.0, 137.1, 137.9,
138.3, 138.4, 153.1, 153.7 (40 C, 4 C6H5, C6H4, C10H7), 165.5, 168.1 (2 C, 2 CO).
Elementary analysis
C58H59NO10 calculated C 74.90 H 6.39 N 1.51
(930.09) found C 74.24 H 6.41 N 1.29
Experiment 50:  MAR-240
(3R,4R)-[2,3,4-tri-O-benzyl-6,7-dideoxy-8-O-(4-methoxyphenyl)-α-L-galacto-
octopyranosyl]-(1→3)-3,4-dihydroxy-N-(2-naphtyl)-pentanoic amide (93): Under an
argon atmosphere, 95 (840 g, 0.86 mmol) was dissolved in freshly dried MeOH to give a
clear solution. 1 M NaOMe in dry MeOH (1.0 mL) was added to bring the solution’s pH to
10. The mixture was stirred for 28h at 25°C, neutralized with Amberlyst 15 and filtered
off through Celite. The Celite was washed with 50 mL MeOH and 80 mL CH2Cl2. The
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solvent was evaporated and dried under high vacuum. Elution with 1:4 toluene-EtOAc
gave 93 (630 g, 84% yield).
1H NMR (500.1 MHz, CDCl3): δ 1.30 (d, 3 H, 
3J4,5 = 6.3 Hz, 1 H, H-5), 1.59 (m, 2 H, Fuc-
H6a, Fuc-H7a), 1.78 (m, 2 H, Fuc-H6b, Fuc-H7b), 2.42 (dd, 2J2a,2b = 14.5,
 3J2a,3 = 3.5 Hz,
1 H, H-2a), 2.70 (dd, 2J2a,2b = 14.5,
 3J2b,3 = 4.2 Hz, 1 H, H-2b), 3.67 (m, 1 H, H-3), 3.74 (s,
3 H, OCH3), 3.78 (m, 1 H, Fuc-H8a), 3.87 (m, 3 H, Fuc-H4, Fuc-H8b, H-4), 3.97 (m, 1 H,
Fuc-H5), 4.03 (m, 1 H, Fuc-H3), 4.28 (dd, 3J1,2 = 3.9 Hz, 1 H, Fuc-H2), 4.85 (d, 
3J1,2 = 3.9
Hz 1 H, Fuc-H1), 4.65-5.00 (m, 6 H, 3 CH2Ph), 6.75-6.80 (m, 4 H, C6H4), 7.20-9.28 (m,
22 H, 3 C6H5, C10H7);
13C NMR (125.8 MHz, CDCl3): δ 25.6, 27.8 (2 C, Fuc-C6, Fuc-C7), 30.9 (C-5), 39.0 (C-
2), 55.7 (OCH3), 68.3, 68.6 (2 C, Fuc-C8, C-4), 72.8, 74.9, 75.2, 75.9, 76.0 (4 C, 3
CH2Ph, Fuc-C2), 80.1 (Fuc-C3), 82.2 (C-3), 98.1 (C-1), 114.6, 115.4, 116.3, 119.8,
124.7, 126.3, 127.2, 127.4, 127.6, 127.8, 128.4, 128.5, 128.6, 128.7, 129.0, 130.4,
133.9, 136.0, 137.0, 138.3, 153.0, 153.7 (34 C, 3 C6H5, C6H4, C10H7), 168.4 (CO).
[α]D
20 = - 104.1 (c = 0.98, CHCl3, 93)
Elementary analysis
C51H55NO9 calculated C 74.16 H 6.71 N 1.70
(825.98) found C 73.98 H 6.83 N 1.72
Experiment 51:  MAR-249
(3R,4R)-{3-[(2S)-Benzyl-3-cyclohexyl-2-hydroxypropanoate-2-O-yl]-2,4,6-tri-O-
benzoyloxy-β-D-galactopyranosyl}-(1→4)-{[methyl 2,3,4-tri-O-benzyl-6,7-dideoxy-8-
O-(4-methoxyphenyl)-α-L-galacto-octopyranosyl-uronate]-(1→3)}-3,4-dihydroxy-N-
(2-naphtyl)-pentanoic amide (92): 93  (270 mg, 0.331 mmol) was added to a
suspension of MS 3Å  (2.0 g) in CH2Cl2 at –5°C under argon. The mixture was stirred for
1 h and 94 (380 mg, 0.49 mmol) was added. The mixture was stirred for 1 h and DMTST
(170 mg, 0.662 mmol) was added. The mixture was stirred for 1 h at –5°C then for 20 h
at 0°C and additional DMTST (85 mg, 0.33 mmol) was added. The mixture was stirred
for 4 h at 0°C, diluted with CH2Cl2 (20 mL) and filtered through Celite. The filtrate was
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quenched with NaHCO3 10% (20 mL) and extracted with CH2Cl2 (3 x 30 mL). The
aqueous layer was extracted with CH2Cl2 (2 x 20 mL). The combined organic layers
were dried with Na2SO4, concentrated and purified by column chromatography (toluene-
EtOAc 19:1) yielding 92 (348 mg, 68%).
1H NMR (500.1 MHz, CDCl3): δ 0.44-1.41 (m, 13 H, C6H11, CH2C6H11), 1.03 (d, 
3J4,5 = 5.6
Hz, 3 H, H-5), 1.59 (m, 2 H, Fuc-H7), 1.80-1.93 (m, 2 H, Fuc-H6), 2.35-2.70 (m, 2 H, H-
2), 3.73 (m, 1 H, Fuc-H4), 3.75 (m, 3 H, OCH3), 3.78-3.84 (m, 2 H, Gal-H3, Gal-H5), 3.90
(m, 2 H, Fuc-H8), 4.00 (m, 2 H, H-3, H-4), 4.03 (dd, 1 H, Fuc-H3), 4.09 (dd, 1 H, Fuc-
H2), 4.12-4.16 (m, 2 H, Fuc-H5, Cyc-H1), 4.25-4.40 (m, 2 H, Gal-H6), 4.48-5.15 (m, 8 H,
4 CH2Ph), 4.51 (d, 
3J1,2 = 8.0 Hz, 1 H, Gal-H1), 5.58 (m, 1 H, Gal-H2), 5.88 (m, 1 H, Gal-
H4), 7.03-9.31 (m, 26 H, C6H4, 3 C6H5, C10H7);
13C NMR (125.8 MHz, CDCl3): δ 15.9 (C-5), 26.0, 26.2, 26.4, 26.5, 33.2, 33.8 (6 C,
C6H11, C6H11), 37.3 (C-2), 40.8 (Cyc-C3), 56.1 (OCH3), 63.3 (Gal-C6), 67.0 (CH2Ph),
69.0 (Fuc-C8), 70.5 (Gal-C4), 71.8 (Fuc-C5), 72.3 (Gal-C5), 72.8 (Gal-C2), 73.3, 74.6,
75.4 (3 C, 3 CH2Ph), 76.3 (Fuc-C2), 76.4 (C-3), 77.0 (Fuc-C4), 77.9 (Gal-C3), 78.7 (Cyc-
C2), 80.3 (Fuc-C3), 97.1 (Fuc-C1), 100.7 (Gal-C1), 112.4, 113.9, 114.2, 115.0, 115.7,
117.4, 118.6, 120.8, 125.0, 125.7, 126.5, 127.4, 127.8, 127.9, 128.0, 128.1, 128.4,
128.6, 128.7, 128.8, 128.9, 129.0, 129.1, 129.4, 129.9, 130.0, 130.1, 130.2, 130.3,
130.4, 130.9, 133.4, 133.5, 133.6, 133.7, 133.9, 134.2, 135.9, 136.3, 137.7, 139.0,
139.1, 153.7, 154.0 (58 C, C6H4, 7 C6H5, C10H7),165.1, 166.3, 166.4, 169.4 (5 C, 5 CO).
Elementary analysis
C94H97NO19 calculated C 73.74 H 6.32 N 0.92
(1514.75) found C 71.51 H 6.33 N 0.48
Experiment 52:  MAR-252 (Partially deprotected)
(3R,4R)-{3-[(2S)-Methyl 3-cyclohexyl-2-hydroxypropanoate-2-O-yl]-2-O-benzoyl-β-
D-galactopyranosyl}-(1→ 4)-{[methyl 2,3,4-tri-O -benzyl-6,7-dideoxy-8-O - (4-
methoxyphenyl)-α-L-galacto-octopyranosyl-uronate]-(1→3)}-3,4-dihydroxy-N-(2-
naphtyl)-pentanoic amide (91b): Under an argon atmosphere, 92 (20 mg, 0.01 mmol)
was dissolved in freshly dried MeOH to give a clear solution. 1 M NaOMe in dry MeOH
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(1.0 mL) was added to bring the solution’s pH to 10. The mixture was stirred for 28h at
25°C, neutralized with Amberlyst 15 and filtered off through Celite. The filter was washed
with 20 mL MeOH and 20 mL CH2Cl2. The solvent was evaporated and dried under high
vacuum. Elution with 1:4 toluene-EtOAc gave 91b (13.8 mg, 79 % yield).
1H NMR (500 MHz, CDCl3): δ 0.44-1.41 (m, 12 H, C6H11, CH2C6H11), 1.05 (d, 
3J4,5 = 5.6
Hz, 3 H, H-5), 1.45 (m, 2 H, Fuc-H7), 1.80-1.93 (m, 2 H, Fuc-H6), 2.35-2.73 (m, 2 H, H-
2), 3.42 (m, 2 H, Gal-H3, Gal-H4), 3.63  (m, 1 H, Gal-H5), 3.72, 3.78 (2 s, 6 H, 2 OCH3),
3.84-3.97 (m, 6 H, H-3, H-4, Fuc-H4, Fuc-H5, Gal-H6), 3.99 (m, 1 H, Fuc-H3), 4.12 (m, 1
H, Fuc-H2), 4.18 (m, 2 H, Fuc-H8), 4.45 (d, 3J1,2 = 8.0 Hz, 1 H, Gal-H1), 4.68-5.05 (m, 6
H, 3 CH2Ph), 4.85 (m, 1 H, Fuc-H1), 5.56-5.60 (m, 1 H, Gal-H2), 6.78 (m, 4 H, C6H4),
7.03-9.31 (m, 27 H, 4 C6H5, C10H7);
13C NMR (125.8 MHz, CDCl3): δ 16.8 (C-5), 51.8 (OCH3), 56.0 (OCH3), 61.8 (C-4), 62.1
(Gal-C5), 68.1 (Fuc-C4), 68.9 (Gal-C6), 70.1 (Fuc-C8), 70.9 (Gal-C2), 73.4, 74.7, 74.8,
75.1 (4 C, CH2Ph), 75.6 (C-3), 75.7, 77.1, 80.1 (3 C, Fuc-C2, Fuc-C3, Fuc-C5), 82.3
(Gal-C4), 94.3 (Fuc-C1), 100.3 (Gal-C1), 114.9, 115.8 126.6, 127.7, 127.8, 127.9, 128.6,
128.7, 128.8, 129.0, 130.1  (40 C, 4 C6H5, C6H4, C10H7), 168.0 (CO).
Elementary analysis
C79H87NO16 calculated C 72.82 H 6.71 N 0.82
(1306.53) found C 69.68 H 6.71 N 1.11
Experiment 53:  MAR-267
(3R,4R)-(α-L-Fucopyranosyl)-(1→3)-4-benzoyloxy-3-hydroxy-N-(2-naphtyl)-
pentanoic amide (103): L-Fucose 102 (0.21 g, 0.48 mmol) was dissolved in dry CH2Cl2
(3.0 mL) and dry DMF (0.5 mL) under argon. The mixture was cooled to 0°C and
(COBr)2 (198 mg, 86.1 µL, 92.0 mmol) was added to give a white suspension, which was
stirred for 5 min. The temperature was raised to 25°C within 20 min and the mixture was
stirred for 2 h, giving a thick white suspension. The suspension was filtered, washed with
dry CH2Cl2 (3 x 5 mL) and the filtrate was concentrated. The residue was dried 30 min at
10-3 Torr to give a dark yellow oil (350 mg). The oil was dissolved in CH2Cl2 (4.9 mL) and
the solution added to a suspension of 42 (348 mg, 0.962 mmol), Ms4Å (0.5 g) and
133
134
Bu4NBr (0.154 g, 0.483 mmol) in dry in CH2Cl2 (1.5 mL) / DMF (1 mL) under argon. The
mixture was stirred for 12 h at 25°C, diluted with CH2Cl2 (20 mL) and filtered through
Celite. The filtrate was quenched with NaHCO3 10% (20 mL) and extracted with CH2Cl2
(3 x 30 mL). The organic layer was washed with 1 M KH2PO4 (30 mL). The aqueous
layer was extracted with CH2Cl2 (2 x 20 mL). The combined organic layers were dried
with Na2SO4, concentrated and purified by column chromatography (toluene-EtOAc 4:1)
yielding 103 (291 mg, 78%).
[α]D
20 = -179.7 (c = 0.95, CHCl3, 103)
1H NMR (500.1 MHz, CDCl3): δ 0.82 (d,
 3J5,6 = 6.5 Hz, 3 H, Fuc-H6), 1.44 (d, 
3J4,5 = 6.5
Hz, 3 H, H-5), 2.49-2.80 (m, 2 H, H-2), 3.49 (d, 2J3,4 = 1.5 Hz, 1 H, Fuc-H4), 3.80 (m, 1
H, Fuc-H5), 3.98 (dd, 3J2,3 = 10.3,
 3J3,4 = 2.7 Hz, 1 H, Fuc-H3), 4.06  (m, 1 H, H-3), 4.19
(dd, 3J1,2 = 3.7,
 3J2,3 = 10.3 Hz, 1 H, Fuc-H2), 4.55-4.93 (m, 6 H, 3 CH2Ph), 4.85 (d, 
3J1,2 =
3.7 Hz, 1 H, Fuc-H1), 5.44 (m, 1 H, H-4), 7.15-9.51 (m, 22 H, 3 C6H5, C10H7);
13C NMR (125.8 MHz, CDCl3): δ 16.7 (Fuc-C6), 17.3 (C-5), 38.8 (C-2), 68.0 (Fuc-C5),
78.3 (Fuc-C4), 76.2 (Fuc-C2), 73.4, 75.3, 76.2 (3 CH2Ph), 71.6 (C-4), 80.2 (C-3), 97.9
(Fuc-C1), 117.0, 120.5, 125.0, 126.5, 127.7, 128.0, 128.1, 128.2, 128.6, 128.7, 128.8,
129.0, 129.1, 129.3, 129.4, 130.0, 130.5, 130.8, 133.4, 134.3, 136.4, 137.5, 138.8 (28 C,
3 C6H5, C10H7), 168.4 (2 C, 2 CO).
Experiment 54:  MAR-268
(3R,4R)-(α-L-Fucofuranosyl)-(1→3)-3,4-hydroxy-N -(2-naphtyl)-pentanoic amide
(104): 103 (285 mg, 0.375 mmol) was solved in dry MeOH/dioxane 2:1 (8 mL) under
argon to give a clear solution. 1 M NaOMe (800 µL) was added to bring the solution to
pH 10. The mixture was stirred for 28h at 25°C, neutralized with Amberlyst 15 and
filtered through Celite. The filter was washed with MeOH (50 mL) and CH2Cl2 (80 mL).
The Celite was evaporated and dried under high vacuum. Elution with toluene-EtOAc
(45:55) gave 104  (219 mg, 89% yield).
1H NMR (500.1 MHz, CDCl3): δ 1.15 (d,
 3J5,6 = 6.5 Hz, 3 H, Fuc-H6), 1.44 (d, 
3J4,5 = 6.3
Hz, 3 H, H-5), 2.43-2.72 (m, 2 H, H-2), 3.67  (m, 1 H, H-3), 3.74 (d, 2J3,4 = 1.5 Hz, 1 H,
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Fuc-H4), 3.88 (m, 1 H, H-4), 3.98 (dd, 3J2,3 = 10.2,
 3J3,4 = 2.6 Hz, 1 H, Fuc-H3), 4.08  (m,
1 H, Fuc-H5), 4.24 (dd, 3J1,2 = 3.8,
 3J2,3 = 10.2 Hz, 1 H, Fuc-H2), 4.65-5.00 (m, 6 H,
CH2Ph), 4.88 (d, 
3J1,2 = 3.8 Hz, 1 H, Fuc-H1), 7.15-9.20 (m, 22 H, 3 C6H5, C10H7);
13C NMR (125.8 MHz, CDCl3): δ 17.1 (Fuc-C6), 19.6 (C-5), 39.7 (C-2), 68.2 (C-4), 73.2,
75.4, 75.6 (3 C, 3 CH2Ph), 76.3 (Fuc-C2), 80.4 (Fuc-C4), 83.0 (Fuc-C1), 116.7, 120.2,
125.1, 126.7, 127.6, 127.8, 128.0, 128.2, 128.7, 128.9, 129.0, 129.1, 129.3, 129.4,
136.3, 138.7, 138.7 (28 C, 3 C6H5, C10H7), 168.1 (CO).
Experiment 55:  MAR-269
(3R,4R)-(2,3,4,6-Tetra-O-benzoyl-β-D-galactopyranosyl)-(1→4)-[(α-L-fucofuranosyl)-
(1→3)]-3,4-dihydroxy-N-(2-naphtyl)-pentanoic amide (106): 104  (113 mg, 0.17
mmol) was added to a suspension of MS 3Å  (1.5 g) in CH2Cl2 at -5°C under argon. The
mixture was stirred for 1 h and 105 (160 mg, 0.25 mmol) was added. The mixture was
stirred for 1 h then DMTST (86 mg, 0.33 mmol) was added. The mixture was stirred for
20 h at –5°C and additional DMTST (43 mg, 0.17 mmol) was added. The mixture was
stirred for 4 h at –2°C, diluted with CH2Cl2 (20 mL) and filtered through Celite. The filtrate
was quenched with NaHCO3 10% (20 mL) and extracted with CH2Cl2 (4 x 30 mL). The
aqueous layer was extracted with CH2Cl2 (2 x 20 mL). The combined organic layers
were dried with Na2SO4, concentrated and purified by column chromatography (toluene-
EtOAc 19:1) yielding 106 (144 mg, 66%), which was directly used in the next step.
Experiment 56:  MAR-270
(3R,4R)-(β-D-galactopyranosyl)-(1→4)-[(Fucosyl)-(1→3)]-3,4-dihydroxy-N-(2-
naphtyl)-pentanoic amide (107): Under an argon atmosphere, 106 (130 mg, 0.85
mmol) was solved freshly dry MeOH to give a clear solution. 1 M NaOMe in dry MeOH
(1.0 mL) was added to bring the solution’s pH to 10. The mixture was stirred for 28h at
25°C, neutralized with Amberlyst 15 and filtered off through Celite. The filter was washed
with 30 mL MeOH and 50 mL CH2Cl2. The solvent was evaporated and dried under high
vacuum to give. Elution with 1:4 toluene-EtOAc gave 107 (82.4 mg, 80% yield).
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1H NMR (500.1 MHz, CDCl3): δ 1.12 (d,
 3J5,6 = 6.2 Hz, 3 H, Fuc-H6), 1.23 (d, 
3J4,5 = 6.0
Hz, 3 H, H-5), 2.47-2.81 (m, 2 H, H-2), 3.36  (m, 1 H, Gal-H5), 3.59 (m, 1 H, Gal-H2),
3.72 (m, 1 H, Gal-H6a), 3.77 (m, 1 H, Gal-6b), 3.92 (m, 1 H, Gal-H4), 4.00 (m, 2 H, Fuc-
H3, H-4), 4.10-4.15  (m, 3 H, Fuc-H2, Fuc-H5, H-3), 4.23 (d, 3J1,2 = 1 H, Gal-H1), 4.61-
4.96 (m, 6 H, 3 CH2Ph), 4.88 (m, 1 H, Fuc-H1), 7.10-9.27 (m, 22 H, 3 C6H5, C10H7);
13C NMR (125.8 MHz, CDCl3): δ 15.8 (Fuc-C6), 31.3 (C-5), 62.5 (Gal-C6), 67.8 (Fuc-
C5), 70.1 (Gal-C4), 71.8 (Gal-C2), 73.2 (Gal-C3), 73.8 (Gal-C4), 74.3, 74.8, 75.3 (4 C,
Gal-C5, 3 CH2Ph), 75.8 (Fuc-C3), 76.2 (Fuc-C2), 77.7 (Fuc-C4), 78.2 (C-2), 80.4 (C-4),
97.5 (Fuc-C1), 101.8 (Gal-C1), 117.2, 120.6, 125.2, 126.7, 127.7, 127.9, 128.1, 128.5,
128.7, 130.9, 134.2, 136.2, 137.8, 138.9, 139.0 (28 C, 3 C6H5, C10H7), 168.1 (CO).
Elementary analysis
C94H97NO19 calculated C 73.74 H 6.32 N 0.92
(1514.75) found C 71.51 H 6.33 N 0.48
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